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Abstract 
The principle aims of this thesis were to determine the effect of lowering plasma fatty acids 
(FA) on muscle microvascular blood volume (MBV) at rest and during exercise, investigate 
whether near-infrared spectroscopy (NIRS) can be used to measure muscle MBV in the obese, 
develop the contrast enhanced ultrasound (CEU) method in our laboratory for measuring 
muscle MBV of the human forearm, and use CEU to measure the MBV response to an oral 
glucose tolerance test (OGTT).  No differences were observed in exercise-induced increases 
in MBV or resting MBV between control and low FA conditions created by niacin ingestion 
in lean and obese individuals.  NIRS was not suited to measure muscle MBV in participants 
with a thick subcutaneous adipose tissue layer.  The CEU method was successfully developed 
to measure MBV in the human forearm.  CEU revealed a significant increase in MBV in 
response to an OGTT in lean trained individuals.  This technique will be used in future studies 
to generate novel information on the suspected impaired MBV response after meal ingestion 
in obese individuals and to assess the effectiveness of interventions aimed at improving the 
MBV response and glycemic control to avoid the development of type II diabetes and 
cardiovascular disease. 
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Chapter 1 
 
 
INTRODUCTION 
 1
1.1 The global obesity problem 
  
1.1.1 Perspectives 
Obesity is a significant global health problem greatly affecting mortality and quality of 
life.  It is a popular topic of conversation for governments, doctors, and the general 
public, and there is great emphasis on the need to stop this global epidemic, especially in 
children.  But what is obesity?  And why exactly is it a health threat?  
 
Obesity is the accumulation of adipose tissue to excess and to an extent which presents a 
health risk to the individual (World Health Organisation 20091).  It is crudely defined 
using the body mass index (BMI) which is calculated from height and weight using the 
formula: [BMI = (weight in kg) / (height in m2)].  A BMI of 30 or greater defines the 
individual as being obese.  The development of obesity involves the interaction of many 
variables including environmental, hormonal, genetic predisposition, adipokine receptor 
defects and many more (Stapleton et al. 20082).  Despite the complex nature, the 
principal contributing factor appears to be an imbalance between energy intake and 
expenditure (Stapleton et al. 20082).  The indisputable change in lifestyle over the last 30 
years, involving reductions in physical activity and increases in consumption of calories 
and fat, has resulted in a dramatic worldwide rise in the prevalence of obesity. 
 
Previously, in many cultures, being overweight was a sign of wealth; a sign that the 
individual did not have to do physical labour and had enough money to purchase ample 
amounts of food.  However, in these modern times, it has become glaringly evident that 
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being obese is a serious health risk associated with the development of numerous 
pathologies which, simplistically, will cost (a) the individual: reduced life expectancy and 
quality of life, and (b) the economy: billions of pounds in health care and medical costs.  
As stated by Professor Philip James, chairman of the International Obesity Taskforce: 
obesity truly does constitute “one of the most important medical and public health 
problems of our time”.   
 
1.1.2 Global and UK increases in obesity rates 
Although the US has led the world in its staggering increases in the prevalence of obesity, 
the rest of the world is flagrantly following suit.  Globally, an estimated 400 million 
adults were classed as obese in 2005, with the expectation of an increase to 700 million 
by 2015 (World Health Organisation 20063).   In the UK, nearly a quarter of the 
population was classed as obese in 2007 and it is predicted that by 2025 almost half of 
men and over a third of women will be obese (NHS Information Centre 20094).  The 
epidemic scale of the UK obesity problem was confirmed in the statistics from the 
government report of the Health Profile of England 2008:  with 23 % of the adult 
population classed as obese, the UK has the highest obesity prevalence in Europe.   
 
Mirroring the adult obesity epidemic is the dramatic global rise in the number of 
overweight and obese children (Figure 1.1).  Although the highest absolute rates are seen 
in children from the USA, the rise in overweight children in the UK between 1995 and 
2000 is alarming.  In the UK, the obesity rates for 4-5 year old children has nearly 
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doubled since 1990, while that for 10-11 year olds has more than tripled since then 
(Figure 1.2; Dinsdale and Rutter 20085).   
 
This increase in overweight and obesity in children is of particular concern as it is related 
to the subsequent overweight or obesity in adulthood, as well as increased risk of adult 
morbidity and mortality (Guo et al. 20026; World Health Organisation 20063).  Indeed, 
the negative health consequences arising from the obese condition, such as type II 
diabetes, will appear at an earlier age, causing the individuals to face subsequent ill health 
for much of their adult life.   
 
 
Figure 1.1 Worldwide increase in the number of overweight children over the past 40 years.  Data shown 
as percentage overweight.   
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Figure 1.2 Childhood overweight and obesity rates of 2006/2007 for 4-5 and 10-11 year olds as compared 
to the averages recorded for children in 1990 in England.  Data from the National Child Measurement 
Programme in the National Obesity Observatory report of June 2008. 
 
 
1.1.3 Obesity-associated pathologies 
According to the World Health Organisation (1998)7 “obesity is becoming one of the 
most important contributors to ill-health in adults”.  In the UK alone, the number of 
deaths attributable to obesity per year has reached 30,000, while in the USA the figure is 
10 times higher and in 2005 obesity overtook smoking as the leading preventable cause 
of illness and premature death (Marinou et al. 20098).  Indeed, as BMI increases, so does 
the risk of certain chronic diseases including cardiovascular disease, type II diabetes, 
hypertension, the metabolic syndrome, peripheral vascular disease, gall bladder disease, 
some cancers, obstructive sleep apnea, arthritic disorders, and non-alcoholic fatty liver 
disease (World Health Organisation 20063; Byrne et al. 20099; Stapleton et al. 20082; 
Shoelson et al. 200710). 
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Amongst the obesity-related diseases, the rise in the worldwide prevalence of type II 
diabetes in adults is particularly striking.  For every unit increment in BMI, the risk of 
type II diabetes increases by 18 % (Helmrich et al. 199111)  and now more than 180 
million adults worldwide are estimated to have diabetes, with this number predicted to 
double by 2030 (World Health Organisation 200612).  In 2005, the annual death rate from 
diabetes was estimated at 1.1 million, with the prediction of a greater than 50 % increase 
in the following 10 years if urgent action is not taken (World Health Organisation 
200612).  
 
The early metabolic defects that lead to the development of type II diabetes are common 
to several other obesity-related pathologies, namely: hypertension, the metabolic 
syndrome, peripheral vascular disease, and cardiovascular disease.  The principal defects 
are vascular endothelial dysfunction and insulin resistance in liver, adipose tissue, and 
skeletal muscle.  Thus in addressing these common defects the development of the 
network of pathologies stemming from the endothelial dysfunction and insulin resistance 
may be limited.  
 
It is of great importance to immediately take measures to prevent further increases in 
obesity and the obesity-related pathologies.  Although life expectancy is still on the 
increase in the UK, healthy life expectancy appeared to be levelling off already in 2001 
(Figure 1.3; Science and technology committee 200513).  With the dramatic increase in 
childhood obesity in the last decade, one can speculate that as these individuals approach 
middle age, there will be a massive increase in the prevalence of obesity-related 
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pathologies prompting a dramatic fall in healthy life expectancy.  Thus despite the 
favourable appearance of an increasing life expectancy, the population will spend an 
increasing number of years in ill health unless immediate measures are taken.  
 
 
Figure 1.3 Life expectancy and healthy life expectancy for males and females in the UK population. 
 
 
1.2 Functional, metabolic, and structural impairments in the obese 
 
It was originally assumed that overweight and obese individuals combined an increased 
subcutaneous and visceral adipose tissue mass with maintenance of relatively normal 
physiological functions, metabolic rates and regulation mechanisms, and organ/tissue 
structure.  However, in recent years it has become apparent that, even in the early stages 
of obesity, abnormalities are present in the function, metabolism, and structure of most 
organs and tissues.  The presence of such abnormalities can be regarded as the early steps 
in the mechanisms that eventually lead to pathology and early mortality in chronically 
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overweight, obese and morbidly obese individuals.  In this section, an overview will be 
given of the most important functional, metabolic, and structural impairments that have 
been described in obese patients in the recent literature.  The focus will be on the 
abnormalities which contribute to impairment of vascular function and promote the loss 
of glycemic control, thus contributing to the development of type II diabetes and 
cardiovascular disease.  
  
1.2.1 Adipose tissue: source of fatty acids and inflammatory cytokines  
Although initially viewed as simply a store for excess fats, the adipose tissue plays a 
crucial role in the regulation of plasma lipid levels, especially in the postprandial periods 
when dynamic changes in plasma lipid concentration occur.  In healthy individuals, the 
adipose tissue will limit the postprandial excursions in circulating fatty acids (FA) and 
lipids by suppressing the release of FA and promoting the uptake of triacylglycerol (TG; 
Frayn 200214) via lipolysis of lipoproteins (especially chylomicrons and very low density 
lipoproteins).  In the obese state however, the adipose tissue is unable to quickly respond 
to the changes in lipid concentration after a meal and, therefore, plasma FA and TG 
excursions are much higher (Frayn 200214).   
 
The impaired ability to regulate postprandial lipid excursions arises from metabolic 
impairments within the adipocytes.  The release of FA from the adipocytes is under the 
control of hormone sensitive lipase (HSL), an enzyme present in the adipocytes.  The 
hydrolysis of TG, leading to the clearance of TG from the blood, and the uptake of FA in 
the adipocytes is under the control of lipoprotein lipase (LPL), an enzyme present on the 
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endothelial cells of adipose tissue capillaries.  Insulin normally inhibits HSL and 
activates LPL (Frayn 200214).  Thus in the postprandial state, when insulin levels are 
elevated, the release of FA is normally suppressed while the clearance of TG from the 
blood will be increased.  This leads to low plasma FA and TG concentrations.  In obesity 
however, the adipocytes develop resistance to insulin, and thus the normal coordination 
between adipose tissue lipolysis and TG clearance is lost and leads to increased 
postprandial lipid excursions (Frayn 200214).  Even the hyperinsulinaemia often present 
in obesity is not able to reduce adipose tissue lipolysis in the postprandial period (Frayn 
200214), therefore, there is a continued net release of FA from the abdominal and visceral 
adipose tissue compartments. 
 
A very important recent observation is that low-grade inflammation always occurs within 
the adipose tissue of obese individuals with substantial increases in the levels of 
macrophage infiltration (Stapleton et al. 20082; Berg and Scherer 200515; Bakker et al. 
200916; Meyers and Gokce 200717).  In obese mice, 50 % of the cells in adipose tissue 
were found to consist of macrophages, compared to 5-10 % in lean mice (Bakker et al. 
200916).  The macrophages lead to a substantial local production of inflammatory 
cytokines (TNFα, IL-1 and IL-6).  These inflammatory cytokines are assumed to be the 
main cause of the insulin resistance of the adipose tissue cells and, therefore, the cause of 
the mentioned loss of coordination between FA release and TG clearance in the 
postprandial state in obese subjects.  Some of these inflammatory cytokines are released 
into the systemic circulation and will, therefore, also be the cause of metabolic 
impairments in the liver,  skeletal muscle, and potentially many other tissues (Berg and 
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Scherer 200515; Bakker et al. 200916; Bastard et al. 200618; Shoelson et al. 200619; 
Goossens 200820).             
 
Adipose tissue in obese individuals has also been observed to contain larger adipocytes as 
opposed to more small cells (Frayn 200214; Goossens 200820).  It has been suggested that 
the larger adipocytes are generally less sensitive to insulin (Frayn 200214; Roberts et al. 
200921; Goossens 200820), and would therefore reduce the ability of the adipose tissue to 
respond appropriately to the lipid excursions in the postprandial state.   Furthermore, it 
has been suggested that there are alterations in the structure of the adipose tissue 
microvasculature in obesity, as the normal postprandial increase in adipose tissue blood 
flow is blunted (Frayn 200214; Karpe and Tan 200522; Goossens 200820).  This could also 
reduce the delivery of TG to the adipose tissue for storage, and explain the reduced lipid 
buffering capacity of the adipose tissue in the obese in the postprandial state (Frayn 
200214).   
 
In addition to the mentioned structural changes, the location of the adipose tissue stores 
seems to play a role in the severity of the resulting metabolic impairments.  Visceral 
adipose tissue, which is stored between the intestines in upper/abdominal obesity, is 
commonly regarded as the most active fat deposit promoting systemic inflammation in 
the obese state (Stapleton et al. 20082; Berg and Scherer 200515; Jensen 200823; Shoelson 
et al. 200619).  Visceral fat has been suggested to contain a greater number of 
macrophages and monocytes than subcutaneous adipose tissue stores (Bakker et al 
200916).  Fatty acids and inflammatory cytokines released by the visceral adipose tissue 
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compartment enter the systematic circulation via the portal vein and the liver.  Most of 
the fatty acids released by visceral adipose tissue are taken up by the liver and used for 
the synthesis of very low density triglycerides (VLDL-TG) thus explaining the high 
plasma TG and VLDL-TG concentrations in individuals with visceral adiposity.  A 
continuous exposure of the liver to high concentrations of fatty acids and inflammatory 
cytokines released by adipose tissue and channelled to the liver via the portal vein has 
been suggested to be the primary cause of non-alcoholic fatty liver disease, the hepatic 
expression of the metabolic syndrome (see section 1.2.2).   
 
1.2.2 Liver and non-alcoholic fatty liver disease: source of VLDL-TG and glucose 
The liver has a multitude of functions, but the central metabolic role is the regulation of 
plasma glucose and fat concentrations in order to maintain homeostasis despite varied 
glucose and fat ingestion with every meal (Fritsche et al. 200824).  In obesity, however, 
the increased visceral and subcutaneous adiposity exposes the liver to increased 
concentrations of FA and inflammatory cytokines.  Chronic delivery of FA in excess of 
its capacity to oxidize FA and synthesize VLDL-TG will lead to the accumulation of TG 
in the liver.  The build up of TG in the liver, in combination with the constant exposure to 
high levels of inflammatory cytokines, eventually results in the development of non-
alcoholic fatty liver disease (NAFLD; Byrne et al. 20099).  NAFLD refers to a wide-
spectrum of liver damage ranging from simple steatosis (fatty liver; that is liver with fat 
content > 5 %) to steatohepatitis (fatty liver with inflammation and apoptotic 
hepatocytes), advanced fibrosis (liver tissue with excessive extracellular matrix and 
increased collagen content) and cirrhosis (liver failure due to the fact that liver tissue is 
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extensively replaced by scar tissue with a poor blood supply).  Advanced liver fibrosis 
and cirrhosis are nearly always attended by inflammation and infiltration with monocytes 
and macrophages (Byrne et al. 20099).  NAFLD is the most common form of abnormal 
liver function among adults in Western countries (Targher et al. 200725).  NAFLD has a 
high prevalence amongst obese individuals (estimates 70-100%), especially in those with 
morbid obesity (Bellentani et al. 200026; Byrne et al. 20099; Marchesini et al. 200827). 
 
A normal healthy liver has a high capacity to produce VLDL-TG from the FA released 
by the visceral and subcutaneous adipose tissue stores and will be able to prevent 
substantial increases in plasma FA concentrations.  A normal healthy liver also plays an 
important role in the clearance of interleukin 6 (IL-6) and potentially other inflammatory 
cytokines released by the visceral and subcutaneous adipose tissue stores (Garibotto et al. 
200728).  However, in the various forms of NAFLD, the capacity of the liver to oxidize 
fatty acids and to synthesize VLDL-TG is reduced, principally due to tissue and 
mitochondrial damage caused by reactive oxygen species (ROS) and leading to a reduced 
capacity to oxidize FA (Byrne et al. 20099).  As NAFLD is often combined with 
inflammation, the liver itself will also become a source of inflammatory cytokines in 
obese individuals with NAFLD.  This implies that obese individuals with NAFLD are 
likely to have higher systemic concentrations of FA and inflammatory cytokines and may 
explain why NAFLD is an independent risk factor for cardiovascular disease (Byrne et al. 
20099).     
 
NAFLD is often regarded as the hepatic expression of the metabolic syndrome as the 
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liver, consequently to the fat accumulation, develops insulin resistance (Byrne et al. 
20099).  The insulin resistance also implies that increased rates of gluconeogenesis are 
seen in obese individuals with NAFLD, and that gluconeogenesis continues in the 
postprandial period.  This increased hepatic glucose production contributes to the 
hyperglycemia in obese individuals with NAFLD (Byrne et al. 20099). 
 
Collectively, the continuous release of FA and inflammatory cytokines from visceral and 
subcutaneous adipose tissue, and the release of FA, VLDL-TG, inflammatory cytokines 
and glucose from the liver in obese individuals with NAFLD, will lead to a high exposure 
of the skeletal muscle and vascular endothelium to these compounds.  This will promote 
the development of functional, metabolic, and structural impairments in these tissues, 
which will result in the loss of glycemic control and over time lead to the development of 
type II diabetes and cardiovascular disease.  The nature of these impairments and their 
consequences are described in sections 1.2.3 – 1.2.5. 
  
1.2.3 Skeletal muscle: key role in glycemic control and energy balance 
The skeletal muscle plays a key role in glycemic control and energy balance.  The 
importance of skeletal muscle in glycemic control stems from the fact that it is the largest 
tissue for glucose uptake in the body, responsible for 80 % of the glucose disposal 
(Ferrannini  et al. 198529; Defronzo et al. 198530; Nuutila et al. 199431).  With regards to 
energy balance, skeletal muscle not only allows for energy to be expended via exercise, 
but also through the energy-requiring processes of nutrient storage occurring within the 
muscle fibres.   
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 Glucose transport into skeletal muscle fibres primarily occurs through the process of 
facilitated diffusion utilising glucose transporter proteins (GLUTs).  GLUT4 is primarily 
responsible for insulin-mediated glucose uptake in skeletal muscle (Watson and Pessin 
200132).  GLUT4 continually cycles between the cell plasma membrane and intracellular 
compartments and under basal fasting conditions the majority of GLUT4 is located 
within interior membrane vesicles of the muscle fibre (microsomes).  Upon insulin-
stimulation, GLUT4 exocytosis increases dramatically resulting in a large proportion of 
GLUT4 becoming incorporated into the cell surface, allowing entry of glucose into the 
muscle cell (Chang et al. 200433; Thong et al. 200534; Wojtaszewski and Richter 200635).  
In the obese population, however, the elevated circulating FA, TG, and inflammatory 
cytokines originating from the adipose tissue and liver promote the accumulation of FA 
metabolites and activate inflammation within the muscle fibre (Schenk et al. 200836).  
Both the accumulation of FA metabolites and inflammatory cytokines have been shown 
to promote impaired insulin signalling in the muscle fibre.  The mechanisms leading to 
insulin resistance in the muscle fibre are very similar to those operating in the 
microvascular endothelium (described in detail in section 1.3) and involve IRS-1 serine 
phosphorylation and activation of the proinflammatory signalling pathways.  Figure 1.4 
presents a summary of the key muscle fibre functions which are controlled, at least in 
part, by the insulin signalling cascade, and which would thus be affected by insulin 
resistance.   
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Figure 1.4 Skeletal muscle fibre insulin signalling cascade and the key muscle functions controlled, at least 
in part, by insulin signalling.  Insulin resistance in the skeletal muscle fibre will result in impaired insulin 
signalling and bear consequences for glucose uptake, glycogen synthesis, and protein synthesis and 
degradation.  Impaired insulin signalling will reduce glucose uptake by impairing GLUT 4 translocation 
(Wojtaszewski and Richter 200635).  Impaired insulin signalling will reduce glycogen synthesis by limiting 
the phosphorylation and thus inactivation of GSK which will result in active GSK phosphorylating and 
inactivating GS, thereby reducing glycogen synthesis (Wojtaszewski and Richter 200635).  Impaired insulin 
signalling will reduce protein synthesis by limiting the activation of mTOR and thus the activation of 
initiation (4EBP-1) and elongation (p70S6K) factors involved in PS (Jackman and Kandarian 200437; 
Kandarian and Jackman 200638).  Impaired insulin signalling will increase protein degradation as the Foxo 
class of transcription factors will remain unphosphorylated and thus not restricted to the cytoplasm, 
allowing it to travel to the nucleus and promote the expression of the ubiquitin ligases (atrogin-1 and 
MuRF-1) which would induce PD via the ubiquitin proteasome system (Sandri et al. 200439).  
Abbreviations: IR, insulin receptor; IRS-1, insulin receptor substrate 1; PI3K, phosphatidylinositol-3-
kinase; PIP2, phosphatidylinositol-4,5-biphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; PDK-1, 
phosphoinositide-dependent kinase 1;  AS160, Akt substrate of 160 kDa; 4EBP-1, 4E binding protein 1; 
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p70S6K, p70S6 kinase; GSK, glycogen synthase kinase; GS, glycogen synthase; PS, protein synthesis; PD, 
protein degradation; mTOR, mammalian target of rapamycin; Foxo, forkhead box O; MuRF-1, muscle 
ring-finger-1; 
 
 
In the muscle fibre, elevated FA metabolites and inflammatory cytokines will impair 
insulin signalling and subsequently reduce GLUT4 translocation and glucose uptake (Pan 
et al. 199740; Ellis et al. 200041; Itani et al. 200142; Itani et al. 200243; Turinsky et al. 
199044; Straczkowski et al. 200445; Yu et al. 200246; Schenk et al. 200836; Belfort et al. 
200547; Dresner et al. 199948; Griffin et al. 199949; Plomgaard et al. 200550).  In addition 
to reducing GLUT4 translocation, insulin resistance can decrease the glucose uptake 
capacity of the muscle fibre, as the capacity for glucose storage is dependent on muscle 
mass.  Under normal conditions, rises in plasma insulin following meal ingestion 
stimulate the transport of amino acids into skeletal muscle (Hundal et al. 198951) and lead 
to increases in protein synthesis rates and decreases in protein degradation rates 
(Wagenmakers 199952), thereby promoting the maintenance and growth of skeletal 
muscle mass.  In obesity, however, the insulin resistance results in impaired amino acid 
uptake into the muscle fibre, reduced meal-induced increases of protein synthesis, and 
reduced meal-induced suppression of protein degradation and therefore a progressive loss 
of muscle mass (Pereira et al. 200853; Chevalier et al. 200554; Kandarian and Jackman 
200638; Sandri et al. 200439; Wang et al. 200655).  In addition, inactivity will also lead to 
muscle mass loss via reductions in protein synthesis and increases in protein degradation 
(Kandarian 200638; Jackman 200437).  As obese individuals often lead a sedentary 
lifestyle, this may accelerate their loss of muscle mass and lead to a vicious cycle.  The 
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net result is a loss of muscle mass and thus a reduction in glucose storage capacity, 
jeopardizing glycemic control.       
 
Skeletal muscle plays a key role in determining total energy expenditure, which is clearly 
of central importance to energy balance and weight management.  There are three 
components of total energy expenditure: basal metabolic rate, diet-induced thermogenesis 
(DIT), and the energy cost of physical activity (Westerterp 200456). DIT is related to the 
stimulation of energy-requiring processes in the postprandial period, including intestinal 
digestion and absorption, the initial steps of nutrient metabolism, and the storage of the 
absorbed but not yet oxidized nutrients (Tappy 199657).  In skeletal muscle, DIT and 
exercise-induced energy expenditure are of particular importance. In skeletal muscle, 
insulin stimulates mitochondrial respiration (Petersen et al. 200558), increases the uptake 
of glucose and amino acids, and stimulates glycogen and protein synthesis. All these 
processes require energy (ATP) and, therefore, make substantial contributions to DIT in 
lean individuals (Petersen et al. 200558; Wagenmakers 200559).  The insulin resistance in 
the muscle of obese individuals, therefore, seems to make a substantial contribution to the 
well-known reduction in DIT in obese individuals (de Jonge and Bray 199760; Tappy 
199657).  Failure of skeletal muscle to increase its metabolic rate in insulin resistant 
individuals in the postprandial state (Petersen et al. 200558) is clinically highly relevant, 
as it may at least partially contribute to the weight maintenance problems that people with 
insulin resistance experience. When there is a gradual reduction in basal and insulin-
induced energy expenditure at the muscle level during the development of type II 
diabetes, food intake should be reduced in proportion to the lower ATP need of the 
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muscles. Failure to correct for the lower muscle energy requirement will lead to a 
positive energy balance and to further weight gain.  
 
The insulin resistance present in the muscle fibres of the obese also promotes a reduction 
in total daily energy expenditure.  The loss of muscle mass in obesity resulting from the 
insulin resistance will reduce muscle force (Jones and Round 199661) and this will have a 
negative impact on mobility and stability in day to day life  and promote the adoption of a 
more sedentary lifestyle.    
 
The combination of a low muscle mass with a high fat mass will also lead to premature 
fatigue during exercise as the workload per kilogram muscle will be substantially higher 
than in the lean.  Inflammation of skeletal muscle tissue in obese individuals leads to a 
further reduction in exercise capacity.  Inflammatory cytokines, especially high levels as 
occur in obese individuals with NAFLD and liver inflammation, have also been 
associated with strong feelings of fatigue (Byrne et al. 20099).  The cause of the fatigue 
may both involve muscle and central fatigue mechanisms.  In the muscle fibres of dogs, 
inflammatory cytokines have been shown to lead to reductions in the resting membrane 
potential (Tracey et al. 198662), which not only reduces contractility but also leads to 
premature fatigue in endurance exercise (Sejersted and Sjøgaard 200063).  Reductions in 
resting membrane potential of 10-50% (Cunningham et al. 197164) and severe reductions 
in intramuscular potassium concentrations (Gamrin et al. 199765) have also been observed 
in critically-ill intensive care unit patients with high systemic concentration of 
inflammatory cytokines.  Smaller decreases in resting membrane potential and 
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intramuscular potassium will also lead to premature fatigue during exercise (Sejersted 
and Sjøgaard 200063)  and cannot be excluded to occur in patients with obesity and 
NAFLD with liver inflammation.  Systemic levels of inflammatory cytokines also have 
strong associations with a poor self-rated health and subjective feelings of a low fitness 
level and little energy (Unden et al. 200766).  The fatigue experienced by obese patients 
with NAFLD, therefore, may also involve central components.  Independent of whether 
the fatigue involves muscle or central mechanisms, the likely consequence are the 
promotion of the adoption of a sedentary lifestyle which will increase the likelihood of 
further weight gain in obese individuals.   
 
These impairments in skeletal muscles of obese individuals jeopardize glycemic control 
and weight maintenance, and are also exacerbated by the impairments in macrovascular 
and microvascular function (described in section 1.2.4) as rarefaction and reduced 
perfusion will limit the delivery of glucose, amino acids, and insulin to the muscle fibres.   
 
1.2.4 The vasculature: key role in glycemic control and obesity-induced pathology 
The entire vasculature is covered with an endothelial cell layer on the luminal side, 
separating the blood from the vessel wall.  The endothelium is a dynamic tissue that plays 
a central role in vascular function and the maintenance of vascular health.  Its main 
functions include maintenance of blood circulation and fluidity, controlling the 
coagulation and inflammatory responses, and regulating vascular tone (Gonzalez and 
Selwyn 200367). In obesity, the elevated FA and inflammatory cytokines lead to 
endothelial dysfunction.  Initially, endothelial dysfunction leads to loss of glycemic 
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control and an imbalance between vasodilation and vasoconstriction in the fasted resting 
state, after meal ingestion and potentially during exercise, while in the longer term it 
leads to micro- and macrovascular pathology and the development of type II diabetes and 
CVD (Caballero 200368; Jonk et al. 200769; Meyers and Gokce 200717; Muniyappa et al. 
200770; Rask-Madsen and King 200771; Stapleton et al. 20082; Bakker et al. 200916).  
 
1.2.4.1 Macrovasculature: supports microvascular function and glycemic control 
The macrovasculature serves to deliver blood to the organs of the body and distribute the 
cardiac output between the organs (Orasanu and Plutzky 200972; Safar et al. 200873).  In 
this way, the macrovasculature supports microvascular function and plays a role in the 
delivery of glucose to the skeletal muscle for adequate disposal after a carbohydrate-
containing meal.  The function of the macrovasculature in distributing blood, oxygen and 
fuels between different organs and tissues is controlled through the selective, timely 
activation of endothelial vasodilation and vasoconstriction mechanisms in response to the 
metabolic needs of these organs and tissues. 
 
In the macrovasculature, shear stress arising from the interaction between a high blood 
flow and the glycocalyx (glycoproteins attached to the luminal side of endothelial cells) 
that covers the endothelium will stimulate nitric oxide (NO) production and lead to 
vasodilation (Gouverneur et al. 200674; Chatzizisisi et al. 200775).  Similarly, increases in 
insulin that result from meal ingestion or insulin infusion will induce NO production and 
lead to vasodilation (Vincent et al. 200676; Clark et al. 200377; Laakso et al. 199078).  
However, in obese individuals endothelial dysfunction will lead to an imbalance between 
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vasodilation and vasoconstriction leading to net vasoconstriction.  In obese individuals 
there are impairments in both shear stress-induced (Brook et al. 200179; Hamdy et al. 
200380; Meyers and Gokce 200717; Arcaro et al. 199981) and insulin-induced (Laakso et 
al. 199078) NO-dependent vasodilation.  Furthermore, in obese individuals, endothelial 
dysfunction activates several mechanisms that lead to vasoconstriction (Bakker et al. 
200916; Meyers and Gokce 200717) 
  
The endothelial dysfunction observed in the macrovasculature of obese individuals is 
induced by the elevated circulating levels of FA, TG, and inflammatory cytokines 
originating from the adipose tissue and the liver (Bakker et al. 200916; Byrne et al. 20099; 
Sulistio et al. 200882).  Chronic hyperglycemia and hyperinsulinemia, as occurs in more 
severe obesity with impaired glucose tolerance, also contribute to the endothelial 
dysfunction (Bakker et al. 200916).  Furthermore, chronic exposure of endothelial cells to 
high levels of FA, TG, glucose and inflammatory cytokines enhances the production of 
ROS, which further exacerbate endothelial dysfunction and increase the imbalance 
between vasodilation (reduced) and vasoconstriction (enhanced) through a number of 
mechanisms (Orasanu and Plutzky 200972; Bakker et al. 200916; Pacher et al. 200783).  
The imbalance between vasodilation and vasoconstriction is an important cause of 
hypertension. 
 
Long term exposure of the endothelium of the macrovasculature to high systemic levels 
of inflammatory cytokines eventually leads to the expression of adhesion molecules and 
the attachment of leukocytes and macrophages to the endothelium.  This will result in 
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local production of inflammatory cytokines followed by the loss of integrity of the 
endothelial lining, macrophage infiltration, atherosclerosis and vascular smooth muscle 
cell proliferation (Wagenmakers et al. 200684; Meyers and Gokce 200717; Bakker et al. 
200916; Gimbrone et al. 200085). 
 
The presence of atherosclerotic plaques will induce oscillatory blood flow and shear 
stress patterns, which have been shown to further activate vasoconstrictor and 
atherogenic pathways (Chatzizisisi et al. 200775).  Atherosclerosis also leads to an 
increase in  arterial stiffness, as well as further increasing hypertension and the 
development of obesity-related pathology (Kurukulasuriya et al. 200886). 
 
Thus the elevated circulating levels of FA, TG, and inflammatory cytokines occurring in 
obesity will induce endothelial dysfunction in the macrovasculature which will impair its 
ability to support microvascular function and oxygen and substrate delivery to skeletal 
muscle, an effect which will worsen over time with the development of atherosclerosis 
and macrovascular pathology.  
 
1.2.4.2 Microvasculature of skeletal muscle: key role in glycemic control 
The microvasculature controls the delivery of oxygen and nutrients to match the 
metabolic needs of skeletal muscle fibres and support normal tissue function over a wide 
range of energy expenditures (Segal 200587; Orasanu and Plutzky 200972).  It is the 
endothelium of the microvasculature that plays a central role in regulating the recruitment 
or opening of previously under-perfused or non-perfused capillaries that surround the 
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skeletal muscle fibres, particularly during exercise and in the postprandial state (Segal 
200587).  During exercise, adenosine and potassium released from the contracting muscle 
fibres are the major players dilating terminal arterioles (Hudlicka 198588; van Teefelen 
200689; Clifford and Hellsten 200490). Opening of the muscle capillary bed together with 
the increase in cardiac output will lead to an increase in blood flow and shear stress and, 
therefore, lead to shear stress induced NO-dependent vasodilation of feeding and 
resistance arteries and potentially the larger arterioles (Clifford and Hellsten 200490; 
Kooijman 200891).  A careful interplay between these mechanisms ensures that perfusion 
of the capillaries surrounding skeletal muscle fibres exactly matches the fuel and oxygen 
demands of each skeletal muscle fibre.  After meal ingestion, insulin stimulates NO-
mediated vasodilation of terminal arterioles to increase skeletal muscle perfusion and 
allow the delivery of insulin, glucose, and amino acids to the muscle fibres for clearance 
(Rattigan et al. 200692; Vincent et al. 200676; Muniyappa and Gokce 200770).    
 
In obesity, however, there appears to be a general impairment in endothelial function of 
both the macrovasculature and the microvasculature (Jonk et al. 200769).  The elevated 
levels of circulating FA and inflammatory cytokines have been shown to impair 
activation of endothelial nitric oxide synthase (eNOS) and thus reduce NO production 
and NO-dependent vasodilation (Kim et al. 200593; Rattigan et al. 200692; Muniyappa and 
Gokce 200770).  Indeed, in response to increases in insulin, resulting from insulin infusion 
and meal ingestion, a marked impairment has been observed in muscle microvascular 
recruitment in obese individuals (Clerk et al. 200694; de Jongh et al. 200495; Laakso et al. 
199078; Keske et al. 200996).  The high concentration of insulin that prevails in obese 
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humans has also been shown to activate a vasoconstriction pathway, thereby potentially 
leading to net postprandial vasoconstriction and reduced perfusion of the 
microvasculature in skeletal muscle (Eringa et al. 200497).  Whether a significant 
limitation exists in the exercise-induced dilation and increase in blood flow of the muscle 
microvasculature is currently not known, but such limitations do exist in the muscle of 
patients with type II diabetes (Womack et al. 200998). 
 
Microvascular perfusion relies on the balance between vasodilation and vasoconstriction, 
and their response to various stimuli.  In obesity, it appears that this balance is lost, with a 
net shift towards vasoconstriction (Bakker et al. 200916) and a reduction in microvascular 
perfusion under basal and/or stimulated conditions.  Reduced skeletal muscle perfusion 
has been observed in the fasted resting state in obese mice and obese Zucker rats (Wallis 
et al. 200299; Frisbee 2007100), and has been proposed to occur in humans with 
hypertension and the metabolic syndrome (Lind and Lithell 1993101).  A multitude of 
mechanisms are involved in creating this shift in vasoregulation and will be described in 
detail in section 1.3.  Also contributing to impaired skeletal muscle microvascular 
function are structural impairments of the microvasculature.  Reduced capillary density 
(rarefaction) has been observed in the skeletal muscle of obese rats (Frisbee 2007100) and 
human individuals (Gavin et al. 2005102), and are likely to contribute to reductions in 
perfusion.  In addition, the early imbalance between vasodilation and vasoconstriction 
can lead to functional rarefaction and may limit skeletal muscle perfusion.  
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Thus the metabolic and structural impairments in the obese skeletal muscle 
microvasculature will hinder its normal function, thereby reducing the delivery of fuel 
and oxygen during exercise, and of insulin and glucose in the postprandial state.  This 
will exacerbate the impairments of the obese skeletal muscle fibre and accelerate the loss 
of glycemic control, promoting the development of type II diabetes and CVD.   
 
1.2.5 Loss of glycemic control   
The increased adiposity of the obese causes functional impairments in various tissues 
with an array of consequences, but a key consequence is the loss of glycemic control.  
Although the subsequent hyperglycemia bathes all cells of every tissue, it is the tissues 
which are unable to reduce glucose uptake in the face of elevated glucose levels which 
incur damage from the excessive glucose concentrations within the cells (Brownlee 
2005103).  The endothelium is one such tissue, and the loss of glycemic control in obese 
but otherwise healthy individuals is of particular importance because the hyperglycemia 
can exacerbate the vascular dysfunction which is conducive to a state of chronic 
hyperglycemia.  Chronic hyperglycemia is also seen as a cause of local inflammation and 
enhances the progression of obesity-related pathology, in particular type II diabetes and 
CVD.   
 
The loss of glycemic control impairs both the function of  skeletal muscle fibres and their 
microvasculature (Muniyappa et al. 200770).  This then leads to a vicious cycle as chronic 
hyperglycemia and hyperinsulinemia further exacerbate the insulin resistance of skeletal 
muscle fibres, and the endothelial dysfunction and insulin resistance of the vasculature, 
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thereby further jeopardizing glycemic control.  Endothelial dysfunction is considered to 
be the earliest marker of impaired vascular health (Meyers and Gokce 200717, Potenza 
and Montagnani 2008104; Kim et al. 2008105), yet it is reciprocally interconnected to 
vascular insulin resistance in the promotion of impaired vascular function and 
hyperglycemia (Figure 1.5; Muniyappa et al. 200770).     
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Figure 1.5 The vicious cycle between hyperglycemia and endothelial dysfunction.  Abbreviations: NO, 
nitric oxide; ROS, reactive oxygen species; ONOO-, peroxynitrite; ET-1, endothelin-1. 
 
 
Glycemic control is commonly assessed by an oral glucose tolerance test (OGTT).  
Despite obesity, some individuals display normal glycemic control during an OGTT, 
which would seem incongruous with the evident excess adiposity.  There are, however, 
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various explanations for this observation in some obese individuals.  Firstly, 
compensatory mechanisms, such as increased pancreatic insulin production (Muniyappa 
et al. 200770) may still be present and sufficient to overcome the insulin resistance and 
promote glucose clearance.  Secondly, in individuals who have only recently gained the 
excess adiposity, the impairments may still be developing and compensatory mechanisms 
may still effectively promote glucose clearance.  Thirdly, lower body adiposity tends to 
involve less macrophage infiltration and less adipokine production than upper body / 
visceral adiposity (Jensen 200823; Shoelson et al. 200619), and would therefore induce a 
less severe glucose intolerance.    
 
Thus the rate of development of chronic hyperglycemia and the related pathologies will 
depend on various factors, however unless action is taken to address the underlying 
vascular and skeletal muscle fibre impairments, the development will continue and type 
II diabetes and CVD will eventually follow.  It is of particular importance to correct 
glucose intolerance before the development of chronic hyperglycemia, because reducing 
elevated glucose levels appears to only limit but not prevent microvascular disease 
progression, while having little effect on improving macrovascular disease progression 
(Johansen et al. 2005106; Orasanu and Plutzky 200972).  
 
 
1.3 The mechanisms that lead to functional, metabolic, and structural 
impairments in the skeletal muscle microvasculature 
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Impairments in skeletal muscle microvascular perfusion have been identified in obese 
individuals and contribute significantly to reduced glucose clearance (Muniyappa et al. 
200770; Clerk et al. 200694; Keske at al. 200996).  The impaired perfusion appears to stem 
from rarefaction as well as an imbalance between vasodilation and vasoconstriction 
mechanisms.  The biochemical mechanisms leading to decreased vasodilation and 
increased vasoconstriction involve the normal and MAPK-dependant insulin signalling 
cascade in the microvascular endothelium, activation of enzymes producing superoxide 
anions and scavenging NO, increased peroxynitrite production, and increased 
sympathetic nerve activity leading to contraction of the vascular smooth muscle cells that 
surround the arterioles. 
 
1.3.1 Insulin signalling cascades 
Within the vasculature, insulin can activate two distinct signalling pathways, namely the 
PI3K-dependent pathway and MAPK-dependent pathway.  The PI3K-dependent pathway 
in the vasculature shares striking similarities with that in the skeletal muscle fibre 
(Jansson 2007107; Muniyappa et al. 200770) and is responsible for endothelial nitric oxide 
synthase (eNOS) activation and NO production, inducing vasodilation.  The binding of 
insulin to the insulin receptor on the endothelium leads to tyrosine phosphorylation of the 
insulin receptor substrate-1 (IRS-1) which then binds to and activates 
phosphatidylinositol-3-kinase (PI3K).  This induces the conversion of 
phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate 
(PIP3) which subsequently activates phosphoinositide-dependent kinase 1 (PDK-1).  
PDK-1 phosphorylates and activates Akt which directly phosphorylates and activates 
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eNOS for NO production (Muniyappa et al. 200770; Figure 1.6).  On the other hand, the 
MAPK-dependent pathway is responsible for endothelin-1 (ET-1) production, inducing 
vasoconstriction (Muniyappa et al. 200770; Jansson 2007107; Bakker et al. 200916).  
Insulin activates this pathway also via the insulin receptor substrate but possibly via IRS-
2 rather than IRS-1, which then activates Ras, subsequently inducing a phosphorylation 
cascade involving Raf, the kinases of mitogen activated protein kinase/extracellular 
signal-regulated kinase (MAPKK/ERKK), and MAPK/ERK, ending with ET-1 
production (Muniyappa et al. 200770; Bakker et al. 200916; Eringa et al. 200497; Figure 
1.6).  Furthermore, in addition to activating ET-1 production, insulin activation of the 
MAPK-dependent signalling pathway also stimulates vascular cell adhesion molecule 
(VCAM-1) and E-selectin expression (Muniyappa et al. 200770; Jansson 2007107), both of 
which contribute to the development of a pro-atherogenic environment and thus promote 
vascular dysfunction. 
 
These two vascular insulin signalling pathways have been shown to interact, with the 
phosphorylated active form of Akt in the PI3K-dependent pathway appearing to suppress 
the MAPK-dependent pathway (Reusch et al. 2001108; Muniyappa et al. 200770).  Thus 
under healthy conditions, insulin will stimulate the PI3K-dependent pathway resulting in 
NO production and, in the process, the activation of Akt will suppress the MAPK-
dependent pathway and prevent ET-1 production.  In this way, insulin would promote a 
vasodilation response.  Indeed, insulin has been shown to recruit and rapidly increase 
blood flow in human skeletal muscle capillaries (Rattigan et al. 200692; Jansson 2007107; 
Barrett et al. 2009109).   
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 In obesity, however, the insulin resistance is characterized by a pathway specific 
impairment:  only the PI3K-dependent pathway is impaired while the MAPK-dependent 
pathway remains intact (Muniyappa et al. 200770; Eringa et al. 200497; Jansson 2007107; 
Bakker et al. 200916; Jiang et al. 1999110).  As hyperinsulinemia is commonly associated 
with insulin resistance, it will lead to excessive activation of the MAPK-dependent 
signalling pathway, and lead to a shift in balance from the vasodilator actions of insulin 
towards the vasoconstrictor actions of insulin (Muniyappa et al. 200770; Jansson 2007107). 
This  has been demonstrated in obese humans (Mather et al. 2002111) and in the skeletal 
muscle arterioles of obese rats (Eringa et al. 2007112).   
 
Thus, an imbalance between insulin-mediated vasodilation and vasoconstriction is 
created through impairments of the PI3K-dependent insulin signalling pathway to reduce 
NO and promote ET-1 production.  Fatty acids have been found to play a central role in 
impairing the endothelial PI3K-dependent pathway and promoting endothelial 
dysfunction, while hyperglycemia, TNFα, and angiotensin II have also been found to 
contribute (Muniyappa et al. 200770).  As the microvascular effects of insulin have been 
suggested to account for 50 % of insulin-mediated glucose clearance (Muniyappa et al. 
200770), understanding the biochemical basis of this impaired vascular function and 
identifying ways in which perfusion may be increased to improve glucose clearance, are 
of clear importance to halt the escalation of impaired glycemic control.   
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Figure 1.6 Vascular insulin signalling.  Abbreviations: IR, insulin receptor; IRS, insulin receptor substrate; 
MAPKK, mitogen-activated protein kinase kinase; ERKK, extracellular signal-regulated kinase kinase; 
MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; ET-1, endothelin-1; 
PI3K, phosphatidylinositol-3-kinase; PIP2, phosphatidylinositol-4,5-biphosphate; PIP3, 
phosphatidylinositol-3,4,5-triphosphate; PDK-1, phosphoinositide-dependent kinase 1; eNOS, endothelial 
nitric oxide synthase; NO, nitric oxide. 
 
 
1.3.2 The fatty acid effect 
Infusion of intralipid-heparin mixtures leading to substantial increases in plasma FA 
concentrations impairs insulin-mediated capillary recruitment and glucose uptake in 
humans and rats (Clerk et al. 2002113; de Jongh et al. 2004114; Liu et al. 2009115).  The 
important role of high plasma FA concentrations in impairing microvascular function is 
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also supported by the improvement in capillary recruitment observed in obese women 
after overnight lowering of plasma FA with Acipimox ingestion (de Jongh et al. 2004114).     
 
FAs play a central role in impairing skeletal muscle microvascular function principally 
through the impairment of the PI3K-dependent insulin signalling cascade.  In addition, 
FA can also increase the production of ROS, which can decrease NO bioavailability via 
NO quenching, thereby further impairing the vasodilatory effect of insulin.  Furthermore 
the peroxynitrite produced in the reaction of NO with superoxide anions (O2-), will 
promote an array of effects which will induce an imbalance between vasodilation and 
vasoconstriction and thus jeopardise skeletal muscle perfusion and glycemic control.  The 
loss of NO not only impairs vascular function through reduced vasodilation, but also 
through the loss of its vasoprotective effects including anti-atherogenic and anti-
proliferative properties and inhibition of leukocyte and platelet adhesion to the vascular 
wall (Johansen et al. 2005106).  Therefore NO production and bioavailability is of central 
importance to vascular function.   
 
1.3.2.1 FA in obesity  
FAs are stored in adipose tissue as TG and can be released into the circulation via 
lipolysis of the TG by the enzyme HSL (Arner 1999116).  In healthy individuals, insulin 
will inhibit HSL activity thereby reducing the efflux of FA from the adipose tissue stores 
in the postprandial period (Arner 1999116; Kamagate and Dong 2008117).  Obesity, 
however, is characterised by increased adiposity and insulin resistance.  The ability of 
insulin to suppress lipolysis in adipose tissue is reduced in insulin resistance (Jansson 
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2007107; Yesilova et al. 2005118; Baldeweg et al. 2000119).  Thus it would seem logical 
that in obese insulin resistant states, a greater efflux of FA from the adipose tissue would 
occur, resulting in elevated blood FA concentrations.  Indeed, there is evidence depicting 
that increased FA is released into the circulation because regulation of lipolysis becomes 
resistant to insulin (Baldeweg et al. 2000119), and numerous studies show elevated FA 
levels in obesity (Bickerton et al. 2008120; Jensen et al. 1989121; Hennes et al. 1996122; de 
Jongh et al. 200495; Coppack et al. 1992123; Hickner et al. 1999124).  Nevertheless, this 
finding is not universal.   
 
For example, Reeds et al. (2006)125 found that even extremely obese people had normal 
circulating FA concentrations.  This could potentially be explained by the very high 
fasting insulin concentrations observed in these participants, sufficient in normalizing the 
plasma FA levels.  It has also been observed that the elevations in plasma FA are not 
directly proportional to the excess fat mass (Bickerton et al. 2008120) which may result 
from variations of lipolysis in different fat depots.  Thus the lack of universality of 
plasma FA concentrations in obesity may be partly explained by the apparent influence of 
fat distribution on FA release.  Subcutaneous abdominal fat appears to be the major depot 
contributing to systemic FA concentrations (Bickerton et al. 2008120).  Indeed, individuals 
with abdominal obesity tend to have higher circulating levels of FA than individuals with 
lower body fat distribution despite a comparable BMI (Guo et al. 1999126).  In 
hyperinsulinaemia, adipose tissue lipolysis is greater in upper body obesity compared 
with lower body obesity or lean controls (Jensen 200823) such that plasma FA 
concentrations are three fold higher in upper body obese than in lower body obese 
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(Jensen 200823).  This would imply a resistance to the antilipolytic effects of insulin on 
adipocytes in upper body obesity (Jensen 200823). 
 
It is also worth noting that FA concentrations would be affected not only by the release of 
FA from adipose, but also by the uptake of FA in various tissues.  Impaired FA uptake by 
skeletal muscle has been demonstrated in obesity (Colberg et al. 1995127) and may 
contribute to elevated FA concentrations.   
 
While FA concentrations in obesity appear equivocal, elevated triacylglycerol (TG) 
levels are often associated with visceral obesity as well as insulin resistance (Kamagate 
and Dong 2008117).  Bickerton et al. (2008)120 found FA concentrations did not differ 
between obese and control groups, while levels of TG were significantly higher in the 
obese group.  Indeed, hypertriglyceridaemia has been shown to result from an increase in 
hepatic TG release in insulin resistant states (Baldeweg et al. 2000119; Kamagate and 
Dong 2008117) with possible contributions from reduced TG clearance via impaired LPL 
(Baldeweg et al. 2000119).   
 
FAs are substrates for TG synthesis in the liver (Arner 1999116).  Increased FA delivery to 
the liver will, in conjunction with the hepatic production of apolipoprotein B100 
(ApoB100; Kamagate and Dong 2008117), stimulate the production of TG (Arner 
1999116), resulting in elevated VLDL-TG secretion from the liver into the circulation 
(Arner 1999116; Bradbury 2006128; Yesilova et al. 2005118).  The secretion of VLDL-TG 
from the liver is tightly controlled by insulin in both a direct and indirect fashion 
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(Kamagate and Dong 2008117).  The direct mechanism has yet to be fully elucidated, 
however it seems to involve insulin directly inhibiting ApoB production and secretion in 
the liver (Lewis et al. 1995129; Alexander et al. 1976130; Taghibiglou et al. 2000131).  
Indirectly, insulin dictates liver VLDL-TG production via controlling the release of its 
substrate, FA, through HSL inhibition in adipose tissue (den Boer et al. 2006132).  
Although, originally, the latter mechanism was thought to be the only way in which 
insulin influenced VLDL-TG production, the inhibition of VLDL-TG production by 
insulin was only partly accounted for by the suppression of FA release from the adipose 
tissue (den Boer et al. 2006132; Baldeweg et al. 2000119), revealing the presence of 
additional ways by which insulin controls liver VLDL-TG production.  Thus, for normal 
healthy individuals, in the fasting state when insulin concentrations are low, VLDL-TG 
release from the liver is increased, while the release is suppressed in the postprandial 
state when insulin concentrations are high (Kamagate and Dong 2008117).   
 
In obese and insulin resistant individuals however, a reduced ability of insulin to suppress 
the release of VLDL-TG from the liver has been observed (Kamagate and Dong 2008117; 
Yesilova et al. 2005118).  More specifically, Lewis et al. (1996)133 found that chronically 
insulin resistant hyperinsulinaemic obese individuals were resistant to the suppressive 
effect of insulin on VLDL ApoB, thereby allowing for VLDL-TG synthesis and 
increased efflux from the liver despite the presence of insulin.   
 
Furthermore, in the obese states where FA levels are elevated, the increased delivery of 
FA to the liver would provide extra substrate for TG synthesis thereby contributing to the 
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VLDL-TG production and release (Lewis et al. 1995129).  It is also possible that despite 
reports of normal plasma FA concentrations in obesity, individuals with visceral obesity 
still supply the liver with excess FA.  This is because visceral fat is the only deposit 
directly connected to the liver by the portal vein (Arner 1999116; Jensen 200823).  Thus it 
is possible that in visceral obesity, a high efflux of FA from this adipose tissue store 
directly supplies the liver with excess FA for increased VLDL-TG synthesis and release 
while the systemic circulation displays normal FA concentrations. 
 
In addition to increased liver VLDL-TG production in obesity, impairments of TG 
clearance into adipose tissue may contribute to the hypertriglyceridaemia as adipose 
tissue is the major site for TG-rich lipoprotein clearance (Jensen 200823).  There is some 
evidence indicating a reduction in VLDL-TG clearance across the abdominal 
subcutaneous adipose tissue in obese humans due to impaired LPL activity despite 
yperinsulinaemia (Coppack et al. 1992123; Knudsen et al. 1995134).    h
 
The clearance of TG from the circulation involves hydrolysis of the TG from the 
lipoproteins and subsequent uptake of the resulting FA into the surrounding tissue.  LPL 
is the rate-limiting enzyme in the hydrolysis of TG lipoproteins and it is expressed in the 
capillaries of adipose tissue, skeletal and cardiac muscle, and the mammary gland 
(Fielding 1998135).  LPL is located on the luminal side of the endothelium in the vascular 
space bound to the endothelium (Fielding 1998135).  In this way, the TG from the 
lipoprotein particles passing through the capillaries with endothelium-bound LPL will be 
hydrolysed and the resulting FA taken up and either stored or oxidized, depending on the 
tissue and nutritional state (Fielding 1998135; Oram and Bornfeldt 2004136).       
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 Although LPL is encoded by the same gene, it is expressed to different extents in 
different tissues and its activity too is regulated in a tissue-specific manner.  LPL is an 
insulin-sensitive enzyme.  In normal conditions, LPL is active in the adipose tissue 
during the fed state when insulin levels are elevated and suppressed during fasting when 
insulin levels are low, whereas the reverse is true in muscle (Fielding 1998135).   In 
insulin resistance, however, elevated insulin levels would not stimulate the hydrolysis 
and uptake of the TG into adipose tissue, contributing to elevated circulating TG levels.  
Furthermore, in the skeletal muscle microcirculation, insulin would not effectively 
suppress the hydrolysis of TG into FA for uptake.  Therefore, in hyperinsulinaemia, the 
elevated circulating TG could theoretically result in elevated local FA concentrations 
with in skeletal and cardiac muscle microvasculature despite potentially normal systemic 
FA concentrations.  Such local elevations in FA can affect the microvascular perfusion of 
the skeletal muscle in the obese through manipulation of vasodilation and 
vasoconstriction.   
 
Elevated plasma FA can directly affect vasodilation and vasoconstriction mechanisms of 
the skeletal muscle microcirculation in three ways: i) promote serine phosphorylation of 
IRS-1, ii) activate nuclear factor κB (NFκB), and iii) promote O2- production.  The latter 
will increase peroxynitrite formation which can affect vasodilation and vasoconstriction 
via several mechanisms which are described below. 
 
1.3.2.2 IRS-1 serine phosphorylation 
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FAs have been shown to reduce insulin-stimulated eNOS activity and NO production via 
impairments in the activation of PI3K, PDK-1, Akt, and eNOS (Muniyappa et al. 200770).  
The impaired activation of these signalling intermediates originates from the serine 
phosphorylation of IRS-1.  Under normal healthy conditions, IRS-1 is phosphorylated on 
the tyrosine residue, allowing it to subsequently bind to and activate PI3K.   The 
phosphorylation of IRS-1 on the serine residue impairs tyrosine phosphorylation 
(Shoelson et al. 200619) and the subsequent binding of IRS-1 to PI3K, thereby halting 
downstream activation of the signalling pathway.   
 
Elevated FA concentrations result in elevated cellular concentrations of lipid metabolites, 
namely diacylglycerol (DAG), ceramide, and long-chain fatty acyl coenzyme A (LCFA-
CoA; Muniyappa et al. 200770).  These metabolites have been found to activate serine 
kinases such as protein kinase C (PKC; Bruce et al. 2006137; Itani et al. 200243; 
Muniyappa et al. 200770), c-Jun NH2-terminal kinase (JNK; Hirosumi et al. 2002138; 
Rizzo et al. 1999139; Shoelson et al. 200619; Shoelson et al. 200710; Muniyappa et al. 
200770), and inhibitory κB kinase (IKKB; Sriwijitkamol et al. 2006140; Kim et al. 200593; 
Shoelson et al. 200710; Evans et al. 2002141; Kuroki et al. 1998142; Muniyappa et al. 
200770).  Activation of PKC has been implicated in promoting the serine phosphorylation 
of IRS-1 and reduced insulin-mediated activation of Akt and eNOS (Muniyappa et al. 
200770; Bakker et al. 200916; Serne et al. 2006143; Kim et al. 2006144).  Likewise, 
activation of JNK has been found to increase IRS-1 serine phosphorylation and 
subsequently decrease insulin-mediated NO production in endothelial cells (Kim et al. 
2005145; Shoelson et al. 200619; Shoelson et al. 200710; Aguirre et al. 2000146; Bakker et 
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al. 200916).  IKKB has also been implicated in promoting serine phosphorylation of IRS-
1 both directly and via NFκB activation (Kim et al. 2001147; Itani et al. 200243; Gao et al. 
2002148; Kim et al. 2005145; Shoelson et al. 200619).  PKC appears to be involved in the 
activation of IKK and JNK (Shoelson et al. 200710; Shoelson et al. 200619)  and may 
therefore exert its phosphorylation effects on IRS-1 via IKK and JNK rather than directly, 
however this has yet to be fully elucidated.   
 
Serine phosphorylation of IRS-1 will inactivate IRS-1 and prevent downstream activation 
of the insulin signalling cascade and thus insulin-stimulated NO production.  The 
impaired Akt activation will relieve the suppression of the MAPK-dependent pathway, 
enhancing ET-1 production and promoting an imbalance between vasodilation and 
vasoconstriction, leading to net vasconstriction (Figure 1.7).   
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Figure 1.7 Effect of an increased fatty acid (FA) load on the skeletal muscle microvascular endothelium.  
Abbreviations: DAG, diacylglycerol; PKC, protein kinase C; JNK, c-Jun NH2-terminal kinase; IKK, 
inhibitor κB kinase; TNFα, tumor necrosis factor alpha; IRS-1, insulin receptor substrate 1; PI3K, 
phosphatidylinositol-3-kinase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; NFκB, nuclear 
factor κB; IκB, inhibitor κB. 
 
 
1.3.2.3 NFκB activation 
NFκB is a crucial transcription factor involved in inflammation and antiapoptopic 
signalling.  It has been found to play a role in the development of lipid-induced insulin 
resistance (Staiger et al. 2006149; Artwohl et al. 2004150; Evans et al. 2002141; Schenk et 
al. 200836).  NFκB is normally found in its inactive form, bound to inhibitor κB (IκB), in 
the cytoplasm.  Its activation requires the phosphorylation and subsequent degradation of 
IκB so that NFκB is free to move into the nucleus to exert its effects (Pacher et al. 
200783; Shoelson et al. 200619).  FAs activate NFκB via activation of IKK, probably via 
PKC (Sriwijitkamol et al. 2006140; Staiger et al. 2006149; Evans et al. 2002141; Muniyappa 
et al. 200770).  The activated IKK will phosphorylate IκB, thereby releasing NFκB 
(Pacher et al. 200783; Sriwijitkamol et al. 2006140).   
 
NFκB can indirectly contribute to impaired insulin-mediated vasodilation by increasing 
the expression and synthesis of TNFα (Sriwijitkamol et al. 2006140; Shoelson et al. 
200710; Barnes and Karin 1997151).  TNFα can stimulate IKK and JNK activation (de 
Alvaro et al. 2004152; Bakker et al. 200916; Muniyappa et al. 200770), thereby inducing 
IRS-1 serine phosphorylation and impeding the progression of the signalling pathway for 
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NO production, as well as further promoting NFκB activation in a self-sustaining cycle 
(Luberto et al. 2000153; Shoelson et al. 200619; Figure 1.7).   
 
Furthermore, activation of NFκB can impair microvascular function via the promotion of 
vascular inflammation and atherosclerosis.  NFκB can activate numerous genes involved 
in inflammation, including vascular cell adhesion molecule (VCAM), inter-cellular 
adhesion molecule-1 (ICAM-1), and E-selectin, which promote the influx of 
macrophages and monocytes to the arterial wall, inducing ROS production and 
atherosclerosis (Bakker et al. 200916; Shoelson et al. 200619; Shoelson et al. 200710; 
Jansson 2007107).   
 
1.3.2.4 FA-induced elevations in ROS 
FAs have been shown to induce ROS production in the vasculature via mitochondrial 
uncoupling (Du et al. 2006154; Evans et al. 2002141; Muniyappa et al. 200770) and by 
increasing the expression and protein content of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (Brandes and Kreuzer 2005155; Inoguchi et al. 2000156; 
Wagenmakers et al. 200684; Muniyappa et al. 200770; Bakker et al. 200916).  FAs induce 
mitochondrial ROS production by providing electron donors to the mitochondrial 
electron transport chain (Du et al. 2006154).  PKC activation by FAs can activate NADPH 
oxidase leading to the production of superoxide anions (O2-; the most reactive form of 
ROS) in endothelial cells (Muniyappa et al. 200770).  The increased generation of ROS, 
in turn, decreases the concentration of intracellular glutathione, an important endogenous 
antioxidant (Evans et al. 2002141), and makes the vasculature more prone to suffer from 
oxidative damage and develop pathology.  
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 Elevated ROS levels impair microvascular function in a number of ways.  FA-induced 
ROS production activates NFκB, which further stimulates pro-inflammatory cytokine 
production (Muniyappa et al. 200770; Itani et al. 200243; Bakker et al. 200916) and impairs 
microvascular function as discussed above.  FA-induced ROS production can also 
activate the hexosamine biosynthetic pathway and increase the formation of advanced 
glycation end-products (AGEs; Muniyappa et al. 200770), both of which may contribute 
to impaired PI3K-dependent signalling pathway (Muniyappa et al. 200770).  This will be 
discussed in section 1.3.3.1.  Furthermore, superoxide anions can impair insulin’s 
vasoactive effects by reducing NO bioavailability.  Superoxide anions have a high 
affinity for NO and in the reaction between the two, peroxynitrite is produced (Pacher et 
al. 200783).  Peroxynitrite can impair microvascular function via several mechanisms as 
explained in the next section.    
 
1.3.2.5 Peroxynitrite formation  
The reaction of NO with O2- leads to peroxynitrite formation (Pacher et al. 200783), and 
despite its short half-life (10 – 20 ms), peroxynitrite (ONOO-) has been suggested to be 
able to cross biological membranes, diffuse one or two cell diameters, and react with 
several reactive biomolecules to exert its effects (Pacher et al. 200783).  Elevated levels of 
ONOO- have been suggested to impair microvascular function via (i) reduced activation 
of guanylate cyclase, (ii) antagonism of calcium-activated and voltage-gated potassium 
channels, (iii) prostaglandin I2 synthase inhibition, (iv) eNOS uncoupling, and (v) Akt 
inhibition (Figure 1.8).   
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Figure 1.8 The effect of peroxynitrite (ONOO-) on mechanisms controlling vasodilation and 
vasoconstriction.  Abbreviations: eNOS, endothelial nitric oxide synthase; NO, nitric oxide; O2-, superoxide 
anion; AA, arachidonic acid; PGH2, prostaglandin H2; PGIS, prostaglandin I2 synthase; PGI2, prostaglandin 
I2; ThA2, thromboxane A2; BH4, tetrahydrobiopterin; cAMP, cyclic adenosine monophosphate; Ca2+, 
calcium ion; K+, potassium ion; SMC, smooth muscle cell.    
 
 
Reduced activation of guanylate cyclase 
In the vasculature, most of the bioavailable NO is generated in the endothelium 
(Muniyappa et al. 200770).  Under normal conditions, NO diffuses into the vascular 
smooth muscle cells (VSMC) where it activates guanylate cyclase to increase cyclic 
adenosine monophosphate (cAMP) levels and evoke vasorelaxation (Pacher et al. 
200783).  However, in insulin resistance, the reduced NO bioavailability will limit 
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guanylate cyclase activation.   Although ONOO- can activate guanylate cyclase in vitro, it 
is only a weak activator, thus reducing the vasodilation response in comparison to that of 
NO (Zou et al. 2002157; Liu et al. 2002158).   
 
Antagonism of calcium-activated and voltage-gated potassium channels 
In the VSMC of coronary arterioles, peroxynitrite has been shown to antagonise calcium-
activated potassium channels partly through nitration of tyrosine residues in channel 
proteins (Bubolz et al. 2007159).  This would inhibit membrane hyperpolarisation in the 
presence of calcium, reducing the relaxation ability of VSMCs, and thereby reducing the 
vasodilation potential (Liu and Gutterman 2002160; Brzezinska et al. 2000161; Benham et 
al. 1986162).  It seems ONOO- may also inhibit voltage-gated potassium channels in 
VSMC (Bubolz et al. 2007159; Li et al. 2004163) which will decrease potassium efflux, 
resulting in the depolarization of the VSMC.  This in turn opens the voltage-sensitive 
calcium channels causing an increase in intracellular calcium and subsequent 
vasoconstriction (Michelakis 2002164).  Whether this impaired vasodilation and increased 
vasoconstriction effect occurs in skeletal muscle arterioles is yet to be determined, but it 
may be one of the ways in which ONOO- impairs vasoregulation in the skeletal muscle 
microvasculature.   
 
Prostaglandin I2 synthase inhibition 
Peroxynitrite has been found to inhibit prostaglandin I2 synthase (PGIS) through tyrosine 
nitration (Pacher et al. 200783; Zou et al. 2004165; Cai et al. 2004166).  This will reduce the 
production of PGI2 (also known as prostacyclin), a potent vasodilator, resulting in 
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reduced vasodilation (Zou et al. 2002157; Pacher et al. 200783).  Furthermore, inhibition of 
PGIS will result in the accumulation of prostaglandin H2 (PGH2), the precursor of PGI2.  
This will increase thromboxane (Th) A2/PGH2 receptor activation causing the 
mobilisation of cytoplasmic calcium and subsequent vasoconstriction (Zou et al. 2002157; 
Zou et al. 2004165; Kent et al. 1993167; Romero and Reckelhoff 1999168).   
 
eNOS uncoupling 
NO is produced by the eNOS dimer via a sequence of tightly coupled reactions requiring 
several cofactors (Bakker et al. 200916).  During NO production, the eNOS dimer is 
stabilised by tetrahydrobiopterin (BH4) (Bakker et al. 200916).  The term ‘eNOS 
uncoupling’ describes the loss of structural interaction between BH4 and eNOS, resulting 
in the production of O2- instead of NO as eNOS will transfer its electrons to molecular 
oxygen rather than to L-arginine (Jasson 2007107; Nickenig and Harrison 2002169).  When 
cofactor or substrate concentrations are low, eNOS may become uncoupled (Jansson 
2007107).  There appear to be two ways in which ONOO- may evoke eNOS uncoupling.  
Firstly, ONOO- is a potent oxidiser of BH4 (Landmesser et al. 2003170; Pacher et al. 
200783; Muniyappa et al. 200770), thus the formation of ONOO- will deplete the cofactor 
(Paravicini and Touyz 2006171; Pacher et al. 200783).  Secondly, it seems ONOO- may 
attack the zinc-thiolate core of eNOS directly to cause enzymatic uncoupling of eNOS, 
thereby reducing NO production and thus decreasing dilation (Zou et al. 2002A172; Zou et 
al. 2004165; Pacher et al. 200783).     
 
Akt inhibition 
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Akt is involved in the activation of eNOS leading to NO production.  ONOO- has been 
found to inhibit Akt (Pacher et al. 200783) which would reduce NO production thereby 
decreasing the vasodilation potential.  Inhibition of Akt will also relieve the suppression 
of the MAPK-dependent pathway of insulin, thereby allowing for ET-1 production and 
subsequent constriction (Reusch et al. 2001108; Gratton et al. 2001173; Federici et al. 
2002174).    
 
1.3.3 Other factors playing a role in impairing vasoregulation 
1.3.3.1 Hyperglycemia 
Hyperglycemia can lead to both a decrease in vasodilation and an increase in 
vasoconstriction, which it accomplishes via several mechanisms.  The most important 
mechanisms are summarised below and appear to stem from the same primary source of 
increased mitochondrial superoxide anion production in endothelial cells (Brownlee 
2001175; Brownlee 2005103; Nishikawa et al. 2000176; Du et al. 2000177).   
 
Increased mitochondrial O2- production leads to reduced vasodilation and increased 
vasoconstriction as it has been show to act as a primer for other sources of O2- 
production.  There are several ways in which this might occur, including (i) activation of 
NADPH oxidase, (ii) eNOS uncoupling, (iii) increased flux through the hexosamine 
pathway, and (iv) increased production of advanced glycation end-products (AGE; Figure 
1.9; Brownlee 2005103; Johansen et al. 2005106; Maritim et al. 2003178; Ceriello 2003179; 
Pacher et al. 200783; Bakker et al. 200916; Muniyappa et al. 200770; Orasanu and Plutzky 
200972).  Additionally, mitochondrial O2- production stimulates increased glucose 
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metabolism through the polyol pathway.  This indirectly contributes to increased O2- by 
promoting AGE formation and by decreasing the intracellular concentrations of reduced 
glutathione, an antioxidant (Brownlee 2005103, Lorenzi 2007180; Pacher et al. 200783).  In 
this way, the excessive O2- produced is met by reduced antioxidant defences which would 
increase the susceptibility of the endothelial cell to oxidative stress. 
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Figure 1.9 Mechanisms by which hyperglycemia increases peroxynitrite formation.  Abbreviations: O2-, 
superoxide anion; NFκB, nuclear factor κB; iNOS, inducible nitric oxide synthase; NO, nitric oxide;  
NADPH oxidase, nicotinamide adenine dinucleotide phosphate oxidase; AGE, advanced glycation end-
product; ONOO-, peroxynitrite. 
 
 
The second step in the impairment of normal vasoregulatory function in hyperglycemia 
involves the subsequent formation of ONOO-.  Increased ONOO- formation is due to the 
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elevations of O2- as well as the activation of an alternative source of NO.  
Hyperglycemia, through mitochondrial O2- generation, can activate NFκB which in turn 
has been shown to increase inducible NOS (iNOS) expression and NO production 
(Ceriello 2003179; Pacher et al. 200783).  In this way elevated levels of O2- and NO are 
simultaneously produced and they will spontaneously combine to form ONOO- (Pacher et 
al. 200783).  ONOO- can reduce vasodilation and promote vasoconstriction as discussed 
in section 1.3.2.5 above.    
 
Thirdly, hyperglycemia can impair vasoregulation by inducing a shift in glucose 
metabolism towards the hexosamine pathway.  This not only results in O2- production, 
but also in the formation of O-linked glycoproteins.  O-linked glycosylation of 
serine/threonine residues of the insulin signalling proteins affects eNOS activation, thus 
reducing NO production (Brownlee 2001175; Federici et al. 2002174; Evans et al. 2002141; 
Bakker et al. 200916; Muniyappa et al. 200770; Figure 1.10).  The result is a decreased 
vasodilation effect as well as increased vasoconstriction due to the reduced Akt 
suppression of the MAPK-dependent pathway leading to ET-1 production.   
 
The fourth mechanism by which hyperglycemia can impair vasoregulation is via 
activation of the IKK and NFκB signaling pathway (Brownlee 2001175; Maritim et al. 
2003178; Pacher et al. 200783, Kim et al. 2005145; Bakker et al. 200916).  Activation of the 
IKK and NFκB signalling pathway may impair Akt activation via IRS-1 serine 
phosphorylation either by IKK directly or indirectly via TNFα production and JNK 
activation as discussed in section 1.3.2.2 (Figure 1.10).  Hyperglycemia-induced NFκB 
activation also appears to increase ET-1 production in endothelial cells and thus lead to 
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vasoconstriction (Muniyappa et al. 200770).  Furthermore, activation of NFκB by 
hyperglycemia can induce endothelial inflammation as it regulates pro-inflammatory and 
pro-atherosclerotic target genes and would thus impair vascular function (Orasanu and 
Plutzky 200972).  
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Figure 1.10 Mechanisms by which hyperglycemia impairs the metabolic insulin signalling cascade.  
Abbrevations: IKKβ, inhibitor κB kinase β; NFκB, nuclear factor κB; TNFα, tumor necrosis factor alpha; 
JNK, c-Jun NH2-terminal kinase; IRS-1, insulin receptor substrate 1; PI3K, phosphatidylinositol-3-kinase; 
eNOS, endothelial nitric oxide synthase; NO, nitric oxide. 
 
 
1.3.3.2 TNFα 
The most extensively studied pro-inflammatory cytokine implicated in insulin resistance 
is TNFα (Muniyappa et al. 200770).  Adipose tissue is a main source of TNFα, and its 
release from adipose tissue is increased in obesity (Berg and Scherer 200515;  Bakker et 
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al. 200916).  The mRNA and protein levels of TNFα are elevated in adipose tissue of 
obese humans (Shoelson et al. 200710) and this overproduction of TNFα appears to be 
associated with adipocyte size (Kahn and Flier 2000181).  The adipocytes are not solely 
responsible for the increased TNFα secretion from the adipose tissue.  In obesity, it seems 
the enlarged adipocytes initiate inflammation by secreting low amounts of TNFα which 
stimulate the production of monocyte chemoattractant protein-1 (MCP-1; Bakker et al. 
200916).  In turn, MCP-1 attracts macrophages to the adipose tissue and these infiltrated 
macrophages contribute significantly to the TNFα production (Bakker et al. 200916).  The 
elevated production of adipokines by adipose tissue also leads to increased circulating 
levels of adipokines and induces endothelial inflammation.  This involves activation of 
NFκB and subsequent TNFα production within the endothelial cell. 
 
Within the endothelial cell, TNFα can activate JNK and IKK (Shoelson et al. 200619; 
Muniyappa et al. 200770).  Subsequently, JNK and IKK, will directly impair the PI3K-
dependent insulin signalling pathway at the level of the IRS-1, reducing NO production 
while alleviating the suppression of ET-1 production (Muniyappa et al. 200770).  TNFα 
activation of IKK will also induce NFκB activation, thus creating an amplification cycle 
for TNFα and its insulin resistance promoting effects (Barnes and Karin1997151; Evans et 
al. 2002141), thus inducing a self-sustaining state of inflammation (Shoelson et al. 200619; 
Shoelson et al. 200710; Jansson 2007107).  Furthermore, TNFα has been implicated in the 
activation of NADPH oxidase (Frey et al. 2002182; Li et al. 2002183; de Keulenaer et al. 
1998184) and the subsequent production of O2- will also contribute to impaired 
vasoregulation, as previously discussed (in section 1.3.2.4).               
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 1.3.3.3 Angiotensin II 
Angiotensin II (Ang II) is an established factor in the pathogenesis of most 
cardiovascular disorders and a natural regulator of blood pressure.  It is the central 
effector of the renin-angiotensin system (RAS; Nickenig and Harrison 2002169) and 
mediates its effects via the Ang II type 1 receptor (AT1R; van Linthout et al. 2009185).  
Ang II is a potent vasoconstrictor, but at low levels, the constriction effect is mild and 
mainly in the larger arteries (Stapleton et al. 20082).  Adipose tissue plays a primary role 
in the production of angiotensinogen, the precursor of Ang II (Cassis et al. 2008186), with 
visceral adipose tissue showing greater expression of angiotensinogen than subcutaneous 
fat (Stapleton et al. 20082).  Indeed, in obesity, Ang II levels are usually elevated (Hall 
2003187)  
 
Elevated levels of Ang II have been implicated in a strong vasoconstrictor response 
which can lead to inflammation, vascular remodelling, thrombosis, and plaque rupture 
(Stapleton et al. 20082).  Ang II, therefore, plays a key role in endothelial dysfunction.  
The most important mechanism by which Ang II operates is the promotion of ROS 
production via increased expression and production of NADPH oxidase (Jansson 2007107; 
van Linthout et al. 2009188; Nickenig and Harrison 2002169).  Ang II also leads to 
endothelial dysfunction via increased expression of ICAM-1 and via increased ET-1 
production by the endothelium (Jansson 2007107).  The mechanism by which  Ang II 
increases ICAM-1 expression most likely involves NFκB activation (Stapleton et al. 
20082), while the mechanisms by which Ang II increases ET-1 release most likely 
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involves its ability to activate JNK and MAPK pathways (Jansson 2007107).  Activation 
of the JNK pathway would impair the PI3K-dependent pathway and thus reduce NO 
production as well as relieve the suppression of the MAPK-dependent pathway for ET-1 
production.     
 
Taken together, the vascular effects of elevated Ang II levels likely play a role in obesity-
related skeletal muscle microvascular impairments leading to endothelial dysfunction and 
reduced tissue perfusion.   
 
1.3.3.4 Sympathetic Nerve Activity 
Sympathetic nerve activity (SNA) is primarily regulated within the areas of the brainstem 
that control cardiovascular function.  SNA is involved in the regulation of vascular tone 
in the microvasculature of skeletal muscle by promoting α-adrenergic vasoconstriction of 
the VSMC (Fisher et al. 2009189).  In obese individuals, skeletal muscle appears to be an 
important peripheral target of increases in SNA  (Seals and Bell 2004190).  Substantial 
elevations in muscle SNA (MSNA) are seen in obesity (Alvarez et al. 2002191; Straznicky 
et al. 2009192), especially in visceral obesity (Alvarez et al. 2002191; Kurukulasuriya et al. 
200886) and have a negative impact on the balance between vasodilation and 
vasoconstriction in the muscle microvasculature.  Weight loss leads to a reduction in 
MSNA in obese individuals and this seems to indicate that there is a direct relationship 
between adiposity and MSNA (Seals and Bell 2004190).  Increased MSNA activity has 
been suggested to lead to elevations in blood pressure and induce vascular remodelling 
which would promote endothelial dysfunction and reduce microvascular perfusion.  
Nevertheless, despite demonstrating an elevated MSNA in the postabsorptive state, obese 
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individuals display a blunted SNA response to meal ingestion (Straznicky et al. 2009192 
and 2009193).  After meal ingestion, increases in MSNA are seen in healthy individuals 
and are important for inducing energy expenditure via DIT (Lowell and Bachman 
2003194; Straznicky et al. 2009193; Schwartz 1987195; de Jonge and Bray 199760; Tappy 
199657).  Indeed, approximately a third of the thermogenic effect of food can be 
accounted for by meal-induced increments in SNA (Lowell and Bachman 2003194; 
Straznicky et al. 2009193).  Failure to increase MSNA in the obese after meal ingestion 
seems to explain a substantial proportion of the reduction in DIT that is observed in obese 
individuals (Lowell and Bachman 2003194; de Jonge and Bray 199760; Tappy 199657).  
Thus not only basal increases in MSNA potentially jeopardize microvascular perfusion 
through increased α-adrenergic vasoconstriction, but the blunted SNA increase to meal 
ingestion will contribute to reduced energy expenditure, making it more difficult to tackle 
and reduce the excess adiposity so central to the impaired microvascular perfusion of the 
skeletal muscle.   
 
 
1.4. Long-term obesity and the development of diabetes type II and 
cardiovascular disease  
 
Over time, the elevated levels of FA, TG, inflammatory cytokines, insulin, glucose, Ang 
II and SNA will damage the microvasculature and lead to the development of 
atherosclerosis.  This will reduce the flow of blood through the vessels and eventually 
lead to an irregular and at times oscillatory rather than constant laminar flow (Chatzizisisi 
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et al. 200775).  The shear stress arising from oscillatory and irregular flow has been 
shown to activate pathways in the endothelium that promote a pro-atherogenic 
environment (Pacher et al. 200783; Thijssen et al. 2009196; Shaaban and Duerinckx 
2000197; Chatzizisis et al. 200775), further exacerbating vascular health and the impaired 
glycemic control.  The long term result is the development of pathology, in particular 
type II diabetes and CVD, both of which impose serious health consequences.  They are 
considered preventable diseases, yet type II diabetes is estimated to kill in excess of 
26,000 people in England yearly (Yorkshire & Humber Public Health Observatory 
2008198), while CVD kills more than 110,000 people in England every year (Department 
of Health 2008199). 
 
Type II diabetes is a metabolic disorder diagnosed, and thus largely defined by, chronic 
hyperglycemia (Orasanu and Plutzky 200972).  It is diagnosed by a fasting plasma glucose 
concentration of ≥ 7.0 mmol and a 2 h post OGTT plasma glucose concentration of ≥ 
11.1 mmol (World Health Organisation 1999200).  It is the most common form of 
diabetes, comprising 90 % of the cases (World Health Organisation 200612).  Type II 
diabetic patients are typically resistant to the action of insulin (World Health 
Organisation 200612) though upon clinical diagnosis, disorders in both insulin action and 
insulin secretion are usually present (World Health Organisation 1999200).  Patients are 
typically obese or display increased abdominal fat deposition despite a BMI below the 
obese range (World Health Organisation 1999200).  Over time, the high glucose levels 
will severely damage the microvasculature leading to irreversible damage to kidneys, 
eyes, and nerves (Bakker et al. 200916).  Indeed, the long-term effects of type II diabetes 
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include progressive development of nephropathy, which may lead to renal failure, 
retinopathy, which may lead to blindness, and neuropathy, which may lead to foot ulcers, 
gangrene, and amputations.  Furthermore, hyperglycemia can also damage the 
macrovasculature, hence the increased risk of cardiovascular, peripheral vascular, and 
cerebrovascular disease (World Health Organisation 1999200) in diabetic patients.   
 
Cardiovascular disease encompasses all diseases that involve the heart and circulatory 
system, including coronary heart disease, angina, heart attack and stroke, and is the most 
common cause of death in the UK (British Heart Foundation 2009201).  The low-grade 
inflammation and insulin resistance characteristic of obesity promotes the development of 
CVD (Gonzalez and Selwyn 200367).  Of particular importance is the loss of the vaso-
protective effects of NO as its bioavailability is reduced (Wagenmakers et al. 200684; 
Johansen et al. 2005106).  Without the protective effects of NO, the systemic inflammation 
will activate NFκB and induce local inflammation in the vasculature which will induce 
the development of vascular pathology through increased monocyte adhesion, enhanced 
platelet aggregation and thrombosis, increased inflammation, and the development of 
foam cell formation for atherosclerosis (Wagenmakers et al. 200684; Marinou et al. 20098; 
Insull 2009202).   
 
Taken together, the serious health consequences of long-term obesity and the principle 
role of the vasculature in the development of obesity-related pathology, delineate the 
urgent need to identify ways to improve vascular function particularly for glycemic 
control in the obese population before the onset of overt type II diabetes and CVD.   
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1.5 Outline of the thesis 
 
1.5.1 General outline 
Chapter 1 gives an introduction of obesity and the functional, metabolic and structural 
impairments occurring in the adipose tissue, liver, skeletal muscle and vasculature of 
obese individuals.  This chapter also delineates the importance of glycemic control in the 
prevention of pathology, primarily type II diabetes and CVD, and provides an overview 
of the biochemical mechanisms that lead to impairments in glucose delivery and uptake 
in the skeletal muscle of obese individuals, thereby jeopardising glycemic control after 
meal ingestion. 
 
Chapters 2 and 3 are experimental studies aiming to determine the role that increased 
FA plays in reducing vasodilation and increasing vasoconstriction during exercise 
(chapter 2) and under resting conditions (chapter 3) using near infrared spectroscopy 
(NIRS) for the measurement of total haemoglobin content (THC) as a measure muscle 
microvascular blood volume (MBV) in lean and obese individuals.  Attempts to measure 
muscle MBV with NIRS in obese subjects in chapters 2 and 3 were not successful.  
Therefore the ability of NIRS to penetrate through different thickness of the adipose 
tissue layer to give skeletal muscle specific THC information was investigated in chapter 
4.  Results showed an inability of NIRS to measure the expected changes in THC, 
oxygenated haemoglobin, and oxygen saturation in the skeletal muscle of the participants 
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with the thickest subcutaneous adipose tissue layer, despite the use of a probe with a 
larger interoptode distance and thus having a greater penetration depth.  Therefore, 
despite previous studies indicating the theoretical ability of NIRS to penetrate even a 
large adipose tissue thickness, we found that in practice this theory did not hold.   
 
Consequently, we decided to undertake a more direct method to measure MBV, namely 
contrast enhanced ultrasound (CEU).  The CEU measurement techniques and analysis 
procedures routinely used in earlier publications lacked detailed descriptions and also had 
limitations, thus we made a number of modifications to generate the optimal CEU testing 
and analysis procedures for measurement of skeletal muscle MBV, microvascular flow 
velocity (MFV), and microvascular blood flow (MBF) in the human forearm (chapter 5).  
This newly developed CEU method was then used to investigate the skeletal muscle 
MBV, MFV, and MBF response to an oral glucose tolerance test (OGTT) in healthy lean 
trained individuals (chapter 6).  This enabled us to see significant increases in MBV and 
MBF during the OGTT.   
 
In chapter 7 (general discussion) the main findings and conclusions of the experimental 
studies are summarized.  This is followed by suggestions for future experiments by 
combining the new information generated in the experimental chapters and that extracted 
from the most recent literature.  These future studies aim to generate new important 
information defining the extent of the impaired MBV response and glucose disposal after 
meal ingestion in obese individuals, as well as developing optimal interventions aimed at 
ameliorating this impairment. 
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 1.5.2 Aims and hypotheses of the experimental chapters 
Section 1.3.2.1 of the introduction depicts the central role of increased adipose tissue 
lipolysis, leading to high plasma FA concentrations and FA uptake in skeletal muscle, 
and in impairing vasodilation and promoting vasoconstriction through numerous 
mechanisms.  This prompted us to investigate the effect of inhibiting adipose tissue 
lipolysis on muscle total haemoglobin content (THC) measured at rest and during 
exercise in obese and lean subjects.  Oral ingestion of niacin, a specific inhibitor of 
adipose tissue lipolysis, was used to create a time window of 90 min with a low plasma 
FA concentration followed by a time window with an increased plasma FA 
concentration. This approach was used during exercise in chapter 2 and at rest in 
chapter 3.  The hypothesis of chapter 2 was that a decrease in plasma FA in obese 
individuals would increase the exercise-induced vasodilation as reflected by an increased 
THC measured by NIRS, while a reduction in the exercise-induced vasodilation would 
occur in lean and obese participants during the period with elevated plasma FA 
concentrations.  In chapter 3 the net balance between vasodilation and vasoconstriction 
was measured at rest during low and high plasma FA levels in lean and obese 
participants.  Here the hypothesis was that in the obese, vasoconstriction mechanisms 
would be active and by lowering plasma FA levels there would be a reduction in 
vasoconstriction and this would be reflected by an increase in THC as measured by 
NIRS.  For the lean participants, we hypothesized that an increase in vasoconstriction, 
and thus a decrease in THC, would be seen in the high FA condition.   
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The results of the experiments in chapters 2 and 3 suggested that the NIRS method did 
not generate the expected muscle specific THC results in obese participants with a large 
adipose tissue thickness (ATT).  We therefore investigated the ability of NIRS to 
penetrate three different ranges of subcutaneous adipose tissue thickness (ATT) (chapter 
4) with two NIRS probes with a different interoptode distance (ID) and therefore 
different theoretical measurement depth. The hypothesis was that the ‘superficial’ probe 
(probe A) would only be able to generate muscle specific information in the subjects with 
a thin or moderate ATT, while the ‘deep’ probe (probe B), manufactured specifically for 
us with a greater ID, would allow us to make muscle specific NIRS measurements at all 
ATTs.   
 
The investigations described in chapter 4 led to the conclusion that NIRS is not able to 
generate muscle specific THC measurements in obese subjects even with the ‘deep’ 
probe.  This prompted us to look for another technique to measure skeletal muscle MBV 
in obese individuals.  We chose to introduce the CEU method to our laboratory.  Once the 
method was developed and modified for our experimental interests (chapter 5) it was 
used to investigate the skeletal muscle MBV, MFV, and MBF response to an OGTT in 
healthy lean trained participants (chapter 6).  Our hypothesis was that the OGTT would 
produce a measureable increase in MBV and this would be reflected by (i) increased 
glucose disposal, (ii) increased energy expenditure, (iii) decreased fat oxidation rates, and 
(iv) increased glucose oxidation rates.  We also measured brachial artery diameter to test 
the hypothesis that increased vasodilation would also be seen higher up the arterial tree 
and not just the microvasculature.  
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2.1 INTRODUCTION 
 
A dramatic rise in obesity is occurring worldwide and with it comes the increased risk for 
development of obesity-related pathologies including hypertension, vascular and 
coronary artery disease, atherosclerosis, insulin resistance, and type II diabetes (World 
Health Organisation 20061).  The obese population suffers from a generalized  
impairment in endothelial function (Jonk et al. 20072).  This involves increased basal 
vasoconstriction caused by endothelin-1, angiotensin II, tumor necrosis factor α (TNFα), 
peroxynitrite and elevated sympathetic neural activity (Cohen 20073; Pacher et al. 20074; 
Bakker et al. 20095; Stapleton et al. 20086; Fisher et al. 20097), and reduced NO-
dependent vasodilation in response to a variety of physiological stimuli, including 
decreased NO-dependent vasodilation of feeding and resistance arteries in response to 
shear stress (humans: Arcaro et al. 19998, Brook et al. 20019; Hamdy et al. 200310, 
Meyers and Gokce 200711; rats: Frisbee and Stepp 200112; Frisbee 200413).  Whether the 
decreased vasodilator response and increased vasoconstriction at the level of feeding and 
resistance vessels also operates at the level of the terminal arterioles, limiting capillary 
perfusion and increases in microvascular blood volume (MBV) during exercise, is 
currently not known.   
 
During exercise, increases in muscle MBV are the result of two vasodilatior processes, 
namely NO-dependent vasodilation of feeding and resistance arteries and potentially 
arterioles (Clifford and Hellsten 200414; Kooijman 200815), and contraction-induced 
vasodilation of terminal arterioles via mechanisms involving, among others, adenosine 
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and potassium release from the contracting muscle fibres (Hudlicka 198516; van Teefelen 
200617; Clifford and Hellsten 200414).  Elevated levels of plasma fatty acids (FA) have 
been found to impair the activation of endothelial nitric oxide synthase (eNOS; Kim et al. 
200518) and vasodilation in response to shear stress (Vogel et al. 199719).  Furthermore, 
elevated FA levels also induce vasoconstriction through a variety of mechanisms in the 
fasted, resting state (Pacher et al. 20074; Eringa et al. 200420; Serne et al. 200621; Brandes 
and Kreuzer 200522; Bedard and Krause 200723; Chinen et al. 200724).  Although the 
contraction-induced vasodilation of terminal arterioles via adenosine and potassium is not 
expected to be affected by high plasma FA concentrations, a limitation in the net 
vasodilation response, due to mechanistic impairments for NO-dependent vasodilation, in 
conjunction with increased activation of vasoconstriction mechanisms, could mean that 
maximal skeletal muscle perfusion is not achieved by the obese during exercise.  
Consequently, the delivery of oxygen and blood-borne fuels, and the clearance of 
metabolic waste products would be restricted, thus reducing exercise tolerance in the 
obese population.  
 
Obesity is commonly associated with increased circulating levels of plasma FA 
(Bickerton et al. 200825; Jensen et al. 198926; Hennes et al. 199627; de Jongh et al. 200428; 
Coppack et al. 199229; Hickner et al. 199930) and triglycerides (TG; Kamagate and Dong 
200831; Bickerton et al.  200825; Lewis et al. 200232; Frayn 200233).  Hydrolysis of plasma 
TG by lipoprotein lipase in the muscle capillary bed may further increase the local FA 
concentration (Oram and Bornfeldt 200434; Fielding 199835).  A large body of recent 
literature suggests that acute and chronic exposure of the microvasculature to high plasma 
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FA play a role both in impairing the mechanisms that determine fasted and insulin-
mediated NO-dependent vasodilation and in activating several of the mechanisms leading 
to vasoconstriction (summarised in Figure 2.1; detailed overview given in Discussion 
section). 
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Figure 2.1 Schematic presentation of the main endothelial mechanisms by which a high concentration of 
plasma fatty acids (FA) reduce vasodilation and increase vasoconstriction of terminal arterioles leading to a 
net increase in vascular tone of the microvasculature and a potential for underperfusion of skeletal muscle 
in the fasted resting state, and potentially during acute exercise.  Abbreviations: IRS-1, insulin receptor 
substrate-1; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; ERK 1/2, extracellular signal-
regulated kinase 1/2;  ET-1, endothelin 1; NFκB, nuclear factor κB; PGH2, prostaglandin H2; ThA2, 
thromboxane A2; O2-, superoxide anion;  ONOO-, peroxynitrite.  Figure compiled with information taken 
from several references (Kim et al. 200518; Gao et al. 200236; McAllister and Laughlin 200637; Landmesser 
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and Drexler 200738; Federici et al. 200239; Reusch et al. 200140; Gratton et al. 200141; Thijssen et al. 200842; 
Eringa et al. 200420; Serne et al. 200621; Cardillo et al. 199943; Artwohl et al. 200444; Chinen et al. 200724; 
Sriwijitkamol et al. 200645; Barnes and Karin 199746; Evans et al. 200247; de Alvaro et al. 200448; Shoelson 
et al. 200749; Hotamisligil et al. 199650; Gao et al. 200351; Yamamoto et al. 199552; Wagenmakers et al. 
200653; Bedard and Krause 200723; Pacher et al. 20074; Zou et al. 200254; Bubolz et al. 200755).  A detailed 
explanation of the mechanisms is given in the Discussion (section 2.4).   
 
 
The aims of the present study, therefore, were to (i) determine if the decreased 
vasodilation response to shear stress seen in obese individuals also leads to reduced 
increases in MBV during exercise, and (ii) investigate whether acute changes in the 
plasma FA concentration induced by niacin can influence skeletal muscle MBV in the 
exercising muscle of obese subjects.  Total hemoglobin content (THC) of the biceps 
brachii muscle, an indirect measure of MBV, was monitored using near-infrared 
spectroscopy (NIRS).  Niacin was used to create an initial low, and subsequent high 
plasma FA concentration (Carlson et al. 196856, Wang et al. 200057).  Exercise was 
introduced to examine the effects of low and high FA levels on net increases in MBV in 
sedentary lean and obese humans.  The experimental protocol involved two trials, niacin 
and placebo, each of which consisted of performing two bouts of incremental arm 
cranking exercise until self-perceived exhaustion.  The first exercise bout (ex 1) 
commenced 1 hour post niacin ingestion during the low FA phase of the niacin trial, 
while the second bout of exercise (ex 2) commenced 3 hours  post niacin ingestion during 
the high FA phase of the niacin trial.  The hypothesis was that, during the placebo trial, 
the increase in THC during the exercise bouts would be greater in the lean subjects, as the 
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obese are expected to have elevated FA levels and impaired increases in MBV in 
response to exercise.  Due to normal fasting plasma FA levels, vasodilation mechanisms 
should not be impaired and vasoconstriction mechanisms should not be active in lean 
participants.  During the niacin trial, the initial decrease in FA was expected to reduce the 
microvascular impairments in the obese, allowing for a greater increase in THC during 
exercise as compared to placebo.  The lean participants would show a distinctly smaller 
THC increase during the exercise bout in the high FA phase of the niacin trial compared 
to placebo as, according to the hypothesis, the elevated FA would create microvascular 
impairments, reducing the vasodilation response to exercise and potentially activating the 
mentioned vasoconstriction mechanisms.   
 
Blood samples were taken throughout the trials for analysis of plasma lactate and FA.  
The expectation was that lactate levels would rise when muscle perfusion was low due to 
an increase in anaerobic respiration resulting from reduced oxygen delivery to the 
working muscle.  We thus hypothesized that the greatest increase in plasma lactate 
concentrations would occur during the second exercise bout in the high FA phase of the 
niacin trial for the lean group, while obese participants would show the smallest increase 
in lactate production during exercise in the low FA phase of the niacin trial as compared 
to placebo.    
     
 
2.2 MATERIALS AND METHODS 
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2.2.1 Subjects 
A total of 8 lean and 8 obese, sedentary, healthy volunteers were recruited by word of 
mouth in The University of Birmingham to participate in this study.  Their physical 
characteristics are displayed in Table 2.1.  Volunteers met individually with the 
researcher to discuss the study, provide written informed consent, and complete 
preliminary measurements including a general health questionnaire, a physical activity 
questionnaire, measurement of height and weight, and determination of NIRS optimal 
probe positioning (see below).  The research has been carried out in accordance with the 
Declaration of Helsinki (2000) of the World Medical Association and has been approved 
by the Ethics Committee of the School of Sport and Exercise Sciences at The University 
of Birmingham.   
 
Table 2.1 Characteristics of the two participant groups.   
 Lean  Obese 
Age (years) 20.4 (± 2.3) 24.6 (± 5.1) 
Gender (m/f) 5/3 3/5 
Skin thickness (mm) 3.1 (± 0.5) 11.4 (± 2.8) 
Height (m) 1.73 (± 0.11) 1.70 (± 0.12) 
Weight (kg) 65.6 (± 8.7) 102 (± 25.2) 
BMI (kg/m2) 21.8 (± 1.6) 34.6 (± 3.5) 
Skin thickness was measured over the biceps brachii with skin fold callipers and represents an average of 
three measurements.  Values given are the mean of 8 participants with standard deviations given in 
brackets.  
 
2.2.2 NIRS measurements 
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NIRS is a non-invasive optical technique based on the oxygen-dependent absorption 
changes of haemoglobin and myoglobin.  While differentiation between oxygenated and 
deoxygenated states of the chromophores can be made, it is not possible to distinguish 
between haemoglobin and myoglobin as their absorption spectra overlap (van Beekvelt et 
al. 200158).  We used a continuous-wave NIR spectrometer (ISS OxyplexTS 95306, 
Champaign IL, USA), which measures the absorbance of the NIRS light at wavelengths 
of 692 nm and 834 nm and uses calibrated software routines to calculate absolute 
concentrations from the measured NIR absorbance.  Deoxygenated haemoglobin and 
myoglobin (Hb/Mb) absorbance was measured at wavelength 692 nm, while the sum of 
deoxygenated and oxygenated Hb/Mb was measured at wavelength 834 nm as they 
exhibit similar absorption coefficients at this higher wavelength (Wilson et al. 198959).  
Since myoglobin concentrations were unlikely to change over the testing period, the sum 
of the absorbance signals at 834 nm was taken to reflect the relative change in THC 
(assuming a constant hematocrit –Kell et al. 200460).  We assumed that the changes in 
THC would reflect changes in capillary blood volume as NIRS measurements primarily 
reflect the microcirculation in skeletal muscle (Mancini et al. 199461).  NIRS 
measurements were carried out on the biceps brachii with a probe having an interoptode 
distance (ID) of 3-4.4 cm.  This ID would allow a measurement depth of up to 2.2 cm 
based on the assumption that the measurement depth is half the ID (van Beekvelt et al. 
200158; Cui et al. 199162; Homma et al. 199663).  The NIRS measurement unit was given 
at least a 2 h warm up time as this minimised the signal drift in time and was calibrated 
before each trial.  Data was sampled at 2000 Hz, displayed in real time, and stored on 
disk for off-line analysis.        
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 2.2.3 Determination of optimal probe position 
The optimum probe position for the individual was identified by systematically drawing 
five marks on the belly of the bicep of their dominant arm and making measurements 
with the NIRS probe for 2 min on each mark.  The mark with the highest THC value was 
noted as the optimum probe position for the individual.  The positioning marks were 
made with a black ballpoint pen and their placement was identified for each participant in 
the following way: (a) half distance between elbow (olcranon process) and shoulder 
(coracoid process) = mark 0; (b) circumference of arm at point 0 divided by 4; (c) value 
(0.25 of circumference) from point 0 across biceps towards inner arm = mark 1; (d) 
marks 2-5 are 1.5cm from mark 1, as shown in Figure 2.2. 
 
 
2
4
1 35
Figure 2.2 Position codes for determination of optimal NIRS probe position on biceps brachii of each 
participant.  The positions were determined by (a) measuring half the distance between the elbow (olcranon 
process) and shoulder (coracoid process) = point 0; (b) measuring the circumference of the arm from point 
0 and dividing it by 4; (c) the value (0.25 of circumference) from point 0 across biceps towards inner arm = 
mark 1; (d) marks 2-5 are 1.5 cm from mark 1.  NIRS measurements were made for 2 min on each point 
and the point with the highest THC value was noted as the optimum probe position for the individual.     
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2.2.4 Niacin 
Niacin (vitamin B3) is a nicotinic acid analogue which inhibits the release of FA from the 
adipose tissue, thereby decreasing blood FA concentrations.  This mechanism involves 
niacin binding to the HM74 receptor on the adipocyte (Tunaru et al. 200364), leading to a 
suppression of intracellular cAMP levels, which in turn decrease cAMP-dependent 
protein kinase activity.  The result is a reduced association of hormone sensitive lipase  
and the lipid droplets within the adipocyte, thereby decreasing lipolysis and the 
subsequent release of FA into the blood stream (Christie et al. 199665).  As skeletal 
muscle does not express the HM74 receptor, this effect of niacin remains specific to 
adipose tissue (Tunaru et al. 200364).  A particular characteristic of niacin is its biphasic 
effect on plasma FA concentrations as after the low FA phase a rebound phase follows, 
elevating FA levels above basal concentrations.  Pilot studies from our laboratory showed 
500 mg of niacin to cause a decrease in FA commencing 10 min post capsule ingestion 
and reaching the lowest point at 60 min before beginning to rise again, surpassing 
baseline values 3 h post capsule ingestion, peaking at about 4 h and slowly returning 
towards baseline levels at about 5-6 h.  For this reason measurements were made over a 6 
h period post niacin ingestion and two exercise bouts were conducted, one being placed 
during the low FA condition and the second in the rebound high FA condition created by 
the niacin.  Side-effects of niacin ingestion include flushing, itching, nausea, 
gastrointestinal complaints, headaches, and skin rashes.  In the present study, 30-50 min 
after capsule ingestion, 15 out of 16 participants showed flushing characterised by 
redness of the face, neck, and arms.  Shortly after capsule ingestion, 3 out of 16 
participants reported a feeling of nausea which lasted approximately 15 min.          
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 2.2.5 Experimental Protocol 
Volunteers visited the laboratory on two occasions, arriving between 6 and 8 am in the 
overnight fasted state.  The day before testing, participants were instructed to refrain from 
exercise and ingestion of caffeine, and to consume a low-fat evening meal at 7 pm, 
followed by only low-fat snacks if they could not resist additional food intake.  They 
were instructed to refrain from food and calorie intake from 10 pm, drinking only water 
until completion of the trial the following day.  Visits were at least two days apart and 
were identical except for the contents of the capsules ingested.  Two capsules were given 
together, each containing 250 mg of either niacin or placebo (microcrystalline cellulose) 
and administration was double-blinded.    
 
Upon arrival at the laboratory, participants were asked to lie down on the bed while a 
flexible 20-gauge Teflon catheter (Quickcath, Becton Dickinson, Plymouth United 
Kingdom) was inserted in the antecubital vein and fitted with a 3-way stopcock (PVB 
Medizintechnik, Kirchseean, Germany) to allow for repeated blood sampling.  The NIRS 
probe was randomly assigned to the left or right arm for each participant and secured 
over the predetermined optimal position on the biceps brachii of the same arm for both 
visits.  After a 10 min NIRS baseline measurement, a baseline blood sample was taken 
and the participant was asked to ingest two 250 mg capsules both containing either 
placebo or niacin.  NIRS measurements continued for the entire duration of the trial.  A 
blood sample was taken 1 h after capsule ingestion and the first arm cranking exercise 
commenced.  Participants cycled with their arms at 50 revolutions per minute while the 
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workload was increased every 5 min until self-perceived exhaustion, as determined by a 
Borg Scale (1979).  Blood samples were taken at the start of exercise, after every other 
exercise stage increment, and at the end of exercise (Figure 2.3).  Participants were then 
asked to sit or lie down quietly again until the second exercise session, occurring 3 hrs 
post capsule ingestion.  A blood sample was also taken 2 h post capsule ingestion 
between exercise sessions.  The second exercise was identical to the first in terms of 
increasing workload and blood sampling.  Upon completion of the exercise, NIRS 
measurements were terminated, the final blood sample was taken, and once the catheter 
and NIRS probe were removed participants could leave the laboratory.    
 
The experiment was performed in a double blind manner with neither participant nor 
experimenter aware which trial was niacin or placebo.  Females were tested in the luteal 
phase of the menstrual cycle to exclude hormonal variations with a potential impact on 
fat metabolism.    
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Figure 2.3 Exercise protocol completed by participants at 1 h and 3 h post niacin ingestion.  Participants 
cycled with their arms at 50 revolutions per minute while the workload was increased every 5 min until 
self-perceived exhaustion, as determined by a Borg Scale (1979).  Blood samples were taken at the start of 
exercise, after every other exercise stage increment, and at the end of exercise. If participants reached 
exhaustion at the end of a stage after which a sample was taken, then no additional blood sample was 
necessary. 
 
2.2.6 Blood Samples 
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Blood samples (7 ml) were collected in EDTA-containing tubes and centrifuged at 1000 
g for 10 min at 4 °C.  Aliquots of plasma were frozen immediately in liquid nitrogen and 
stored at -80 °C. Plasma FA concentrations were analysed (NEFA-C; Wako Chemicals, 
Neuss, Germany), with a COBAS Mira Plus semiautomatic analyzer (ABX Diagnostics).  
Plasma lactate concentrations were analysed (lactic acid; Horiba ABX, Monpellier, 
France) with a COBAS Mira Plus semiautomatic analyzer (ABX Diagnostics). 
 
2.2.7 Statistical Analysis 
Two-tailed independent samples t-tests were carried out between lean and obese groups 
for THC increase values from start to end of exercise 1 and 2 in the placebo trial to 
investigate whether there are differences between groups in the ability to increase THC in 
response to exercise. 
 
Two-tailed paired samples t-tests were carried out between trials for the THC increase 
values from start to end exercise 1 and 2 in both lean and obese groups to investigate 
whether there was a difference in perfusion with different plasma FA conditions for each 
participant group. 
 
Two-tailed paired samples t-tests were carried bout between exercise 1 and 2 for the 
niacin trials in both participant groups to investigate whether the different FA conditions 
affected the lactate increase in each exercise bout for both participant groups.  Two-tailed 
paired samples t-tests were also carried out between trials for the lactate increase values 
from start to end exercise 1 in the obese group and exercise 2 in the lean group to 
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investigate whether there was a difference in perfusion with different plasma FA 
conditions for each participant group.   
 
Two way ANOVAs for repeated measures were carried out on plasma FA data for trial 
and time between the two exercise bouts and participant groups to investigate whether 
there were significant changes in FA during exercise bouts between trials for both 
participant groups.   
 
If significance was found the Bonferroni post hoc test was applied. 
 
All statistical tests were carried out using SPSS for Windows version 16.0 software 
package (Chicago, IL, USA).  All data are reported as means ± SD and statistical 
significance was set at P < 0.05. 
 
 
2.3 RESULTS 
 
2.3.1 Total Haemoglobin Content 
For both groups there was an increase in THC over time during each of the exercise 
bouts, though the increase is more distinguishable in the lean groups.  Figure 2.4 shows 
the mean data of the groups in both trial conditions.  The THC increase from start to end 
exercise in the placebo trials was not found to be significantly different between lean and 
obese groups for exercise 1 and 2 (P = 0.078 and P = 0.420, respectively).  The THC 
increase from start to end exercise was not significantly different between trials for 
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exercise 1 or 2 in the lean group (P = 0.878 and P = 0.897, respectively) nor the obese 
group (P = 0.377 and P = 0.721, respectively).  Table 2.2 shows the mean THC values at 
the key time points for both groups and trial conditions.      
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Figure 2.4 Total haemoglobin content (µM) for lean and obese groups during niacin (N) and placebo (P) 
trials.  As there was individual variation in exercise duration, data has been expressed as start and end 
exercise values for each group and trial condition.  Values given are the mean of 8 subjects per group. 
 
Table 2.2 Total haemoglobin content (µM) for lean and obese groups during niacin (N) and placebo (P) 
trials. 
 Lean –N  Lean –P  Obese –N Obese –P 
Baseline 70.0  (±14.3) 78.3  (±19.5) 31.1  (±17.6) 36.3  (±25.7) 
Start ex1 73.9  (±15.2) 79.8  (±21.2) 31.9  (±17.2) 35.6  (±27.8) 
End ex1 81.9  (±17.3) 87.3  (±22.9) 36.0  (±18.3) 36.7  (±21.1) 
Start ex2 73.9  (±14.5) 86.5  (±21.3) 35.4  (±18.4) 32.1  (±19.2) 
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End ex2 82.7  (±14.6) 92.7  (±22.9) 39.9  (±18.9) 35.8  (±23.0) 
Values are given as the means ± standard deviations (SD) of 8 subjects in each group. 
 
2.3.2 Plasma fatty acids 
The blood samples confirmed that the ingestion of 500 mg niacin led to an initial 
decrease in plasma FA concentrations followed by a rebound phase in which the plasma 
FA concentrations increased above baseline (Figure 2.5).  In exercise 1, plasma FA was 
significantly different between trials for lean and obese groups (P = 0.017 and P = 0.001, 
respectively).  In exercise 2, plasma FA was not significantly different between trials for 
lean and obese groups (P = 0.253 and P = 0.207, respectively) though plasma FA was 
higher in the niacin trial in both groups as compared to placebo.  Table 2.3 presents the 
exact mean plasma FA values and their standard deviations.       
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Figure 2.5 Plasma fatty acid values (µM) for lean and obese groups during niacin (N) and placebo (P) 
trials.  Due to individual variation in exercise duration, data has been expressed as start and end exercise 
values for each group and trial condition.  Values given are the mean of 8 subjects per group.   
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 Table 2.3 Plasma fatty acid values (µM) for lean and obese groups during niacin (N) and placebo (P) trials  
 Lean –N  Lean –P  Obese –N Obese –P  
Baseline 363.5  (±135.0) 356.6  (±138.2) 379.6  (±132.2) 370.9  (±126.9) 
Start ex1 155.8  (±76.5) 292.1  (±108.3) 211.0  (±100.9) 341.5  (±122.8) 
Median ex1 118.0  (±58.6) 253.3  (±94.9) 176.4  (±90.4) 306.6  (±114.1) 
End ex1 133.3  (±82.9) 256.1  (±105.1) 183.5  (±77.4) 288.4  (±117.9) 
Start ex2 378.0  (±192.0) 293.4  (±138.4) 382.5  (±194.2) 338.9  (±101.8) 
Median ex2 350.3  (±137.1) 286.0  (±132.4) 479.9  (±225.4) 302.4  (±101.9) 
End Ex2 424.1  (±146.0) 297.0  (±139.2) 453.6  (±230.4) 317.3  (±153.9) 
Values given as means ± standard deviations (SD) of 8 subjects in each group 
 
 
2.3.3 Plasma lactate 
A distinct rise in lactate levels can be seen at the end of both exercise bouts for all groups 
and trials.  The lactate increase over exercise in the niacin trial between exercise bouts 1 
and 2 is not significantly different for the obese group (P = 0.074).  Higher lactate 
concentrations were observed after the first exercise bout than after the second exercise 
bout (5.6 mM and 3.7 mM, respectively).  In the lean group the lactate increase over 
exercise in the niacin trial between exercise bouts 1 and 2 does reach significance (P = 
0.050) with greater lactate concentrations at the end of the first exercise bout than after 
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the second exercise bout (5.4 mM and 4.5 mM, respectively). The lactate increase over 
exercise 1 is not significantly different between trials for the obese group (P = 0.672) nor 
is it significant between trials in exercise 2 for the lean group (P = 0.356).  Figure 2.6 
shows the change in lactate concentrations for niacin and placebo trials in lean and obese 
groups, while Table 2.4 presents the exact mean lactate values and their standard 
deviations.       
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Figure 2.6 Mean lactate values (mM) for lean and obese groups during niacin (N) and placebo (P) trials.  
Due to individual variation in exercise duration, data has been expressed as start and end exercise values 
for each group and trial condition.  Values given are the mean of 8 subjects per group.   
 
Table 2.4 Lactate values (mM) for lean and obese groups during niacin (N) and placebo (P) trials 
 Lean –N  Lean –P  Obese –N  Obese –P 
Baseline 1.0  (±0.3) 1.1  (±0.4) 1.5  (±0.5) 1.8  (±1.0) 
Start ex1 1.3  (±0.4) 1.0  (±0.2) 1.3  (±0.6) 1.5  (±0.8) 
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End ex1 6.7  (±4.5) 4.8  (±2.1) 6.9  (±1.9) 9.4  (±5.5) 
Start ex2 1.3  (±0.6) 1.2  (±0.6) 1.8  (±1.4) 1.4  (±0.6) 
End ex2 5.8  (±3.8) 4.8  (±1.5) 5.5  (±1.3) 4.6  (±1.7) 
Values given as means ± standard deviations (SD) of 8 subjects in each group 
 
 
2.4 DISCUSSION 
 
Obese individuals have been reported to have impairments in insulin-induced NO-
dependent vasodilation and insulin-induced increases in microvascular perfusion (Jonk et 
al. 20072; Clerk et al. 200666; de Jongh et al. 200428; Laasko et al. 199067).  As obese 
individuals also show a reduction in NO-dependent vasodilation in response to shear 
stress (Arcaro et al. 19998; Brook et al. 20019; Hamdy et al. 200310; Meyers and Gokce 
200711), this may reduce microvascular perfusion during exercise.  It has been suggested 
that the elevated levels of circulating FA contribute significantly to the reduced net 
vasodilation response by both impairing vasodilation mechanisms and activating 
vasoconstriction mechanisms. This provided the rational to reduce plasma FA 
concentration in this study with niacin, a vitamin naturally occurring in our food, to 
investigate the potential for increasing exercise-mediated vasodilation and MBV in obese 
individuals.   
 
The mechanisms through which FA impair vasodilation include (i) increased insulin 
receptor substrate-1 (IRS-1) serine phosphorylation, (ii) activation of nuclear factor κB 
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(NFκB) network, and (iii) production of superoxide anions (O2-) and are summarized in 
Figure 2.1.  IRS-1 serine phosphorylation will prevent downstream activation of the 
insulin-signaling cascade, resulting in reduced Akt activation, eNOS activation and the 
subsequent NO production (Kim et al. 200518; Gao et al. 200236).  A reduction in NO 
production will decrease the vasodilation response, but will also reduce the protective 
effect of NO on atherosclerosis and vascular damage (McAllister and Laughlin 200637; 
Landmesser and Drexler 200738).  Furthermore, the decreased Akt activation will relieve 
the inhibition of the mitogenic insulin signaling pathway, thus explaining the high plasma 
levels of endothelin-1 (ET-1), which is a potent local vasoconstrictor produced by the 
endothelial cells (Federici et al. 200239; Reusch et al.  200140; Gratton et al. 200141; 
Thijssen et al. 200842; Eringa et al. 200420; Serne et al. 200621; Cardillo et al. 199943).  
Activation of the NFκB network by elevated FA has been shown in cultured endothelial 
cells (Kim et al. 200518; Artwohl et al. 200444; Staiger et al. 200668), skeletal muscle of 
healthy (Itani et al. 200269) and type II diabetic humans (Sriwijitkamol et al. 200645), and 
in obese Zucker rats (Chinen et al. 200724).  NFκB can indirectly lead to increased IRS-1 
serine phosphorylation through stimulation of inflammatory cytokine production (Barnes 
and Karin 199746; Evans et al. 200247; de Alvaro et al. 200448; Sriwijitkamol et al. 200645; 
Shoelson et al. 200749) which will activate IKK and promote IRS-1 serine 
phosphorylation (Hotamisligil et al. 199650; de Alvaro et al. 200448; Gao et al. 200236; 
Gao et al. 200351).  NFκB pathway activation also leads to vasoconstriction via 
accumulation of prostaglandin H2 (PGH2) leading to thromboxane A2 (ThA2)/PGH2 
receptor activation (Barnes and Karin 199746; Yamamoto et al. 199552).  Furthermore, 
activation of NFκB will increase the expression of cellular adhesion molecules and 
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leukocyte adhesion (vascular inflammation) and, therefore, will increase local exposure 
to inflammatory cytokines (Wagenmakers et al. 200653).  Lastly, high circulating levels 
of FA have been proposed to activate NADPH oxidase in the endothelium and vascular 
smooth muscle (VSM), leading to excess production of superoxide anions (O2-; Brandes 
and Kreuzer 200522; Bedard and Krause 200723; Chinen et al. 200724).  Superoxide anions 
scavenge NO thereby reducing basal vasodilation, while peroxynitrite, the end product of 
this reaction, has been shown to increase vasoconstriction and reduce vasodilation 
through a variety of mechanisms (Pacher et al. 20074; Zou et al. 200254; Bubolz et al. 
200755).  Silver et al. (2007)70 recently provided evidence that the above mechanisms not 
only operate in obese subjects with the metabolic syndrome and cardiovascular disease, 
but also in overweight and obese individuals without obvious pathology, by showing 
increased protein expression of ET-1, NADPH oxidase and NFκB, and evidence of 
protein nitrosylation by peroxynitrite in vascular endothelial cells harvested from these 
individuals.  
 
Ingestion of niacin produced a biphasic response in plasma FA concentrations in line 
with previous studies (Wang et al. 200057).  Initially FA decreased maximally 53 % and 
43 % from placebo in lean and obese groups, respectively, and this was found to be 
significantly different from placebo.  This decrease was followed by a maximal FA 
increase of 43 % and 59 % from placebo in lean and obese groups, respectively, though 
this did not reach statistical significance.  In this way, niacin created two experimental 
conditions, allowing testing of the hypotheses that low FA concentrations would increase 
MBV and high FA concentrations would decrease MBV during exercise.   
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 Despite the biphasic manipulation of plasma FA, the THC and lactate responses to 
exercise in the two participant groups were not in line with our hypothesis.  There was no 
significant difference in the exercise-induced THC increase between trials during 
exercise-1 or -2 in the obese or lean group.  Nor was there a significant difference in the 
exercise-induced THC increase between groups during the placebo trial.  In the obese 
group, lactate concentrations were expected to be reduced during exercise-1 in the niacin 
trial (low FA phase), however no significant difference between trials was found during 
exercise-1, nor was there a significant difference between exercise bouts for the niacin 
trial.  In the lean group, a significant difference in lactate levels was seen between 
exercise bouts for the niacin trial; however, the lactate levels were higher during exercise 
in the low FA phase as opposed to the high FA phase.   
 
One of the potential explanations as to why the THC and lactate data was not in line with 
our hypotheses could be the short duration of the low and high FA phase created by 
niacin.  Alterations in gene expression and protein content of NADPH oxidase and NFκB 
which would be required to modify the balance between vasoconstriction and 
vasodilation (Silver et al. 200770) are likely to take longer than the periods with high and 
low FA concentrations induced by niacin ingestion (Figure 2.5).  Furthermore, acute 
changes in plasma FA concentrations do not necessarily lead to acute decreases in 
endothelial concentrations of fatty acid metabolites (long-chain fatty acyl-CoA and 
diacylglycerol) that activate protein kinase C and increase serine phosphorylation of IRS-
1 and thus reduce NO production and vasodilation in the resting fasted state (Serne et al. 
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200621; Naruse et al. 200671).  Thus it is possible that the FA manipulation effects were 
too transient to alter NADPH oxidase and NFκB gene expression, and IRS-1 serine 
phosphorylation.   
 
In conclusion, the manipulation of plasma FA concentrations with niacin did not have a 
clear effect on THC and lactate levels during exercise.  This may be explained by the FA 
manipulation effects being too transient to alter NADPH oxidase and NFκB gene 
expression, and IRS-1 serine phosphorylation.  Future studies should use alternative ways 
to induce prolonged alterations in FA concentrations.     
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Chapter 3 
 
 
THE EFFECT OF ACUTE CHANGES IN PLASMA FATTY ACID 
CONCENTRATIONS ON RESTING MUSCLE MICROVASCULAR 
BLOOD VOLUME IN LEAN AND OBESE INDIVIDUALS AS A 
FUNCTION OF PHYSICAL ACTIVITY LEVELS 
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3.1 INTRODUCTION 
 
With the obesity epidemic spreading rapidly, more and more people are at risk of 
compromising their health and reducing their quality of life (World Health Organisation 
20061).  Chronic obesity leads to substantial increases in the risk of developing 
hypertension, vascular and coronary artery disease, atherosclerosis, insulin resistance and 
type II diabetes (World Health Organisation 20061).  Impairments in endothelial 
metabolism have a negative impact on (micro)vascular function and have been proposed 
to represent the earliest common abnormality in the development of the obesity-related 
pathologies (Jonk et al. 20072; Meyers and Gokce 20073; Hartge et al. 20074; Cersosimo 
and Defronzo 20065; Kim et al. 20066).  An important role of the endothelium in the 
microvasculature of skeletal muscle is to regulate the recruitment and blood perfusion of 
capillaries that surround the skeletal muscle fibres, such that perfusion matches fuel and 
oxygen demands (Segal 20057).  Most of the control of perfusion of skeletal muscle 
capillaries is at the level of the terminal arterioles (Segal 20057).  A reduced skeletal 
muscle perfusion has been observed in the fasted resting state in obese mice (Traupe et al. 
20028; Traupe et al. 20029) and obese Zucker rats (Wallis et al. 200210; Frisbee 200711), 
and has been proposed to occur in humans with hypertension and the metabolic syndrome 
(Lind and Lithell 199312).  The impaired skeletal muscle perfusion in obesity has been 
suggested to be the result of (i) a decreased capillary density, also called rarefaction 
(Frisbee 200711; Gavin et al. 200513), and (ii) an increased basal vascular tone (Traupe et 
al. 20028; Traupe et al. 20029; Frisbee 200711; Ribeiro et al. 200114).  The increased 
vascular tone is likely to be the result of an imbalance in the mechanisms that lead to 
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vasodilation and to vasoconstriction (Frisbee 200711) and plays an important role in the 
development of hypertension. 
 
Obesity is commonly associated with increased circulating levels of fatty acids (FA) and 
triglycerides (TG; Lewis et al. 200215; Frayn 200216).  Hydrolysis of plasma TG by 
lipoprotein lipase in the muscle capillary bed may further increase the local FA 
concentration (Oram and Bornfeldt 200417).  A large body of recent literature suggests 
that acute and chronic exposure of the microvasculature to high plasma FA play a role 
both in impairing the mechanisms that determine fasted and insulin-mediated NO-
dependent vasodilation and in activating several mechanisms leading to vasoconstriction 
(Figure 3.1; detailed overview is given in the Discussion section).  
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Figure 3.1 Schematic presentation of the main endothelial mechanisms by which a high concentration of 
plasma fatty acids (FA) reduce vasodilation and increase vasoconstriction of terminal arterioles leading to a 
net increase in vascular tone of the microvasculature and a potential underperfusion of skeletal muscle in 
the fasted resting state. Insulin activates two pathways in the microvascular endothelium. The metabolic 
pathway (traditionally called insulin-signalling pathway) leads to vasodilation via production of nitric oxide 
(NO) which then diffuses to the vascular smooth muscle layer of the terminal arterioles, while the 
mitogenic pathway leads to vasoconstriction via production of endothelin-1 (ET-1). Elevated levels of FA 
promote serine rather than tyrosine phosphorylation of IRS-1 thereby impairing downstream activation of 
Akt/PKB leading to reduced NO production and vasodilation as well as reduced inhibition of the mitogenic 
pathway leading to increased ET-1 production and vasoconstriction. FA will also activate endothelial 
NADPH oxidase leading to superoxide anion production (O2-), which reduces NO bioavailability and basal 
vasodilation by scavenging NO. This reaction generates peroxynitrite, which increases vasoconstriction via 
mechanisms specified in the first paragraph of the Discussion. NADPH oxidase activation and scavenging 
of endothelial NO also reduces the protective effect of NO on atherosclerosis and vascular damage, and is 
one of the pathways playing a role in the transition from obesity into the metabolic syndrome and 
cardiovascular disease. Elevated FA levels can activate the NFκB signalling pathway which, in addition to 
contributing to the mechanisms reducing vasodilation and increasing vasoconstriction, leads to increased 
expression of cellular adhesion molecules and leukocyte adhesion (vascular inflammation) and activates the 
mechanisms that lead to atherogenesis and endothelial apoptosis. Abbreviations: IRS-1 – insulin receptor 
substrate-1; PI3K – phosphotidylinositol 3-kinase; Akt/PKB – protein kinase B; eNOS – endothelial nitric 
oxide synthase; MAPK – mitogen activated protein kinase; MAPKK – MAPK kinase; MAPKKK – 
MAPKK kinase; ERK 1/2 – extracellular signal-regulated kinase 1/2; NFκB – nuclear factor κB; O2-  – 
superoxide anion; ONOO-  – peroxynitrite.  Figure 3.1 is compiled with information taken from several 
references (Kim et al. 200518; Eringa et al. 200419; Brandes and Kreuzer 200520; Bedard and Krause 200721; 
Wagenmakers et al. 200622; Silver et al. 200723; Cardillo et al. 199924; Cusi et al. 200025; Jiang et al. 199926; 
Federici et al.  200227; Seger and Krebs 199528). 
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Inactivity appears to play an important role in the mechanisms that lead to 
vasoconstriction, as it is a cause of rarefaction and of increases in endothelin-1 (ET-1; 
Frisbee 200711; Thijssen et al. 200729; Thijssen et al. 200830).  Exercise training, on the 
other hand reduces vascular tone in the fasted resting state via decreases in ET-1 
(Thijssen et al. 200729; Thijssen et al. 200830), increases in endothelial nitric oxide 
synthase (eNOS) expression and protein content (McAllister and Laughlin 200631) and 
increases in capillary density both in healthy lean subjects (Andersen and Henriksson 
197732; Shono et al. 200233) and in obese subjects (Frisbee 200711; Gavin et al. 200513; 
Frisbee and Delp 200634).  
 
The aims of the present study were to (i) measure the blood volume present in the muscle 
microvasculature in the overnight fasted resting state and (ii) investigate whether acute 
changes in plasma FA concentration in lean and obese participants would change the 
microvascular blood volume (MBV).  Total haemoglobin concentration (THC) of the 
biceps brachii muscle, an indirect measure of MBV, was monitored using near-infrared 
spectroscopy (NIRS).  Niacin was used to reduce the plasma FA concentration (Carlson 
et al. 196835; Wang et al. 200036).  Participants underwent two 3 h trials, namely, placebo 
and niacin trials, to test the hypothesis that lowering of the plasma FA levels with niacin 
would reduce the basal vascular tone, and thus would increase the THC in the muscle. 
Four participant groups were studied: (i) lean active, (ii) lean sedentary, (iii) obese active, 
and (iv) obese sedentary.  The hypothesis was that the obese sedentary subjects, and 
potentially the lean sedentary subjects, would show an increased vascular tone in the 
fasted resting state and, therefore, would show an increase in THC upon lowering of the 
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circulating FA.  We also hypothesized that regular exercise counteracts the negative 
impact of obesity on endothelial function and that, therefore, the active groups would 
have a higher capillary density leading to a higher basal THC, and would have little or no 
increase in THC upon lowering of plasma FA due to the lack of active vasoconstriction 
mechanisms. 
 
Niacin ingestion is known to lead to an initial (3 hour)  decrease in plasma FA and then to 
a subsequent increase (rebound) within a period of 5-6 h (Carlson et al. 196835; Wang et 
al. 200036).  To monitor the size of the changes in plasma FA concentration and 
investigate the effect of the FA rebound on THC, we also performed a 6 hour study with 
blood samples taken to measure plasma FA. These studies were only performed in the 
two sedentary groups, as physical inactivity, by both decreasing capillarisation and 
promoting vasoconstriction, was regarded to be the main determinant of endothelial 
impairments leading to reduced skeletal muscle perfusion. The hypothesis to be tested in 
this second study was that the increase in plasma FA in the rebound phase after niacin 
ingestion would be large enough to increase net vasoconstriction in the lean sedentary 
group and would lead to a decrease in THC comparable to that of the obese sedentary 
group.  
 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Subjects 
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Thirty two healthy volunteers were recruited by word of mouth in the University of 
Birmingham.  The volunteers were divided into four groups of eight participants, namely 
(i) lean active, (ii) lean sedentary, (iii) obese active, and (iv) obese sedentary.  Their 
physical characteristics are displayed in Table 3.1.  Volunteers met individually with the 
researcher to discuss the study, provide written informed consent, and complete 
preliminary measurements including a general health questionnaire, a physical activity 
questionnaire, measurements of height and weight, and determination of NIRS optimal 
probe positioning (see below). The research has been carried out in accordance with the 
Declaration of Helsinki (2000) of the World Medical Association and has been approved 
by the Ethics Committee of the School of Sport and Exercise Sciences at The University 
of Birmingham.   
 
Table 3.1 Characteristics of the four participant groups   
 Lean Active Lean Sedentary Obese Active Obese Sedentary 
Age (years) 20.4 (±1.7) 20.4 (±2.3) 21.6 (±2.6) 24.0 (±5.1) 
Gender (m/f) 4/4 5/3 3/5 3/5 
Skin thickness (mm) 2.4 (±0.5) 3.1 (±0.5) 8.1 (±2.4) 11.4 (±2.8) 
Height (m) 1.72 (± 0.10) 1.73 (± 0.11) 1.72 (± 0.10) 1.70 (± 0.12) 
Weight (kg) 64.7 (± 0.13.3) 65.6 (± 8.7) 86.3 (± 25.7) 102 (± 25.2) 
BMI (kg/m2) 21.5 (±2.3) 21.8 (±1.6) 28.5 (±6.0) 34.6 (±3.5) 
Skin thickness was measured over the biceps brachii with skin fold callipers and represents an average of 
three measurements.  Values given are the mean of 8 subjects with standard deviations given in brackets.    
 
 
3.2.2 NIRS measurements 
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NIRS is a non-invasive optical technique based on the oxygen-dependent absorption 
changes of haemoglobin and myoglobin.  While differentiation between oxygenated and 
deoxygenated states of the chromophores can be made, it is not possible to distinguish 
between haemoglobin and myoglobin as their absorption spectra overlap (van Beekvelt et 
al. 200137).  We used a continuous-wave NIR spectrometer (ISS OxyplexTS 95306, 
Champaign IL, USA), which measures the absorbance of the NIR light at wavelengths of 
692 nm and 834 nm and uses calibrated software routines to calculate absolute 
concentrations from the measured NIR absorbance. Deoxygenated haemoglobin and 
myoglobin (Hb/Mb) absorbance was measured at wavelength 692 nm, while the sum of 
deoxygenated and oxygenated Hb/Mb was measured at wavelength 834 nm as they 
exhibit similar absorption coefficients at this higher wavelength (Wilson et al. 198938).  
Since myoglobin concentrations were unlikely to change over the testing period, the sum 
of the absorbance signals at 834 nm was taken to reflect the relative change in THC 
(assuming a constant haematocrit; Kell et al. 200439).  We assumed that the changes in 
THC would reflect changes in capillary blood volume as NIRS measurements primarily 
reflect the microcirculation in skeletal muscle (Mancini et al. 199440).  NIRS 
measurements were carried out on the biceps brachii with a probe having an interoptode 
distance (ID) of 3-4.4 cm.  This ID would allow a measurement depth of up to 2.2 cm 
based on the assumption that the measurement depth is half the ID (van Beekvelt et al. 
200137; Cui et al. 199141; Homma et al. 199642).  The NIRS measurement unit was given 
at least a 2 h warm up time as this minimised signal drift in time and was calibrated 
before each trial.  Data was sampled at 2000 Hz, displayed in real time, and stored on 
disk for off-line analysis.        
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 3.2.3 Determination of optimal probe position 
The optimum probe position for the individual was identified by systematically drawing 
five marks on the belly of the biceps brachii muscle of their dominant arm and making 
measurements with the NIRS probe for 2 min on each mark.  The mark with the highest 
THC value was noted as the optimum probe position for the individual.  The positioning 
marks were made with a black ballpoint pen and their placement was identified for each 
participant in the following way: (a) half distance between elbow (olcranon process) and 
shoulder (coracoid process) = mark 0; (b) circumference of arm at point 0 divided by 4; 
(c) value (0.25 of circumference) from point 0 across biceps towards inner arm = mark 1; 
(d) marks 2-5 are 1.5 cm from mark 1, as shown in Figure 3.2.   
 
 
2
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Figure 3.2 Position codes for determination of optimal NIRS probe position on the biceps brachii muscle 
of each participant. The positions were determined by (a) measuring half the distance between the elbow 
(olcranon process) and shoulder (coracoid process) = point 0; (b) measuring the circumference of the arm 
from point 0 and dividing it by 4; (c) the value (0.25 of circumference) from point 0 across biceps towards 
inner arm = mark 1; (d) marks 2-5 are 1.5 cm from mark 1. NIRS measurements were made for 2 min on 
each point and the point with the highest THC value was noted as the optimum probe position for the 
individual.   
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 3.2.4 Niacin 
Niacin (vitamin B3) is a nicotinic acid analogue which inhibits the release of FA from 
adipose tissue, thereby decreasing blood FA concentrations.  This mechanism involves 
niacin binding to the HM74 receptor on the adipocyte (Tunaru et al. 200343), leading to a 
suppression of intracellular cAMP levels which in turn decrease cAMP-dependent protein 
kinase activity.  The result is a reduced association of hormone sensitive lipase and the 
lipid droplets within the adipocyte, thereby decreasing lipolysis and the subsequent 
release of FA into the blood stream (Christie et al. 199644).  As skeletal muscle does not 
express the HM74 receptor, this effect of niacin remains specific to adipose tissue 
(Tunaru et al. 200343).  A particular characteristic of niacin is its biphasic effect on 
plasma FA concentrations as after the low FA phase a rebound phase follows, elevating 
FA levels above basal concentrations.  Pilot studies from our laboratory showed 500 mg 
of niacin to cause a decrease in FA commencing 10 min post capsule ingestion and 
reaching the lowest point at 60 min before beginning to rise again, surpassing baseline 
values 3 h post capsule ingestion, peaking at about 4 h and slowly returning towards 
baseline levels at about 5-6 h.  For this reason, the initial study only measured 3 h post 
niacin ingestion to investigate the effects of low FA, while measurements lasting 6 h post 
ingestion were made later in two of the four groups to investigate both the low and high 
FA conditions created by the niacin ingestion.  Side-effects of niacin ingestion include 
flushing, itching, nausea, gastrointestinal complaints, headaches, and skin rashes.  In the 
present study, 30-50 min after capsule ingestion, 31 out of 32 participants showed 
flushing characterised by redness of the face, neck, and arms.  Shortly after capsule 
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ingestion, 5 out of 32 participants reported a feeling of nausea which lasted 
approximately 15 min.          
 
3.2.5 Experimental protocol 1 
Participants visited the laboratory on two occasions arriving between 6 and 8 am in the 
overnight fasted state.  The day before testing, participants were instructed to refrain from 
exercise and ingestion of caffeine, as well as to consume a low fat evening meal at 7 pm, 
followed by only low-fat snacks if they could not resist additional food intake. They were 
instructed to refrain from food and calorie intake from 10 pm, drinking only water until 
completion of the trial the following day.  Visits were at least two days apart and were 
identical except for the contents of the capsules ingested.  Two capsules were given 
together, each containing 250 mg of either niacin or placebo (microcrystalline cellulose) 
and administration was double-blinded.      
 
Upon arrival at the laboratory, participants were asked to be seated and the NIRS probe 
was placed over the biceps brachii muscle in the previously identified optimum probe 
position.  The probe was randomly assigned to the left or right arm of each participant 
and placed on the same arm for both visits.  Once participants had the probe fastened with 
a Velcro strap on their arm, resting measurements were made for 10 min.  Subjects were 
then asked to ingest two 250 mg capsules both containing either niacin or placebo.  
Following ingestion, volunteers remained in the resting state for a 3 h measurement 
period after which the probe was removed and the subjects could leave the laboratory. 
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3.2.6 Experimental protocol 2 
The 16 volunteers from the sedentary lean and obese groups were asked to take part in 
two additional trials in which the measurement duration was increased to 6 h to include 
the FA rebound phase of niacin. Participants arrived at the laboratory between 6-8 am in 
the overnight fasted state.  Upon arrival at the laboratory, they were asked to lie down on 
the bed while a flexible 20-gauge Teflon catheter (Quickcath, Becton Dickinson, 
Plymouth, United Kingdom) was inserted in the antecubital vein and fitted with a 3-way 
stopcock (PVB Medizintechnik, Kirchseean, Germany) to allow for repeated blood 
sampling.  The NIRS probe was placed over the predetermined optimum position on the 
biceps brachii, and after a 10 min baseline measurement, a baseline blood sample was 
taken, and participants were asked to ingest two 250 mg capsules both containing either 
placebo or niacin, depending on the trial.  The 6 h NIRS measurement then commenced.  
Blood samples were taken every 30 min during the 6 h and participants were asked to 
remain at rest for the length of the trial.        
 
3.2.7 Blood samples 
Blood samples (7 ml) were collected in EDTA-containing tubes and centrifuged at 1,000 
g for 10 min at 4 °C.  Aliquots of plasma were frozen immediately in liquid nitrogen and 
stored at -80 °C.  Plasma FA concentrations were analyzed (NEFA-C; Wako Chemicals, 
Neuss, Germany), with a COBAS Mira Plus semiautomatic analyzer (ABX Diagnostics). 
 
3.2.8 Calculations  
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van Beekvelt (2001)37 proposed a calculation of the contribution of adipose tissue (+ 
skin) to the NIRS signal using the theoretical measurement depth and the recorded 
adipose (+ skin) thickness of the participants.  As the theoretical measurement depth 
equals half the ID (van Beekvelt et al. 200137; Cui et al. 199141; Homma et al. 199642) we 
should be able to measure a maximal depth of 2.2 cm (22 mm) with our 3-4.4 cm ID 
probe. The thickness of the skin and subcutaneous adipose tissue layer (skin thickness) 
for each participant group is shown in Table 3.1.  Based on this, the contribution of 
subcutaneous adipose tissue (+ skin) in our four participant groups can be calculated by: 
 
x  100      Skin thickness (mm) 
  ½ maximal ID (mm)  
 
3.2.9 Statistical Analysis 
One-tailed independent samples t-tests were carried out between niacin and placebo 
plasma FA values for the lowest average FA point and the highest average FA point of 
the niacin trials to determine if there was a significant difference in FA concentrations 
between trials at the low and high FA points.   
 
Two-tailed independent samples t-tests were carried out between baseline THC values of 
the four participant groups to investigate whether there are differences between groups 
that result either from a difference in capillary density and/or the net balance between 
vasodilation and vasoconstriction. 
 
For protocol 1 (3 h resting measure), THC data from 0-3 h (low FA phase) was 
summarized to four time points (Matthews et al. 199045), namely baseline, summary time 
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1, 2, and 3 as shown in Figure 3.2.  A three way analysis of variance (ANOVA) for 
repeated measures was carried out on THC data for trial and time between the four 
participant groups which completed the 3 h resting measure to investigate whether there 
were changes in THC content over time and between trial conditions in the low FA phase 
(0-3 h) for the 4 participant groups. 
 
For protocol 2 (6 h resting measure), THC data from 3-6 h (high FA phase)  was 
summarised to three points, namely summary time 1, 2, and 3 as shown in Figure 3.3.  A 
three way ANOVA for repeated measures was carried out on the THC data for trial and 
time between the two sedentary participant groups which completed the 6 h resting 
measure (protocol 2) to investigate whether there were significant changes in THC 
content over time and between trial conditions in the high FA phase (3-6 h). 
 
If significance was found the Bonferroni post hoc test was applied. 
 
All statistical tests were carried out using SPSS for windows version 16.0 software 
package (Chicago, IL, USA).  All data are reported as means ± SD and statistical 
significance was set at P < 0.05. 
 
 
3.3 RESULTS 
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In both protocols, there was no significant change in THC over time, and no difference in 
THC between trials. There were significant differences in baseline THC between lean and 
obese groups, but not between active or sedentary participants within the groups.   
 
3.3.1 Plasma fatty acids 
The blood samples taken in protocol 2 confirmed that the ingestion of 500 mg niacin led 
to an initial decrease in plasma FA concentrations of 48.4 % vs placebo followed by a 
rebound phase in which the plasma FA concentrations increased by 44.2 % vs placebo 
(Figure 3.3).  The lowest FA value of the niacin trial was significantly different from FA 
at the same time point (60 min) of the placebo trial (P = 0.004), and this was also true for 
the highest FA value of the niacin trial (210 min; P = 0.0085).      
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Figure 3.3 Plasma fatty acid (FA) data for niacin and placebo trials over 6 h. The niacin trial showed 
significantly lower FA levels at 60 min (FA = 172 ± 81 µM) compared to placebo (FA = 334 ± 132 µM) 
and significantly higher FA levels at 210 min (FA = 533 ± 190 µM) compared to placebo (FA = 370 ± 167 
µM; * P < 0.05).  Values given are the mean of 16 subjects (8 sedentary lean and 8 sedentary obese).   
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 3.3.2 Protocol 1 (low FA condition only) 
Analysis of baseline THC data showed that although active participants had greater THC 
values compared to their sedentary counterparts, these differences were not significant 
when assessed separately in the obese (P = 0.380) or lean (P = 0.502) subgroups.  The 
active lean and obese groups had significantly different baseline THC (P = 0.005) as did 
the sedentary lean and obese groups (P = 0.001).  Over the 3 h measurement period, no 
effect of trial on THC was found (P = 0.639), nor was there any change in THC over time 
(P = 0.122).  The lack of change in THC over time was not affected by groups (P = 
0.965).  Data is shown in Figure 3.4 and Table 3.2.  
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Figure 3.4 Mean total haemoglobin content (THC) for all 4 participant groups in placebo (P) and niacin 
(N) trials over 3 h. LA – lean active, LS – lean sedentary, OA – obese active, OS – obese sedentary. 
Numbers 1-4 reflect the summary time points used in analysis.   
 
Table 3.2 Total haemoglobin content at baseline in niacin and placebo trials for all 4 participant groups.   
 Lean Active Lean Sedentary Obese Active Obese Sedentary 
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Baseline niacin (µM) 83.76  (±28.60) 75.41  (±18.91) 42.33  (±21.20) 33.68  (±16.75) 
Baseline placebo (µM) 88.08  (±21.50) 73.84  (±13.97) 36.83  (±19.91) 32.49  (±19.24) 
Values are given as the means ± SD of 8 subjects in each group. 
 
 
3.3.3 Protocol 2 (low and high FA conditions) 
Figure 3.5 shows the THC data for the 6 h resting measure.  In the second half of the 6 h 
measurement period (reflecting the high FA phase), no significant effect of trial was 
found on THC (P = 0.364).  There was, however, a significant effect of time on THC (P 
= 0.022) which was attributable to a significant difference between time point 1 and 2 (P 
= 0.019).   THC was significantly different between lean and obese groups (P = 0.001). 
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Figure 3.5 Total haemoglobin content (THC) in protocol 2 for niacin (n) and placebo (p) trials with obese 
(O) and lean (L) sedentary groups. Numbers 1-3 reflect the summary time points used in analysis. 
 
 
3.4 DISCUSSION 
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 A large body of recent literature suggests that the acute and chronic exposure of the 
microvasculature to high circulatory FA concentrations plays a key role in the 
mechanisms that lead to an imbalance between resting fasted vasodilation and 
vasoconstriction in the overweight and obese state.  This provided the rationale to reduce 
plasma FA concentrations with niacin, a vitamin naturally occurring in our food.  Acute 
exposure of the microvasculature to high circulation FA levels prevented insulin-induced 
capillary recruitment in healthy lean rats in vivo (Clerk et al. 200246).  High levels of FA 
also reduced insulin-induced IRS-1 tyrosine phosphorylation and downstream activation 
of protein kinase B (PKB/Akt) and eNOS in cultured endothelial cells (Kim et al. 
200518), while insulin-induced Akt- and eNOS-activation were blunted in the aorta of 
obese Zucker rats (Naruse et al. 200647).  In the fasted resting state FA-induced 
impairments in Akt-activation have been suggested to not only reduce basal nitric oxide 
(NO) production and vasodilation in obese subjects with and without the metabolic 
syndrome, but to also relieve the inhibition of the mitogenic insulin signalling pathway 
(Figure 3.1) and thus explain the high plasma levels of ET-1, which is a potent local 
vasoconstrictor produced by the endothelial cells (Eringa et al. 200419; Thijssen et al. 
200830; Serne et al. 200648).  Secondly, high circulating levels of FA have been proposed 
to activate NADPH oxidase in the endothelium and vascular smooth muscle cells 
(VSMC) of the vascular wall and thus lead to excess production of superoxide anions 
(O2-; Brandes and Kreuzer 200520; Bedard and Krause 200721; Chinen et al. 200749).  
Superoxide anions scavenge NO thereby reducing basal vasodilation, while peroxynitrite, 
the end product of this reaction, has been shown to increase vasoconstriction via a variety 
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mechanisms (Pacher et al. 200750).  Excess O2- production, by scavenging endothelial 
NO, has also been suggested to reduce the protective effect of NO on atherosclerosis and 
vascular damage (McAllister and Laughlin 200631; Landmesser and Drexler 200751).  
Thirdly, FA have been shown to activate the nuclear factor κB (NFκB) signaling network 
in cultured endothelial cells (Oram and Bornfeldt 200417; Kim et al. 200518; Artwohl et 
al. 200452) and in obese Zucker rats (Chinen et al. 200749).  Activation of the NFκB 
pathway leads to reduced vasodilation as it decreases basal and insulin-stimulated Akt-
activation  (Figure 3.1; Chinen et al. 200749) and, via accumulation of prostaglandin H2 
(PGH2) resulting in thromboxane A2 (ThA2)/PGH2 receptor activation also leads to 
vasoconstriction (Barnes and Karin 199753; Yamamoto et al. 199554).  Activation of the 
NFκB pathway induces increased expression of cellular adhesion molecules and 
leukocyte adhesion (vascular inflammation) and activates the mechanisms that lead to 
atherogenesis and apoptosis (Wagenmakers et al. 200622).  Silver et al. (2007)23 recently 
provided evidence that the above mechanisms not only operate in obese subjects with the 
metabolic syndrome and cardiovascular disease, but also in overweight and obese 
individuals without obvious pathology, by showing increased protein expression of ET-1, 
NADPH oxidase and NFκB, and evidence of protein nitrosylation by peroxynitrite in 
vascular endothelial cells harvested from these individuals. 
 
Niacin was successfully used in this study to first decrease plasma FA concentrations 
with an average minimum value of only 49 ± 25 % of the overnight fasted baseline level 
and to then increase plasma FA concentrations in the rebound phase with an average 
maximum value of 153 ± 71 % of baseline.  This observation is in line with previous 
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studies showing this biphasic response to niacin (Wang et al. 200036).  Despite this 
successful manipulation of plasma FA there were no significant differences in THC 
between the niacin and placebo trials in each group.  No significant changes in THC over 
time were observed in any of the participant groups in protocol 1, but in protocol 2, time 
had a significant effect in the high FA phase.  However, inspection of the mean THC data 
(56.03, 57.27, and 57.15 μM for time points 1-3, respectively) revealed a small 
statistically significant 1.24 μM difference in THC between points 1 and 2.  Despite the 
statistical significance, this small difference is not regarded to be of physiological 
relevance and can be encompassed by the noise of the measurement signal. 
   
This absence of a relevant significant change in THC over time during the niacin trials for 
all participant groups leads us to conclude that our hypothesis that decreases in plasma 
FA concentrations would improve the net balance between vasodilation and 
vasoconstriction in the microvasculature of the muscle of sedentary subjects, while 
increases in plasma FA would increase net vasoconstriction in both lean sedentary and 
obese sedentary subjects, was not confirmed.  The results do show a significant difference 
in THC values between lean and obese groups in both protocols with higher values 
occurring in the lean. 
 
The fact that the THC in the muscle microvasculature, which represents the volume of 
blood in the muscle microvasculature, was higher in lean individuals than in obese 
individuals seems to indicate that obese individuals either have an increased net 
vasoconstriction, a lower density of capillaries (rarefaction), or a combination of the two.  
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Regular exercise is known to lead to angiogenesis (formation of new capillaries leading 
to a higher muscle capillary density; Frisbee 200711; Gavin et al. 200513; Andersen and 
Henriksson 197732; Shono et al. 200233).  In line with this, the active individuals in our 
study also had a higher THC than their sedentary counterparts, although the differences in 
THC between the two lean and the two obese groups were not significant due to the large 
individual variation in both of the groups.    
 
Alternatively, the large adipose tissue thickness (ATT) over the biceps muscle of the 
obese participants may be affecting the observed NIRS absorption.  The NIRS light 
photons pass through three tissues during measurement, namely the skin, the 
subcutaneous adipose tissue layer, and skeletal muscle tissue, and each one will 
contribute in varying degrees to the NIRS absorbance.  Skin capillaries apparently make a 
very small contribution (<5 %) to the NIRS signal when the ID is greater than 20 mm 
(van Beekvelt et al. 200137), as it was in our study.  Furthermore, the absence of a visible 
increase in THC despite obvious flushing following niacin ingestion supports the notion 
that skin contribution to NIRS absorption is negligible.  The NIRS absorbance due to 
adipose tissue (+ skin) in the four participant groups was estimated through a calculation 
proposed by van Beekvelt (2001)37.  The contribution of adipose tissue (+ skin) was as 
high as 51.8 % of the NIRS absorbance in the obese sedentary, 36.8 % in the obese 
active, 14.1 % in the lean sedentary, and 10.9 % in the lean active.  As there is evidence 
suggesting that the capillarisation of the adipose tissue is approximately one third lower 
than that of the most poorly perfused skeletal muscles in animals (Gersh and Still 194555), 
it is possible that the lower THC content in the obese groups may in part originate from 
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the increased contribution of the subcutaneous adipose tissue layer to the NIRS 
absorbance signal rather than being solely the reflection of rarefaction in the skeletal 
muscle bed.   
  
The calculation of tissue contribution to the NIRS signal also shows that over 
approximately half the NIRS absorbance should occur in skeletal muscle for both lean 
and obese groups.  This implies that the lowering of plasma FA did not lead to a change 
in the balance between vasodilation and vasoconstriction of either the skeletal muscle or 
adipose tissue microvasculature in any of the groups studied.  This is not in line with our 
observations of skin microvascular recruitment as clear flushing was seen shortly after 
niacin ingestion in 31 out of 32 participants, pointing at an increase in skin capillary 
perfusion.  The lowering of FA with acipimox also showed increased skin microvascular 
perfusion (de Jongh et al. 200456) when it was measured with capillaroscopy. Therefore, 
it would seem that a decrease in plasma FA has a different effect on skeletal muscle and 
subcutaneous adipose tissue microvascular perfusion as compared to skin.  
 
However, in the obese group, the absence of an effect on THC by the lowering of FA can 
possibly be explained by the short duration of the low FA phase.  Important causes of an 
imbalance between vasodilation and vasoconstriction in the obese are the increased gene 
expression and protein content of the enzyme NADPH oxidase and the transcription 
factor NFκB (Silver et al. 200723).  A reduction of the content of both of these proteins is 
quite likely to take more than 3 hours, which is the period with low FA concentrations.  
Furthermore, decreases in plasma FA concentrations do not necessarily lead to acute 
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decreases in the endothelial concentrations of the fatty acid metabolites (long-chain fatty 
acyl-CoA and diacylglycerol) that activate protein kinase C and increase serine 
phosphorylation of IRS-1 and thus reduce NO production and vasodilation in the resting 
fasted state (Naruse et al. 200647; Serne et al. 200648).  The duration of the low FA phase 
in other words may have been too transient to correct the most important mechanisms 
that lead to net vasoconstriction in the obese and this may explain the absence of an acute 
change in THC levels in this study.  To investigate whether more prolonged activation 
generates data in line with our hypotheses future studies should be carried out using 
prolonged use of niacin, a prolonged release form of niacin such as niaspan (Vogt et al. 
200757), or longer term acipimox (Bajaj et al. 200558) to induce low plasma FA over 
periods lasting several days.   
 
In conclusion, although it would be ideal if a vitamin like niacin could be used to acutely 
improve net balance between vasodilation and vasoconstriction our data support the 
conclusion that ingestion of a single bolus of niacin does not have this effect in a young 
obese group with a BMI of 31.6 ± 5.7.  The likely reason is that the FA lowering effect is 
too transient to reverse induction of NADPH oxidase and NFκB gene expression and 
reduce serine phosphorylation of IRS-1.  No effect on THC was seen in the 
microvasculature of both the muscle and subcutaneous adipose tissue in this study.  
Baseline THC measurements suggest that lean subjects have a higher muscle capillary 
density and/or an improved balance between vasodilation and vasoconstriction than obese 
subjects and that trained individuals in both groups have a higher capillary density than 
their inactive counterparts.  The actual differences in microvascular blood volume 
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between lean and obese groups might be smaller than the difference in THC observed 
with NIRS due to the fact that, in the obese groups, a larger proportion of the NIRS 
absorbance resides in the thicker subcutaneous adipose tissue layer which is known to 
have a lower microvascular density than skeletal muscle (Gersh and Still 194555).  
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Chapter 4 
 
 
LIMITATIONS OF NEAR-INFRARED SPECTROSCOPY AS A 
METHOD TO MEASURE MUSCLE MICROVASCULAR BLOOD 
VOLUME IN OBESE INDIVIDUALS 
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4.1 INTRODUCTION 
 
Obesity is associated with the development of a multitude of pathologies including type II 
diabetes and cardiovascular disease (CVD).  Both chronic diseases greatly contribute to 
increased morbidity and mortality rates in obese populations (for references see Chapter 
1).  Endothelial dysfunction of the microvasculature in skeletal muscle is considered  to 
be an early and central event in the mechanisms by which obesity leads to insulin 
resistance, type II diabetes and CVD (Bakker et al. 20091; Orasanu and Plutzky 20092; 
Jonk et al. 20073; Meyers and Gokce 20074; World Health Organisation 20065; World 
Health Organisation 19996).  In the skeletal muscle microvasculature, the loss of 
endothelial function has been shown to lead to reductions in (a) the microvascular blood 
volume present in skeletal muscle (Rattigan et al. 20067; Clerk et al. 20068), (b) the blood 
perfusion rate of the microvascular bed (Clark 20089), and (c) the capillary permeability 
surface area product (Gudbjornsdottir et al. 200310; Gudbjornsdottir 200511).  The 
capillary permeability surface area product is a measure of a molecule’s ability to be 
transported  from the capillary lumen into the interstitial fluid surrounding the muscle 
fibres (when applied to muscle) and thus is a major determinant of transendothelial 
nutrient, oxygen and insulin transport (Gudbjornsdottir et al. 200310).  While capillary 
permeability depends on molecule size and endothelial transport characteristics, capillary 
surface area depends on capillary recruitment and filling, and thus on terminal arteriolar 
vasodilation.  In addition to increasing the capillary surface area, vasodilation of the 
terminal arterioles is a major determinant of increases in microvascular blood volume 
(MBV) and microvascular flow velocity and thereby controls nutrient, insulin and oxygen 
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delivery to, and uptake by, skeletal muscle.  Endothelial dysfunction will result in an 
imbalance between vasodilation and vasoconstriction, and will reduce increases in MBV 
(Clerk et al. 20068) and permeability surface area product (Gudbjornsdottir et al. 200310; 
Gudbjornsdottir 200511) in response to glucose ingestion and insulin infusion.  The NO-
dependent vasodilation response to shear stress in feeding and resistance arteries is 
reduced by endothelial dysfunction in humans (Arcaro et al. 199912; Brook et al. 200113; 
Hamdy et al. 200314; Meyers and Gokce 20074) and in obese Zucker rats (Frisbee and 
Stepp 200115; Frisbee 200416).  Thus, during exercise, endothelial dysfunction may 
prevent shear-stress induced dilation of feeding and resistance arteries leading to a 
reduced supply of blood to the muscle microvascular bed.  Furthermore, net dilation of 
terminal arterioles by contraction-induced adenosine production and potassium release 
(Hudlicka 198517; van Teefelen 200618; Clifford and Hellsten 200419) is likely to be 
counteracted by several vasoconstriction mechanisms (Serne et al. 200620; Bakker et al. 
20091; Pacher et al. 200721) and to result in reduced increases in MBV during exercise.   
 
An imbalance between vasodilation and vasoconstriction will lead to net vasoconstriction 
and functional rarefaction (less blood in the muscle capillary bed as results of net 
vasoconstriction in the resting fasted state, after meal ingestion, and during exercise).  A 
sedentary lifestyle and endothelial dysfunction also leads, via impaired NO synthesis, to 
reduced angiogenesis and a decrease in the total number of capillaries (rarefaction).   
MBV measures the sum of rarefaction and functional rarefaction and is thus an important 
indicator of endothelial function.  An indirect measure of MBV can be obtained by near-
infrared spectroscopy (NIRS).  This simple, non-invasive technique involves placing a 
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NIR-light emitting probe on the skin above the desired sampling area.  NIRS is based on 
the absorption of NIR-light (650-1000nm) by haemoglobin and deoxyhaemoglobin, and 
on the Beer-Lambert absorption law.  The underlying principle is that the higher the total 
haemoglobin content (THC) in the sampling area, the more NIR-light is absorbed and not 
seen by the detectors.  Light photons that travel though large vessels in muscle and skin, 
such as arteries and veins, are unlikely to be detected due to 100 % absorption by the high 
local haemoglobin concentration.  Therefore, successful photon pathways in muscle will 
primarily proceed through minimal biological absorbers and in previous literature it has 
often been assumed that the NIR light absorption changes will mainly reflect changes in 
the haemoglobin content and oxygen saturation of the capillary network (Mancini et al. 
199422).  It is, however, quite likely that the smaller arterioles and venules also contribute 
to the observed NIR light absorption changes.  As NIRS equipment is relatively 
inexpensive and non-invasive, and the method uses simple assumptions and calculations, 
NIRS could in principle be the ideal method to measure changes in muscle MBV.    
 
The light photons, however, have to travel through the skin and adipose tissue layer 
before entering the muscle and then have to pass through the adipose tissue and skin once 
more to return to the detector on the skin surface.  As the subcutaneous adipose tissue 
layer can vary considerably between individuals it may very well present a limitation in 
the use of NIRS (van Beekvelt  et al. 200123).  It is possible that with a thick adipose 
tissue layer, the amount of light able to reach the muscle layer is affected, as is the 
amount of light returning to the detector from the muscle.  Thus in the obese population it 
remains uncertain as to whether NIRS can provide reliable information on skeletal 
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muscle MBV in vivo.  Therefore, the aim of the present study was to investigate the 
effect of the thickness of the subcutaneous adipose tissue layer on the THC measured 
with NIRS at rest and during incremental arm cranking exercise.  Exercise was chosen as 
means to increase MBV as it leads to much larger increases in MBV than meal ingestion 
or insulin infusion (Vincent et al. 200624; Clark 20089).  Three groups of individuals with 
skin thicknesses of < 3 mm, 4-6 mm, and > 8 mm above the biceps brachii, named group 
I, II, and III, respectively, were tested.  Two NIRS probes with different penetration depth 
properties, determined by the distance between light source and detector (termed 
‘interoptode distance’) were used to help verify the extent of the confounding effect of 
adipose tissue.  Probe A (‘superficial’) had interoptode distances of 2.0-3.5 cm and probe 
B (‘deep’) of 3.0-4.4 cm.  Participants had a NIRS probe strapped to the biceps of their 
dominant arm for 10 min resting measures followed by an incremental arm cranking 
exercise till self-perceived exhaustion. Measurements were made during exercise as this 
is known to lead to substantial increases in muscle MBV (Vincent et al. 200624), while 
only small MBV changes are assumed to occur in the subcutaneous adipose tissue.  This 
protocol was repeated twice: once with each NIRS probe, in participants from each of the 
3 skin thickness groups mentioned above.      
 
We hypothesize that when the subcutaneous adipose tissue layer is very thin, both probe 
A and B will give comparable THC measures at rest and during exercise, and we expect 
this to be the case in group I.  When the thickness is such that a significant part of the 
signal originates from the subcutaneous adipose tissue, then probe A will measure lower 
THC than probe B due to the adipose tissue contributing more to the NIRS signal and the 
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adipose tissue having a lower capillarisation (Gersh and Still 194525).  A thicker 
subcutaneous adipose tissue layer is also expected to reduce the increase in MBV during 
exercise.  We expect this to be the case in group II and III.  The extreme result could be 
that no light photons that have travelled through muscle tissue will be ‘seen’ by the NIRS 
detector in group III due to the large adipose tissue thickness.  In that case both probe A 
and B will measure low THC concentrations as the NIRS signal will principally reflect 
the adipose tissue perfusion and no increase in THC will be detected during exercise as 
there are only minimal changes in subcutaneous adipose tissue perfusion during exercise.  
 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Subjects 
Twenty four healthy volunteers were recruited by word of mouth in the University of 
Birmingham.  The volunteers were required to have skin thicknesses covering the biceps 
muscle falling into one of the three following categories, 0-3 mm, 4-6 mm, and 8-14 mm, 
termed group I, II, and III, respectively.  Their physical characteristics are displayed in 
Table 4.1.  Volunteers met individually with the researcher to discuss the study, provide 
written, informed consent, and complete preliminary measurements including a general 
health questionnaire, measurements of height and weight, and determination of NIRS 
optimal probe positioning (see below).  The research has been carried out in accordance 
with the Declaration of Helsinki (2000) of the World Medical Association and has been 
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approved by the Ethics Committee of the School of Sport and Exercise Sciences at The 
University of Birmingham, UK.    
 
Table 4.1 Characteristics of the three participant groups   
 Group I  Group II  Group III  
Gender (m / f) 5 / 3 4 / 4 3 / 5 
Age (yrs) 23.3 (± 3.01) 26.5 (± 2.45) 23.0 (± 3.11) 
Skin thickness (cm) 0.22 (± 0.05) 0.51 (± 0.06) 1.25 (± 0.22) 
Height (m) 1.76 (± 0.09) 1.75 (± 0.09) 1.71 (± 0.09) 
Weight (kg) 68.8 (± 9.56) 72.7 (± 12.5) 98.0 (±26.1) 
BMI (kg / m^2) 22.1 (± 1.85) 23.7 (± 3.00) 33.2 (± 5.60) 
Skin thickness was measured over the biceps brachii with skin fold callipers and represents an average of 
three measurements.  Values given are the mean of 8 participants ± standard deviations. 
 
4.2.2 NIRS measurements 
NIRS is a non-invasive optical technique based on the oxygen-dependent absorption 
changes of haemoglobin and myoglobin.  While differentiation between oxygenated and 
deoxygenated states of the chromophores can be made, it is not possible to distinguish 
between haemoglobin and myoglobin as their absorption spectrums overlap (van 
Beekvelt et al. 200123).  We used a continuous-wave NIR spectrometer (ISS OxyplexTS 
95306, Champaign IL, USA), which measures the absorbance of the NIRS light at 
wavelengths of 692 nm and 834 nm and uses calibrated software routines to calculate 
absolute concentrations from the measured NIR absorbance.  Deoxygenated haemoglobin 
and myoglobin (Hb/Mb) absorbance was measured at wavelength 692 nm, while the sum 
of deoxygenated and oxygenated Hb/Mb was measured at wavelength 834 nm as they 
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exhibit similar absorption coefficients at this higher wavelength. (Wilson et al. 198926).  
Since myoglobin concentrations were unlikely to change over the testing period, the sum 
of the absorbance signals at 834 nm was taken to reflect the relative change in total 
haemoglobin content or THC (assuming a constant haematocrit; Kell et al. 200427).  We 
assumed that the changes in THC would reflect changes in MBV as NIRS measurements 
primarily reflect the microcirculation in skeletal muscle (Mancini et al. 199422).  NIRS 
measurements were carried out on the biceps brachii with two probes of different 
interoptode distances (ID), namely 2.0-3.5 cm (probe A ‘superficial) and 3.0-4.4 cm 
(probe B ‘deep’).  The NIRS unit was given at least a 2 h warm up time as this minimised 
signal drift in time and was calibrated before each trial.  Data was sampled at 2000 Hz, 
displayed in real time, and stored on disk for off-line analysis.        
 
4.2.3 Determination of optimal probe position 
The optimum probe position for the individual was identified by systematically drawing 
five marks on the belly of the biceps brachii muscle of their dominant arm and making 
measurements with the NIRS probe for 2 min on each mark. The mark with the highest 
THC value was noted as the optimum probe position for the individual. The positioning 
marks were made with a black ball point pen and their placement was identified for each 
participant in the following way: (a) half distance between elbow (olcranon process) and 
shoulder (coracoid process) = mark 0;  (b) circumference of arm at point 0 divided by 4;  
(c) value (0.25 of circumference) from point 0 across biceps towards inner arm = mark 1; 
(d) marks 2-5 are 1.5 cm from mark 1, as shown in Figure 4.1.   
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Figure 4.1 Position codes for determination of optimal NIRS probe position on the biceps brachii muscle 
of each participant. The positions were determined by (a) measuring half the distance between the elbow 
(olcranon process) and shoulder (coracoid process) = point 0; (b) measuring the circumference of the arm 
from point 0 and dividing it by 4; (c) the value (0.25 of circumference) from point 0 across biceps towards 
inner arm = mark 1; (d) marks 2-5 are 1.5 cm from mark 1. NIRS measurements were made for 2 min on 
each point and the point with the highest THC value was noted as the optimum probe position for the 
individual.   
 
 
4.2.4 Protocol 
Participants were required to come to the laboratory for two visits, each at least one hour 
apart and maximum one day apart.  The two visits were identical apart from the NIRS 
probe, namely probe A or B.  To which visit probe A and probe B were assigned was 
randomised.  Participants were asked to refrain from exercising or ingesting a large meal 
less than an hour before testing.  
 
Visit 1.  Upon arrival to the laboratory participants were invited to sit in front of the arm 
crank machine and the assigned NIRS probe was fixed above the previously determined 
optimum position with a Velcro strap.  After a 10 min rest measurement period, stage 1 
5
4
1
of the exercise commenced.  The participant was asked to start arm cranking at one 
revolution per beat, as sounded by a metronome set to 50 beats per minute, at 12.5 Watts 
for 5 min.  At 15 sec before the end of stage 1, participants were asked to rate the 
perceived exertion of their arms, and of their body as a whole, using the Borg Scale of 
Perceived Exertion (1978), before progressing to exercise stage 2 at 25 Watts.  
Participants continued through the stages, reporting perceived whole body and arm 
exertion at the end of each stage, until they felt they could no longer continue.  All stages 
lasted 5 min and progressed from 12.5 Watts through 25, 37.5, 50, 75, and up to 87.5 
Watts (Figure 4.2).  Once participants completed their last stage, they were required to sit 
at rest with their arm on their lap for another 10 min rest measurement.  The probe was 
then removed and the first trial thus complete.   
  
Visit 2.  Participants were invited to sit in front of the arm crank machine while the other 
probe was placed over their previously selected optimum probe position mark.  With their 
arm resting on their lap, 10 min rest measurements were taken before commencement of 
exercise through the stages up to the same stage the individual had completed in the first 
visit.  A final 10 min rest measurement was made, after which the probe was removed 
and participants completed their testing.   
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10min      5 min     5min      5min        5min        5min       5min  10min 
REST  12.5W    25W    37.5W   50W  75W   87.5W REST 
Workload / Intensity of Arm-crank 
Exercise (Watts) 
Start 
Measurement  
Start of 
Exercise 
End of 
Exercise*  
END  
* exercise ends upon self-reported exhaustion at any point during progression through the 
set exercise stages 
  
 
Figure 4.2 Testing protocol.  The protocol begins with a 10 min resting measurement period.  Arm 
cranking exercise commences at 12.5 W for 5 min and continues with work load increments every 5 min 
until self-perceived exhaustion.  Another 10 min rest period follows. 
 
 
4.2.5 Statistical Analysis 
Two-tailed paired-sample t tests were carried out to locate differences observed between 
probes A and B at rest and during maximal exercise within each of the three groups for 
THC, percentage oxygen saturation (%O2), and oxygenated haemoglobin (HbO2).  Two-
tailed paired-samples t tests were also used to identify differences between rest and 
maximal exercise for probes A and B in the three participant groups.  Two-tailed 
independent-samples t tests were used to identify differences between groups for both 
probes at rest and maximal exercise THC, %O2, and HbO2.   
 
If significance was found the Bonferroni post hoc test was applied. 
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All statistical tests were carried out using SPSS for windows version 16.0 software 
package (Chicago, IL, USA).  All data are reported as means ± SE and statistical 
significance was set at P < 0.05. 
 
 
4.3 RESULTS 
 
4.3.1 Total haemoglobin content  
The principal finding was the distinct difference in THC measures between group I (ATT 
< 3 mm) and III (ATT > 8 mm) despite all participants exercising until exhaustion.  In 
group II (4 mm < ATT < 6 mm), a difference was visible between the measurements 
made by probe A and B, while both probes tended to have similar readings within group I 
and group III.  For all participants, there was a gradual increase in THC values as they 
progressed from rest through the exercise stages.  Figure 4.3 shows the mean results of 
each group, with the first and last phases of each group reflecting resting measurements 
and the phases in between reflecting the incremental exercise stages.  The number of 
exercise stages completed differed between participants thus in the last two exercise 
stages represented in Figure 4.3, the n numbers are less than 8 for all groups.  In order to 
eliminate the variation in exercise stages completed, the data was viewed in terms of 
mean baseline resting THC value (termed ‘rest’) and mean THC value of the final 
exercise stage completed (termed ‘max exercise’) for all participants.  The mean group 
values for rest and max exercise THC, as well as for the difference between these THC 
values (termed ‘increase’) are shown in Table 4.2.  
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Figure 4.3 Total haemoglobin content (THC) values observed in groups I, II, and III during rest, 
incremental arm exercise, and followed by rest again.  Values observed with probe A and B are given as 
means of 8 individuals.  Due to individual differences in exercise increments achieved, n < 8 for the final 2 
exercise increments in each group.   
 
Table 4.2 Total haemoglobin content (THC) at rest and during the final increment of exercise (max 
exercise) for probes A and B in groups I, II, and III.   
 Probe A Probe B 
Group I   
Rest 87 (± 12) 93 (± 12) 
Max exercise 103 (± 13) 111 (± 14) 
Increase 16 (± 3) 18 (± 3) 
Group II   
Rest 47 (± 25) 71 (± 13) 
Max exercise 62 (± 31) 94 (± 18) 
Increase 14 (± 10) 23 (± 9) 
Group III   
Rest 38 (± 12) 35 (± 16) 
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Max exercise 45 (± 15) 42 (± 19) 
Increase 7 (± 5) 7 (± 6) 
The increase shown is the change in THC from rest to maximal exercise.  Data is expressed as mean ± 
standard deviations in micromolars (μM). 
 
 
For group I, both probes gave the highest THC readings compared to groups II and III, 
and both rest and max exercise readings did not differ significantly between probes (P = 
0.076 and P = 0.057, respectively).  The THC increases from rest to max exercise for 
both probes were statistically significant (P = 0.001 for both probes) indicating a clear 
rise in MBV as participants progressed from rest through to maximal exercise for the 
measurement area underneath the probe. 
 
For group III, THC values did not differ significantly between probes at rest and during 
max exercise (P = 0.541 and P = 0.698, respectively). THC was significantly lower in 
group III than in group I for both probes at rest and during max exercise (P = 0.001 for all 
comparisons) as can be seen in Table 4.2.  The increase in THC from rest to max exercise 
for both probes did reach statistical significance (probe A P = 0.006, probe B P = 0.011) 
in group III, though the absolute increase in MBV was smaller than that seen in group I.     
 
In group II a significant difference was seen between probes for THC measures at both 
rest and during max exercise (P = 0.014 and P = 0.005, respectively).  Both probes 
showed significant increases in THC from rest to max exercise (probe A P = 0.006, and 
probe B P = 0.001), as was seen in group I and III.  Comparison of the THC measures at 
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rest and max exercise of probe A between groups I and II, showed statistically significant 
lower values in group II (P = 0.003 and P = 0.006, respectively).  However, the THC 
measures at max exercise of probe B between groups I and II were not significantly 
different (P = 0.052).  Conversely, comparison of the THC measures at rest and max 
exercise of probe A between groups II and III, showed no significant differences (P = 
0.359 and P = 0.186, respectively) while the THC measures at rest and max exercise with 
probe B were significantly different between groups II and III (P = 0.001 for both). 
 
4.3.2 Haemoglobin oxygenation 
In group I lower values for the HbO2 concentration were seen during max exercise than at 
rest for both probes, but the difference was not significant for either probe.  In groups II 
and III, however, higher values for the HbO2 concentration were seen during max 
exercise than at rest. The difference was only significant for probe A in both groups (P = 
.049 and P = .019, respectively).  HbO2 concentration data are shown for all groups and 
probes in Figure 4.4 and Table 4.3. 
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Figure 4.4 Oxygenated haemoglobin (HbO2) concentrations are given as mean values for groups I, II, and 
III at rest and maximal exercise (mean HbO2 value during the individual’s maximal workload) for probes A 
and B.   
 
Table 4.3 HbO2 expressed as group averages at rest and the final stage of exercise completion (max 
exercise) from each individual for probes A and B in groups I, II, and III.   
 Probe A Probe B 
Group I   
Rest 61.1 (± 9) 51.3 (± 15) 
Max exercise 55.7 (± 9) 45.6 (± 28) 
Increase -5.4 (± 10) -5.7 (± 19) 
Group II   
Rest 35.5 (± 21) 48.4 (± 8) 
Max exercise 41.6 (± 21) 49.8 (± 13) 
Increase 6.1 (± 7) 1.4 (± 12) 
Group III   
Rest 28.9 (± 10) 27.0 (± 9) 
Max exercise 31.7 (± 11) 30.4 (± 13) 
Increase 2.8 (± 3) 3.4 (± 7) 
The increase shown is the change in HbO2 concentration from rest to maximal exercise.  Data is expressed 
as mean ± standard deviations in micromolars (μM) 
 
 
4.3.3 Percentage oxygen saturation   
The % O2 saturation decreased significantly from rest to max exercise in group I for 
probe A (P = 0.001) and in group II for probe B (P = 0.038).  No significant decrease was 
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seen in group III. % O2 saturation data can be seen for all groups and probes in Figure 4.5 
and Table 4.4. 
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Figure 4.5 Percentage oxygen saturation (%O2) mean values for groups I, II, and III at rest and maximal 
exercise (mean %O2 value during the individual’s maximal workload).  Values are given for probe A and B.   
 
Table 4.4 Percent oxygen saturation (%O2) at rest and final stage of exercise completion (max exercise) 
from each individual for probes A and B in groups I, II, and III.   
 Probe A Probe B 
Group I   
Rest 69.8 (± 4) 54.6 (± 13) 
Max exercise 53.8 (± 6) 41.6 (± 23) 
Increase -16.0 (± 8) -13.0 (± 16) 
Group II   
Rest 74.1 (± 15) 67.8 (± 6) 
Max exercise 69.1 (± 15) 55.2 (± 17) 
Increase -5.0 (±6) -12.6 (± 14) 
Group III   
Rest 75.1 (± 9) 73.3 (± 11) 
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Max exercise 71.1 (± 7) 67.7 (±17) 
Increase -4.0 (± 5) -5.6 (± 9) 
The increase shown is the change in %O2 from rest to maximal exercise.  Data is expressed as mean ± 
standard deviations. 
 
 
4.4 DISCUSSION 
 
The present study demonstrates that NIRS may have major limitations if it is used to 
estimate MBV in skeletal muscle of obese individuals.  The significantly lower resting 
THC values in the obese group suggest that most of the signal is originating from the 
adipose tissue which has a lower capillarisation than skeletal muscle (Gersh and Still 
194525).  Furthermore, with increasing exercise intensity MBV and thus THC is expected 
to increase while HbO2 concentration and especially %O2 saturation are expected to 
decrease.  In the obese group (III) THC showed the smallest increase over the exercise 
period even though all groups achieved maximal exercise according to the ratings of 
perceived exertion (Borg scale 1978; Table 4.5).  Similarly, HbO2 concentration was very 
low for group III in comparison to groups I and II, and actually increased from rest to 
maximal exercise, with the increase from probe A reaching statistical significance.  The 
%O2 saturation showed the smallest decrease from rest to max exercise in the obese 
group as compared to groups I and II, and the decrease was not significant for either 
probe.  Taken together these results suggest that despite the increase in the ID (probe B), 
and the resultant increase in the penetration depth of NIR-light, the skeletal muscle made 
only a minor contribution to the absorbance of NIR light in the obese group.  
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 Table 4.5 Borg ratings for arms and whole body 
 
Group 
   Borg ratings 
          -arms-                       -body- 
Exercise duration 
(min) 
I 17.7 (± 1.3) 15.4 (± 2.9) 23:48 (± 3.5)  
II 17.5 (± 1.3) 13.9 (± 1.2) 20:36 (± 3.2) 
III 17.7 (± 2.0) 15.9 (± 3.2) 18:48 (± 4.4) 
Values are expressed as group means ± standard deviations and represent the final stage of exercise as well 
as mean exercise duration per group (n = 8).  
 
 
It has been suggested that the measurement depth of the NIRS is equal to half the ID.  
Initially this was based on in vitro experiments.  For example, Cui et al. (1991)28 found 
this to be true using intralipid emulsions as a phantom medium.  Later, Homma et al. 
(1996)29 tested this theory in the human leg with ATT ranging from 4-10 mm and IDs of 
20, 30, and 40 mm to find that the NIRS light penetrated at least deep enough to reach 
half the ID on all their tested combinations of ID and ATT.  However, in the present 
study, participants in group III had a mean adipose tissue thickness of 12.5 mm (± 0.22) 
and despite probe B having an ID of 44 mm our data indicates that the skeletal muscle 
made only a minor contribution to the absorbance of NIR light.  
 
A simple calculation of the theoretical skeletal muscle tissue contribution to the returning 
NIRS signal (not taking into account the different light-scattering properties of fat and 
muscle; van Beekvelt et al. 200123) would suggest a 47.5 % contribution with probe B for 
group III (Figure 4.6; Table 4.6).  The fact that we were unable to observe a substantial 
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increase in MBV from the skeletal muscle despite nearly half the signal theoretically 
originating from the muscle appears inconsistent with the calculations of the theoretical 
measurement depth.  This can potentially be explained by the scattering and absorption 
properties of the adipose tissue layer.  Rather than the adipose tissue layer simply adding 
to the penetration depth the photons need to travel in order to reach the muscle, the 
adipose tissue appears to scatter the photons thereby increasing their path length within 
the adipose tissue and thus reducing their penetration depth (Matsushita 199830).  Thus 
although the moderate ATT of our group II could be overcome by increasing the ID, the 
thickness of the adipose tissue layer in the obese group may have caused photon 
scattering and thus increased the adipose tissue path length to such an extent as to 
significantly reduce penetration depth and skeletal muscle contribution to the NIRS 
measurement.   
 
Figure 4.6 Theoretical contribution of adipose tissue (dots) and muscle tissue (lines) to the NIRS signal for 
probe A and B in groups I, II, and III.  The maximal theoretical penetration depth is calculated as half the 
interoptode distance (ID).  Probe A has a maximal ID of 3.5 cm, reflecting a theoretical penetration depth 
of 1.75 cm while probe B has a maximal ID of 4.4 cm, reflecting a theoretical penetration depth of 2.2 cm.   
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 Table 4.6 Relative contributions of adipose and muscle tissue to the NIRS signal for probes A and B. 
 
 
Probe A 
            Adipose                      Muscle 
Probe B 
            Adipose                        Muscle 
Group          % mm       % mm           %   mm        % mm 
I 12.6 2.2 87.4 15.3 10.0 2.2 90.0 19.8 
II 29.1 5.1 70.8 12.4 23.0 5.1 76.8 16.9 
III 71.4 12.5 28.0 5.0 56.8 12.5 47.5 9.5 
 
Values are expressed as percentage and millimetre contributions and are based on the theoretical 
calculation of measurement depth equalling half the interoptode distance (ID).  Probe A has a maximal ID 
of 35 mm, reflecting a theoretical penetration depth of 17.5 mm while probe B has a maximal ID of 44 mm, 
reflecting a theoretical penetration depth of 22 mm. 
 
 
It is not possible to underpin the above conclusion with hard evidence as part of the 
reason for the lower resting THC value in group III may also be the result of a lower 
capillary density and net vasoconstriction in the muscle of obese individuals (Gavin et al. 
200531; Frisbee 200732). Furthermore, the reduced increase in MBV during exercise may 
in part originate from a reduced net vasodilation of the terminal arterioles and therefore a 
reduced increase in MBV in the muscle during exercise (Arcaro et al. 199912; Brook et al. 
200113; Hamdy et al. 200314; Meyers and Gokce 20074).  However, the differences 
observed between groups I and III are large, and together with the theoretical estimates of 
the adipose tissue contribution to absorbance of the NIRS photons, lead to the conclusion 
that NIRS cannot be used to generate reliable estimates of MBV and oxygen saturation in 
obese subjects.   
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 In conclusion, the data in the present study suggest that NIRS does not produce reliable 
information on the MBV in skeletal muscle even when a probe with an ID of 44 mm is 
used in obese participants with an ATT of 12.5 mm ± 0.22.  This appears to be due to the 
fact that the detected signal primarily originates from the adipose tissue layer and 
differences in the microvasculature of adipose tissue and muscle will confound the 
adaptation of the muscle to the obese state.  Thus for the obese population contrast 
enhanced ultrasound (Vincent et al. 200624) seems to be required for the measurement of 
muscle MBV and for the detection of capillary recruitment defects in response to meal-
induced increases in insulin concentration and exercise.   
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Chapter 5 
 
 
METHOD DEVELOPMENT OF CONTRAST ENHANCED 
ULTRASOUND FOR THE MEASUREMENT OF SKELETAL 
MUSCLE MICROVASCULAR BLOOD VOLUME  
AND FLOW IN THE HUMAN FOREARM 
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The results of the experiment investigating the influence of adipose tissue thickness 
on NIRS measurements of skeletal muscle total haemoglobin content in chapter 4 led 
to the conclusion that NIRS was not a suitable tool to make such measurements in the 
muscle of obese individuals.  We thus moved on to use a direct method to measure 
microvascular blood volume and blood flow, namely contrast enhanced ultrasound 
(CEU).  This method was not in use in our laboratory and publications from groups 
using CEU lacked detailed descriptions and explanations of the procedures involved 
in preparation, testing, and analysis.  Therefore this chapter describes in detail the 
effects of various preparation, testing, and analysis procedures on the data obtained 
with CEU, concluding with a description of the ideal CEU protocol for research in 
skeletal muscle perfusion of the human forearm.   
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5.1 The theory of contrast enhanced ultrasound 
 
The contrast enhanced ultrasound method involves the infusion of microspheres 
which serve as a contrast-enhancing agent by acting as reflectors of the ultrasound 
beam.  The microspheres remain entirely within the vascular space and have a similar 
size and rheology to red-blood cells.  As they have a high echogenicity and, therefore, 
increase the contrast between blood and the surrounding tissues, they are an excellent 
tracer to measure the main perfusion variables (blood volume and blood flow 
velocity).  The microspheres are administered as a constant infusion into the venous 
circulation and can be visualised by ultrasound in the tissue of interest.  The 
videointensity of the image that is obtained with ultrasound is proportional to the 
concentration of the microspheres within the volume of tissue being imaged 
(microvascular blood volume) and is dependent on the frequency of the ultrasound 
beam.  A single pulse of high-energy ultrasound is subsequently administered to 
simultaneously destroy all the microspheres within the ultrasound beam.  Following 
this destruction, the rate of microsphere replenishment is measured and will reflect the 
blood flow velocity, while the plateau level of microspheres reached after the 
destruction again will reflect blood volume.  As the larger vessels will fill more 
quickly, a background subtraction of the average videointensity generated within 1 
second after the high-energy pulse is applied.  This will eliminate the larger vessels 
from the analysis.  Although it is not exactly known which size vessels are included in 
this analysis, it is generally assumed that they are terminal arterioles, capillaries 
(major contribution), and first and second degree venules.  In this way, the CEU 
technique is expected to provide information on microvascular blood volume (MBV) 
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and microvascular blood flow velocity (MFV), while the product of the two gives 
microvascular blood flow (MBF). 
 
 
5.2 Aim of the chapter 
 
The main reason to develop the CEU technique in our laboratory is our interest in 
impaired endothelial function in obesity and its potential negative impact on skeletal 
muscle perfusion in the period following meal ingestion and during exercise.  The 
primary aim of this chapter is to establish optimal conditions for maximal 
reproducibility and sensitivity of the CEU technique in human beings.  In chapter 6 
the optimal method will be subsequently used to investigate whether an oral glucose 
tolerance test in healthy trained men will lead to a detectable increase in skeletal 
muscle MBV, MFV and blood flow (product of MBV and MFV).  
 
 
5.3 Protocol 1: CEU with Luminity and a multiple microsphere destruction 
protocol  
 
The first protocol that we tested to make CEU measurements of MBV and MFV was 
the protocol used by Vincent et al. 20061.  As the paper contains very little detail of 
the CEU method used, Dr. George Balanos of our School went to the laboratory in 
Virginia to see the procedure and subsequent analysis.  The preparation, testing, and 
analysis procedures used by Vincent et al. 20061 are described below. 
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 5.3.1 Preparation procedures 
Brand of microbubble 
As Luminity was used in Vincent et al. 20061 (product name in the USA is ‘Definity’) 
we too ordered Luminity microspheres and their characteristics are shown in Table 
5.3.  
 
Dilution of microspheres 
We followed the recommendation by the manufacturer and diluted one vial of 
Luminity in 50 ml of 0.9 % isotonic saline.   
 
Ultrasound machine 
The ultrasound machine requires certain presets to perform CEU imaging protocols.  
In most situations, the machine will also dictate the acquisition and analysis program 
that can be used as well as the probe that can be used.  In our experiments we used the 
Philips Sonos 5500, the same as used in Vincent et al. 20061, with the cardiac 
transducer (S3).    
 
Ultrasound imaging protocol  
There are essentially two different imaging protocols which can be used to capture an 
imaging sequence for calculation of MBV and MFV.  One protocol involves a 
sequence of microsphere destructions, using a high energy ultrasound pulse, with 
increasing time intervals to monitor the microsphere replenishment.  The other 
protocol involves a single destruction followed by one complete replenishment curve 
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until plateau.  The laboratory in Virginia uses the multiple microsphere destruction 
protocol and that is the method we initially adopted.   
 
Multiple microsphere destruction protocol.  The protocol involves simultaneously 
imaging and destroying all microspheres within the ultrasound beam by using a high-
energy ultrasound pulse.  In this protocol the ECG waveform was used to trigger the 
image capture and microsphere destruction at specific pulse intervals.  Three images 
were captured at each of the following pulse intervals: 1, 2, 3, 4, 5, 8, 12, 15, and 20.  
In this way, the increasing length of time between the simultaneous image captures 
and destructions allowed for greater microsphere replenishment and eventually 
plateau formation in the higher pulse intervals.  The data was then collated in relative 
time to create a single replenishment curve occurring over 20 heartbeats.  The length 
of time required to complete this protocol was dependent on the individual heart rate 
and was approximately 5 minutes.   
 
5.3.2 Experimental protocol in human volunteers 
Measurement set up  
The participants arrived in the morning after fasting overnight.  Participants were 
asked to lie down on a bed and their dominant arm was rested on a pillow in a natural 
and relaxed position so as to be able to maintain this position without movement for 
the entire acquisition period.  The ultrasound probe was positioned manually over the 
forearm flexor muscles and held in the desired place by a clamp attached to a flexible 
arm and fixed onto a heavy metal base.  The probe position was drawn on the 
participant’s arm so that CEU measurements at later time points during the testing 
were made in a close to similar position for reasons of comparison.  A single lead 
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ECG was used to generate the pulse intervals required during the CEU protocol to 
trigger microsphere destruction and image capture.  
 
Administration of microspheres 
The administration of the microspheres required several steps including activation, 
dilution, handling once activated, infusion, and timing of acquisition commencement.  
The activation of Luminity microspheres involved vigorous shaking for 40 seconds in 
a mechanical shaking device (VIALMIX®) provided by the company.  The activated 
microspheres were transferred to a syringe containing 50 ml saline and were then 
ready for infusion.  Once activated, the microspheres need to be maintained in 
suspension to ensure a constant infusion concentration.  This was achieved by gentle 
manual rotation of the infusion pump containing the syringe. The Luminity 
microspheres were infused at a rate of 1.6 ml/min, as recommended by the suppliers, 
and a steady state (constant plateau level of the videointensity) was reached in the 
vasculature in 3 min.  The multiple destruction imaging protocol explained above was 
activated 3 min after the start of the constant intravenous infusion.  
 
Data acquisition protocol  
On the ultrasound machine, the programmed autobeat sequence was located by  
selection of ‘tools’ => ‘contrast agent’ => ‘physio’ => ‘autobeat sequence’.  Once the 
3 min of infusion was complete the ‘acquire’ command was selected.  The ultrasound 
then commenced with the autobeat sequence and went through the programmed pulse 
intervals (1, 1, 1, 2, 2, 2, 3, 3, 3, etc) explained above.  Once the sequence was 
completed the data were automatically saved and the acquisition stopped.   
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Care was taken to avoid accidentally touching or changing any controls which alter 
the intensity of the ultrasound image during measurement and between measurements 
in the same participant.  Changes in MBV in response to a physiological signal (e.g. 
glucose ingestion or exercise) are based on relative changes of the intensity of the 
ultrasound image.  Thus changing any of the settings that influence the echo-intensity 
will invalidate comparisons between CEU measurements.  These settings include 
compression, gain (including the sliding time gain compensation and lateral gain 
controls) and frequency.   
 
5.3.4 Analysis procedure and data quality check using QLAB 
The CEU data acquired was originally analysed with the QLAB software from Philips 
(version 5.0), which was designed for cardiac CEU work.  The data was imported into 
QLAB, images for analysis were selected and a region of interest was drawn as a 
contour of the flexor muscles.  Imaging sequences with artifacts or movement were 
edited, an automatic background subtraction and curve fit was then applied, and MBV 
and MFV data automatically generated.  It soon became clear, however, that the 
automatic background subtraction did not work properly in the QLAB software.  
When a background subtraction is applied in QLAB, for some reason, the ± 1.5 
decibels (dB) difference between the first image and the last image of the sequence is 
lost as the first image is given an unexplained echo mean of 1 dB, while the 
subsequent images remain in echo means similar to the values before the background 
subtraction was applied (Figure 5.1).  We were unable to make sense of this and 
Philips was unable to explain to us how their QLAB program calculated the 
background subtraction for the sequence or to provide us with a solution for this 
problem.  For this reason, we simply used QLAB to define the images for analysis, 
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create regions of interest and check images for movement.  The data was then 
exported from QLAB for manual completion of the analysis.        
 
 
 
Figure 5.1 Background subtraction using QLAB.  Depicting the data before (A) and after (B) 
background subtraction of first image in sequence.  Graph presented in absolute time for easier 
visualization.  
 
 
5.3.5 In house analysis procedure 
Exporting data form QLAB to Microsoft Excel  
In QLAB, brackets were used to define the start and end of the sequence, any 
erroneous slides (movement or other artifacts) were eliminated, the sequence was 
selected to be graphed in relative time on the x-axis and, without any background 
subtraction or fitting to a curve, the data was exported by saving it as a Microsoft 
Excel file.  In Excel the data was converted from decibels to acoustic intensity (AI) 
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and the average of three images taken at the end of the first pulse interval was used as 
the background value, and was thus subtracted from the rest of the data.  The data was 
converted from dB to AI because the latter has a linear relationship with increasing 
blood volume thus any increase in blood volume is reflected by an equally 
proportional increase in AI, where as this relationship is not simple and linear with 
dB.    
 
Curve fitting 
Once having been converted to AI and undergone background subtraction, the data 
were inserted into SigmaPlot where the following exponential function was applied to 
the curve: f=a*(1-exp(-b*(x-1))), where f is the videointensity, a is plateau 
videointensity representing MBV, b is rate constant reflecting the rate of rise of 
videointensity representing MFV, and x is the pulsing interval.  This resulted in the 
generation of MBV and MFV values.   
 
Creating an optimal region of interest 
As previous studies in rats and man did not explain how to select the region of interest 
(ROI) we performed a series of analyses to define the ROI that gave the most 
reproducible result.  Originally we created detailed ROIs of the contour of the muscle 
on the ultrasound image in line with practice at the University of Virginia (Figure 
5.2).  However, a small change in the ROI gave a rather large change in the measured 
MBV and MFV (Table 5.1).  This was thought to possibly be due to variation in the 
presence of larger vessels in close proximity to the muscle, and we therefore rejected 
this method.   
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 Figure 5.2 Three slightly different contours ROIs.  The sequences are plotted below to show increasing 
videointensity created by the microspheres over relative time. 
 
Table 5.1 Microvascular blood volume and flow velocity values for contours ROIs 
 MBV (AI) % difference 
from ROI 1 
MFV 
(1/sec) 
% difference 
from ROI 1 
ROI 1 121790.6 / 0.074277 / 
ROI 2 133099.0 9.29 0.060595 18.42 
ROI 3 128755.9 5.72 0.062154 16.32 
Data presented in acoustic intensity (AI) obtained from SigmaPlot after analysis with QLAB and Excel 
as described in section 5.5 for the three variations in contours ROI.  The percentage difference from 
ROI 1 is presented for both MBV and MFV values.   
 
 
In the subsequent analysis we created ROIs that had a more general shape, were 
slightly smaller than the muscle on the image, and would fit within the contour.  In 
this way we expected to exclude a variable contribution of larger vessels surrounding 
the contours of the muscle.  I refer to these as ‘medium’ ROIs and these are shown in 
Figure 5.3.  The variations in the MBV and MFV of these medium ROIs were also 
large.  In addition, a substantial proportion of the medium size ROIs did not give an 
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acceptable exponential curve fit in Sigmaplot and thus no MBV and MFV values 
could be attained.  
 
 
Figure 5.3 Medium ROIs, all of which did not converge in SigmaPlot and thus no A and B values 
could be attained.  The sequences are plotted below to show increasing videointensity created by the 
microspheres over relative time. 
 
 
We thus attempted to use very small ROIs, as routinely done in cardiac CEU.  These 
were created to fit clearly within a central aspect of the muscle which showed little or 
no artifact influence, as discerned by continuously running through the sequence of 
images to ensure the ROI was placed as accurately as possible in such a desired 
position (Figure 5.4).  However, once again, there were problems with the curve 
fitting in SigmaPlot so only MBV and MFV values for ROI 3 were obtained.  
Therefore the use of ‘small’ ROIs was also rejected. 
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 Figure 5.4 Small ROIs.  Only one of the 3 small ROIs gave data that could be converged by SigmaPlot 
to give MBV and MFV values.  These were distinctly different from those given by the full and 
contour ROIs.  The sequences are plotted below to show increasing videointensity created by the 
microspheres over relative time. 
 
 
Furthermore, it can be seen in the plotted graph for the three small ROIs (Figure 5.3), 
that there is much more variation in the videointensity over time than with the 
contours and medium ROIs.  This is likely explained by the larger ROIs being able to 
‘average out’ regional variations in videointensity (potentially the consequence of 
smaller variation in larger vessel contribution or other echogenic structures), and 
provide a more homogenous, and therefore reproducible and accurate, representation 
of the muscle microvascular blood volume.   
 
We next attempted the use of an entire image ROI, which will be referred to as ‘full 
ROI’.  Full ROIs are used by the laboratory of Dr. Stephen Rattigan in rat muscle 
CEU (Figure 5.5).  Although this would also include non-muscle tissue surrounding 
the muscle, the background subtraction done to eliminate the contribution of large 
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vessels, according to Dr. Rattigan, would also eliminate the contribution of non-
muscle tissues as their perfusion would not be changing.  In order to confirm this, 
ROIs were created in the tissue outside and surrounding skeletal muscle in the video 
image. The resultant QLAB analysis indicated that there was no replenishment of the 
microsphere videointensity in the surrounding tissues after high-energy pulse 
destruction.  
 
SigmaPlot analysis produced MBV and MFV values for the three full ROIs, and the 
variability in these values between the three full ROIs was smaller as compared to the 
contours, medium and small ROIs (Table 5.2).  Furthermore, in the plotted graph for 
the three full ROIs (Figure 5.5), there is clearly less variation in the videointensity 
over time as compared to the small and medium ROIs, and even the contours ROIs.  
For this reason, and because the full ROIs are much easier to create, we chose to use 
the full image ROI.   
 
 
Figure 5.5 Three slightly different full image ROIs, plotted below to show increasing microsphere 
intensity over relative time.  
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Table 5.2 Microvascular blood volume and flow velocity values for full ROIs 
 MBV  
(AI) 
% difference 
from ROI 1 
MFV  
(1/sec) 
% difference 
from ROI 1 
ROI 1 41864.78 / 0.157826 / 
ROI 2 44601.81 6.54 0.158246 0.27 
ROI 3 39207.20 6.35 0.162030 2.66 
Data presented in acoustic intensity (AI) obtained via SigmaPlot after analysis with QLAB and Excel 
as described in section 5.5 for the three variations in full ROI.  The percentage difference from ROI 1 is 
presented for both MBV and MFV values.   
 
 
5.3.6 Conclusions on CEU with Luminity and multiple microsphere destruction 
protocol 
The alterations made in the analysis procedure as described above gave us confidence 
in our ability to accurately and consistently analyse CEU data in single sequences 
using the multiple microsphere destruction protocol.  However, when we used this 
procedure for repeated measurements before and during oral glucose tolerance tests 
(see Chapter 6) it became clear that there were other sources of variation in 
physiological experiments lasting longer than 1 hour and consisting of several CEU 
measurement time points.  
 
One source of variation came from the removal and replacement of the ultrasound 
probe on the participant’s arm between CEU measurements within the experimental 
protocol.  This likely disrupted the acquisition of consistent and comparable CEU data 
because, although the probe was being placed as accurately as possible on the same 
place over the forearm flexor muscles, it was difficult to be very accurate with the 
flexible arm which held the probe and we had no means to control the angle at which 
the probe was placed at each measurement time point.  A change in probe angle meant 
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a different section of the muscle was imaged and thus comparisons between CEU data 
with slightly different muscle sections were not very meaningful.   
 
A second source of variation was that many subjects were not able to prevent arm 
movement, or muscle contraction and movement, during the ± 5 min acquisition time 
for the multiple microsphere destruction protocol.  The arm movements which 
occurred during testing resulted in several imaging sequences having to be discarded 
in the analysis process when movement of the muscle within the image was identified 
and/or led to poor curve fits, thereby resulting in incomplete data. 
 
For these reasons we decided to further optimize the positioning and stability of the 
arm and the positioning and stability of the probe, while reducing the acquisition time 
of one sequence by using a single microsphere destruction protocol.  
 
 
5.4 Protocol 2: CEU with SonoVue and single microsphere destruction protocol  
 
5.4.1 Preparation procedures  
Brand of microsphere 
As Luminity microspheres were withdrawn from the European market in August 2008 
and legal restrictions prevented us from purchasing them in the USA, where 
production continued, we were forced to switch to SonoVue®.  It is heavily used in 
cardiac CEU imaging and gave promising results in a few pilot studies in the human 
forearm (data not shown).  The characteristics of SonoVue microspheres are shown in 
Table 5.3.   
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 Table 5.3 Comparison of the characteristics of commercially available microspheres. 
  Luminity® perflutren 
 
SonoVue® sulphur hexafluoride 
Supply company Bristol Myers Squibb 
 
Bracco 
Storage requirements Before activation: refrigerator (2-8°C) 
After activation: do not store above 30°C 
 
Does not require any special storage 
conditions 
Contents of microsphere kits 1.5 ml vial of Luminity® perflutren  1 vial containing 25 mg lyophilised 
powder in an atmosphere of sulphur 
hexafluoride, 1 pre-filled syringe of 5 ml 
sodium chloride (0.9 %), 1 Mini-Spike 
transfer system   
 
Activation method Vigorous shaking via shaking device 
VIALMIX® 
 
Mix  powder and solvent by hand shaking  
Concentration of microsphere 
gas per ml 
1ml of Luminity contains approximately 
150 μL of perflutren gas 
 
1ml contains 8 μL of sulphur hexafluoride 
gas 
Mean diameter range of 
microspheres 
 
1.1-2.5 µm 2.5 µm 
Active shelf-life 12 hours; but it can be re-activated up to 
48 hours after initial activation and used up 
to 12 hours after the second activation 
Sonovue should be used within 6 hours of 
preparation;  If sonovue is not used 
immediately after reconstitution, the 
dispersion needs to be shaken again before 
being drawn up into a syringe  
 
Stability in suspension Increased stability of microspheres due to 
high molecular weight of perflutren gas 
thus stable in suspension for 12 hours 
 
Chemical and physical stability has been 
shown for up to 6 hours 
Infusion concentration safety 
limit 
 
1 vial (1.6 ml) per person per study 4 vials per person per study 
Recommended dilution 1 vial in 50 ml isotonic saline When mixed each vial results in 5 ml 
solution which requires no further dilution 
 
Recommended infusion rate for 
skeletal muscle use 
 
1.6 ml/min or 96 ml/h  1ml /min 
Support for use Mechanical shaking device VIALMIX® 
for microsphere activation; no support for 
maintaining suspension once activated - 
infusion pump is rotated manually 
All microspheres supplied with activation 
kit  and infusion kit (Vueject kit); mixing 
infusion device (Vueject pump) is 
available for maintaining bubbles in 
suspension once activated  
 
All information obtained directly from the respective supply companies. 
 
 
Ultrasound imaging protocol 
After consultation with Dr. Stephen Rattigan we set up an alternative imaging 
protocol measuring replenishment after a single microsphere destruction. This 
protocol has been repeatedly used in his laboratory in experiments in rats.  In this 
protocol we record replenishment as a continuous sequence of images taken at every 
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heartbeat for 20 beats after the destruction pulse.  A low ultrasound intensity 
(mechanical index) was used to capture the images so as not to destroy the 
microspheres during replenishment.  This protocol took approximately 20 seconds to 
complete and we ran 8 of these sequences at a frequency of 1 sequence per 40 sec for 
each measurement time.  The average MBV and MFV of the 8 sequences was used to 
obtain an accurate value of MBV and MFV at each time point.  The key benefit of 
using this protocol was the short duration, which reduced the risk of participant 
movement during imaging and also allowed repeated measurements for each time 
point to strengthen the reliability of data comparisons made between time points.   
 
5.4.2 Experiment protocol in human volunteers 
In the testing procedures, there are three differences compared to protocol 1.  These 
differences lie in the positioning of the arm and the probe, the infusion protocol of the 
microspheres, and the data acquisition sequence and mode of analysis. 
 
Stable and reproducible positioning of arm and probe 
During the first series of tests with Luminity we discovered that it is of vital 
importance to avoid movement of the arm and contractions of the skeletal muscles 
when acquiring the ultrasound imaging sequence, as movement will reduce the quality 
and reliability of the data.  
 
To ensure a stable position of the probe under a fixed angle we created a holder for 
the ultrasound probe.  The holder consists of two detachable parts: one part contains a 
mold in which the probe fits securely, and this fits precisely into the second part 
which is fixed to the arm (Figure 5.6).  This second part of the holder is fixed in place 
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by double sided medical tape to help avoid movement during testing.  This allowed us 
to detach the probe between ultrasound measurements if necessary, while being able 
to accurately reposition the probe in both placement and angle for subsequent 
measures within the same testing visit.  In this way, we were able to measure the same 
tissue section over the different measurements, allowing for comparisons of MBV and 
MFV between time points.  To our knowledge, such a holder to improve probe 
position reproducibility between measurements has not been used in any of the 
previous studies using CEU in man (Vincent et al. 20061, Clerk et al. 20062, Keske et 
al. 20093; Liu et al. 20094).   
 
To ensure a comfortable and relatively immobile positioning of the patient’s arm, with 
ideal exposure of the measurement area, we used a vacuum support cushion (RBF 
products limited, Essex, UK).  When the vacuum is created by use of a foot pump, the 
cushion will form a cast of the participant’s arm, thereby supporting their arm in this 
comfortable position and limiting the potential for arm movement. 
 
 
Figure 5.6 Stable measurement set up with vacuum support cushion and ultrasound probe holder  
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 Administration of microspheres 
The administration of SonoVue microspheres involves several steps, namely, 
activation and transfer to a single syringe, set up of syringe in mechanical mixing 
infusion pump, infusion rate selection, and timing of acquisition commencement.   
 
SonoVue comes in powder form and is activated by mixing with 5 ml of 0.9 % saline 
solution.  The vial containing the lyophilized powder, the pre-filled syringe containing 
the saline, and the Mini Spike transfer system to connect the vial to the syringe, are all 
provided in each SonoVue microsphere kit.  The saline is emptied from the syringe 
into the vial via the transfer system and to activate the microspheres the vial is shaken 
vigorously by hand for 20 sec until a white milky liquid is seen.  In line with the 
supplier recommendation we used 4 vials per person per testing visit. This implies 
that the content of 4 activated vials was transferred via the Mini Spike system to a 
single 20 ml syringe also provided in the infusion kit (Vueject kit).  The Vueject kit 
also contained an infusion line and cannula, both of which should be used as other 
cannuli and infusion lines may bind or damage the microspheres during infusion.  In 
our hands, the use of standard lines and cannulae substantially reduced the echo signal 
and did not lead to replenishment curves with a good exponential fit (data not shown).  
The activated microspheres in the 20 ml syringe were kept in suspension by use of a 
mechanical mixing infusion pump (Vueject pump, Bracco, UK).  
 
In order to achieve a steady state of microspheres in the circulation before 
commencement of acquisition, we found that a priming of 2 ml/min for 1 min 
followed by 1 ml/min for another 1 min was sufficient in creating a steady state.  The 
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principle of a priming dose is that the sum of the decline in microsphere enrichment 
from the priming dose and the rise in microspheres from the continuous infusion will 
equal the eventual plateau microsphere enrichment (Wolfe and Chinkes 20045).  In 
this way, after 2 min of infusion, steady state was achieved and acquisition could 
begin.  The infusion rate during acquisition was then maintained at 1 ml/min as this 
was found to be sufficient to produce optimal ultrasound images during the single 
microsphere destruction protocol.   
 
Data acquisition protocol 
Once the 2 min infusion was complete ‘acquire’ was selected on the ultrasound 
machine, the timer was started, and immediately ‘impulse’ was selected in the ‘tools’ 
menu.  A flash appeared with the high-energy ultrasound pulse and 20 heart beats 
from the impulse were counted before ‘acquire’ was selected again to stop acquisition 
and save the data.  This sequence took approximately 20 sec, depending on the 
participant’s heart rate. When the timer approached 40 sec ‘acquire’ was selected and 
at 40 sec ‘impulse’ was selected.  Once again, 20 heart beats were counted before 
stopping the acquisition as described above.  A total of 8 sequences were collected at 
40 sec intervals for the time point before the infusion was stopped.      
 
5.4.3 Detailed analysis procedure  
The analysis of the ultrasound data involved three basic steps: (1) the conversion of 
the microsphere intensity on the image sequences to numerical data via QLAB, (2) the 
background subtraction to provide data reflecting microvascular perfusion in 
Microsoft Excel, and (3) fitting the data to an exponential curve to obtain MBV and 
MFV in SigmaPlot. 
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5.4.3.1 QLAB 
We used the Philips QLAB version 5.0 for the initial step in the analysis of our CEU 
data.  This initial step required several procedures, as discussed below. 
 
Importing images on to QLAB 
The ultrasound sequences were transferred from the ultrasound disk to the computer 
and the first sequence to be analysed was opened via the QLAB program.   
 
Selecting the optimal region of interest 
As explained in section 5.3.5, the full image ROI was found to be ideal, and was thus 
applied to the analysis here.    
 
Using same ROI for all subsequent measurements  
In order to make accurate comparisons between sequences it is best to use the exact 
same full image ROI for all sequences.  This was done via a standard ‘copy and paste’ 
procedure of the desired ROI into other sequences.  First, an ROI (shape did not 
matter) was inserted in all the sequences that required copying of the desired ROI 
into.  In the standard procedure the ‘square 5mm’ ROI was selected for this purpose 
and placed at random in each of the relevant sequences.  The ‘square 5 mm’ ROI was 
used for two reasons:  firstly, since it could be selected in one click and secondly, 
because this ROI was much smaller than the full image ROI and could, therefore, be 
easily recognised as the initial ROI used for copying purposes only.  
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Once the desired ROI was created in the first sequence, and the square 5 mm ROIs 
were placed in all the other sequences that needed to be analysed, the subsequent steps 
were followed to copy and paste the desired ROI into the other sequences.   
 
1.  ‘My Computer’ => ‘C drive (C:\)’ => ‘program files’ => ‘Philips’ => ‘QLAB’ => 
‘persistent data’.  In ‘persistent data’ the folder with the folders of the sequences for 
analysis was identified and opened. 
2.  Inside, the folders of all the sequences which have ROIs drawn were found.  The 
sequence with the desired full ROI to be copied was identified.   
3.  The folder of that sequence was opened and by right clicking over the 
‘parameters.xml’ file a little menu appeared in which ‘copy’ was selected. 
4.  Selecting the ‘back’ button we then opened the next sequence folder and, by right 
clicking within it, selected to ‘paste’.  The computer asked if we wanted to replace the 
existing ‘parameters.xml’ file and provided the sizes of the files for comparison.  
Indeed we wanted to replace the little ‘parameters.xml’ (for the square 5mm ROI) 
with the larger one which was our desired full image ROI.  We clicked ‘yes’ and 
moved on to paste it in the next sequence. 
5.  When the desired ROI was pasted in the folders of all the sequences needing to be 
analysed, we returned to QLAB.   Each sequence in which the desired ROI was pasted 
needed to be opened and the new ROI activated by left clicking slowly twice on the 
ROI, being careful not to move it or alter its shape.  This caused QLAB to reset its 
calculations using the pasted ROI instead of the square 5 mm ROI with which it had 
previously run its calculations.  Right clicking twice resulted in a flash on the screen 
as though it was resetting itself with the new calculations for the new ROI but it was 
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not!  To activate the new ROI, we had to left click slowly twice, being careful not to 
move the ROI.    
 
Checking sequence images 
Once the ROI was in place, each sequence was checked image by image for any 
movement or artifact within the sequence.  In the rare occurrence that affected slides 
were found and these greatly altered the final A and B values, the slide could be 
discarded if occurring near the end of the sequence or the entire sequence could be 
discarded and the average A and B values for that time point obtained from 7 as 
opposed to 8 sequences.   
 
Exporting the echomean of each sequence from QLAB to Microsoft Excel 
We simply used the brackets to define the true start and end of the sequence, 
eliminated any erroneous slides if applicable, ensured the sequence was graphed in 
relative time for multiple destruction protocol and absolute time for single destruction 
protocol on the x-axis and, without any background subtraction or fitting to a curve, 
exported the data by saving it as a Microsoft Excel file.   
 
5.4.3.2 Analysing the Excel file 
Upon opening of the Excel file, the data for the ROI was presented in three columns, 
namely (i) Absolute Time (sec), (ii) Echomean (dB), and (iii) Echomean Std Dev 
(dB).  The first two columns were copied and pasted into a separate Excel sheet and in 
this new sheet the steps detailed below were carried out.  Figure 5.7 shows the final 
layout of the Excel sheet in a format that can be used for SigmaPlot analysis. 
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 Figure 5.7 Microsoft Excel sheet final layout of data ready for SigmaPlot analysis.  Data shown for 
single destruction protocol. 
  
 
Converting the echomean units from decibels to acoustic intensity 
As QLAB 5.0 only provided the videointensity values of the data in decibels (dB), 
which has a non-linear relation to MBV, the data needed to be converted to acoustic 
intensity (AI) as this has a linear relationship which means increasing MBV values are 
linearly represented by increasing AI values, thereby allowing for relative analysis.  
To convert the videointensity from dB to AI, a new column (column C) was created 
adjacent to that of echomean in dB (column B) and the function [=10^(B2/10)] was 
applied, with ‘B2’ being the cell which has the echomean in dB for that time point.  
Then the ‘C2’ cell which contained the dB to AI conversion function and all the 
empty cells beneath it were selected.  The commands ‘edit’ => ‘fill’ => ‘down’ were 
used to automatically apply the function to the rest of the time points and the result 
was a column of echomean in AI (column C).   
 
Background subtraction 
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The background value was selected as the echomean in AI for the image taken closest 
to 1 sec after microsphere destruction.  In the example shown in Figure 5.7, the image 
taken at 0.66 sec was selected as the background image.  Two new columns were 
created (column F and G) to display the background value and time selected for that 
sequence particular sequence.  Column D was created for the values in which the 
background value was subtracted from the AI data in column C.  The absolute time 
and echomean in AI with background subtraction (column A and D starting from and 
including row 3) were used in SigmaPlot to fit an exponential curve to the data for the 
calculation of MBV and MFV, as described below. 
 
5.4.3.3 SigmaPlot 
Importing data into SigmaPlot  
To import data into SigmaPlot columns A and D (starting from and including row 3) 
were copied from the Excel spreadsheet and pasted into the SigmaPlot spreadsheet as 
columns 1 and 2. 
 
Fitting a curve to the data 
Before proceeding to fit the curve, the cells which contain the relevant data were 
selected.  This was done quickly by clicking on the little box icon as shown circled in 
Figure 5.8.  Alternatively this was achieved by clicking on ‘edit’ => ‘select all’.  If 
this was not done, the data was not graphed correctly, though the numeric results were 
the same.  The steps below were subsequently carried out:   
1.  ‘Statistics’ => ‘regression wizard’ => ‘exponential rise to max’ 
2.  In the equation category ‘single, 2 parameter’ equation name was selected 
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3.  To incorporate the background subtraction, the equation was modified by clicking 
the ‘edit code’ tab and then the ‘add as…’ tab and providing the new equation name 
(“background subtraction”) in the box that appeared.  The equation was then adjusted 
by adding the subtraction of the background time in sec from ‘x’.  In our example, the 
background image was taken at time 0.66 sec, thus the equation was adjusted from 
f=a*(1-exp(-b*x)) to f=a*(1-exp(-b*(x-0.66))).  We then clicked ‘ok’ to save the 
equation.  In the future this equation appeared under the ‘user-defined’ equation 
category and had to be modified in this way for every individual sequence by 
incorporating the precise background value time for that sequence.   
4.  Once the sequence was modified, the ‘next’ commands were used to continue 
through the steps of the regression wizard during which the columns for the data and 
the outputs were selected.  The ‘first empty’ columns for the outputs were always 
selected.    
 
Sigmaplot output 
In the ‘parameters’ column of the data page, the first value given was the A value or 
MBV, and the second value was the B value or MFV.  Both were calculated from the 
data after curve fitting (Figure 5.8).  The graph produced by SigmaPlot displaying the 
curve fit of the data to the exponential rise to max equation is shown in Figure 5.9. 
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 Figure 5.8 SigmaPlot output spreadsheet. 
 
 
Figure 5.9 Graph produced by SigmaPlot representing the curve fit of the data for the equation f=a*(1-
exp(-b*(x-0.66))). 
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5.4.3.4 Conclusions on CEU with SonoVue and single microsphere destruction 
protocol 
Two key alterations were made to the testing procedure, namely the stable 
measurement set up with the probe holder and vacuum cushion and the single 
destruction protocol.  These alterations greatly reduced the chances of arm and muscle 
movement and increased the accuracy of probe placement and angle between time 
points if the probe was temporarily removed.  This allowed for the collection of MBV 
and MFV data which was comparable between time points. 
 
Furthermore, the use of the single destruction protocol reduced the chance of arm and 
muscle movement during sequence acquisition due to its short duration.  This also 
permitted the collection of 6-8 sequences per measurement time point.  By collecting 
several sequences per time point, outliers potentially caused by involuntary movement 
could be discarded and the data for the particular time point simply averaged from 
less sequences.  This is a major difference with the multiple microsphere destruction 
protocol in which movement often meant that the data at that particular time point 
were lost.  By using the average of multiple sequences, a more accurate value of MBV 
and MFV for a given time point was obtained, thus increasing the reliability of the 
statistical comparison between time points.  For MBV, the intra-individual coefficient 
of variation (CV) of our first subject at baseline and 1 h post glucose ingestion was 
17.8 % and 23.7 %, respectively, and this assured us the method was effective and 
promoted us to continue with other subjects. 
 
These alterations made to the testing procedure, namely the single destruction 
protocol and the stable measurement set up, provided us with reproducible and 
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meaningful data during pilot testing.  This gave us confidence in our ability to 
measure a change in MBV over repeated time intervals.  We thus used this method to 
measure MBV in response to an OGTT in lean trained healthy individuals, as detailed 
in Chapter 6.      
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Chapter 6 
 
 
MICROVASCULAR BLOOD VOLUME INCREASES IN RESPONSE 
TO AN OGTT IN FOREARM SKELETAL MUSCLE OF LEAN 
TRAINED HUMANS 
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6.1 INTRODUCTION 
 
The world is facing an obesity epidemic accompanied by a dramatic increase in obesity-
related pathologies (World Health Organisation 20061).  Particularly striking is the 
increase in type II diabetes and cardiovascular disease (CVD; World Health Organisation 
20062; Gonzalez and Selwyn 20033).  An important contributor to the pathogenesis of 
obesity is impaired glycemic control after meal ingestion.  Skeletal muscle is the largest 
site for glucose disposal (Ferrannini  et al. 19854; Defronzo et al. 19855; Nuutila et al. 
19946) and the meal-induced increase in circulating insulin promotes glucose clearance 
by (i) activating signalling pathways in the vascular endothelium which induce 
vasodilation and microvascular perfusion under normal conditions (Liu et al. 20097), and 
(ii) activating insulin signalling in skeletal muscle leading to GLUT4 translocation from 
the microsomal stores to the plasma membrane (Chang et al. 20048; Thong et al. 20059; 
Wojtaszewski and Richter 200610).  The obese population, however, show impaired 
vasodilation and skeletal muscle perfusion in response to insulin infusion (Clerk et al. 
200611; de jongh et al. 200412) and to meal-induced increases in insulin (Keske et al. 
200913).  Consequently, glucose and insulin delivery to the muscle and subsequent 
glucose uptake is impaired, resulting in prolonged glucose excursions after meal 
ingestion (Krentz et al. 200914).  Elevated glucose levels exacerbate the endothelial 
dysfunction (Brownlee 200515), and over time chronic hyperglycemia will develop.  
These sustained elevations in plasma glucose play a significant role in promoting 
vascular dysfunction and further devastate glycemic control (Krentz et al. 200914).    
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It is therefore important to develop interventions for improving the vascular response to 
insulin after meal ingestion in individuals with non-complicated obesity so as to halt the 
developing vascular dysfunction, restore glycemic control, and avoid the progression to 
type II diabetes and CVD (Krentz et al. 200914).  A principal outcome measure of such 
interventions would be a greater increase in skeletal muscle microvascular blood volume 
(MBV) in response to physiological (nutrient-stimulated) increases in insulin.  A larger 
MBV by definition leads to an increased capillary permeability surface area product and 
a faster rate of glucose uptake by skeletal muscle (Gudbjornsdottir et al. 200316).  In 
addition, improved endothelial function as a result of successful intervention may lead to 
increases in microvascular flow velocity (MFV) and microvascular blood flow (MBF), 
the product of MBV and MFV.  In order to be able to evaluate the effect of obesity and 
the effectiveness of interventions in future studies, in the present study we aim to test the 
reliability of the CEU method developed in chapter 5 to measure skeletal muscle MBV 
and MFV responses during an oral glucose tolerance test (OGTT) in healthy lean trained 
individuals.   
 
Contrast enhanced ultrasound (CEU) is emerging as the preferred method for the 
measurement of human skeletal muscle MBV and MFV (Vincent et al. 200617; Clerk et 
al. 200611; Porter 200918; Womack et al. 200919; Keske et al. 200913).  CEU involves the 
infusion of microspheres (contrast agent the size of red blood cells) which can be 
visualised by ultrasound in the tissue of interest.  The videointensity of the image 
obtained is proportional to the concentration of microspheres within the volume of tissue 
being imaged.  A single pulse of high-energy ultrasound is administered to 
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simultaneously destroy all the microspheres within the ultrasound beam.  Subsequently, 
the rate of microsphere replenishment is measured and will reflect MFV while the plateau 
level of microspheres reached after destruction will reflect MBV.  As the larger vessels 
will fill more quickly, a background subtraction of the average videointensity generated 
within 1 second after the high-energy pulse is applied.  This will eliminate the larger 
vessels from the analysis.  Although it is not exactly known which size vessels are 
included in this analysis, it is generally assumed that they are terminal arterioles, 
capillaries (major contribution), and first and second degree venules.  In this way, the 
CEU technique is able to provide measures of MBV and MFV, and the product of these 
variables: MBF. 
 
In the present study, we used CEU to measure MBV and MFV in 10 lean, healthy 
participants before and 1 h into an oral glucose tolerance test (OGTT).  An OGTT was 
used as it induces a greater insulin response than a mixed meal (Vincent et al. 200617; 
Keske et al. 200913) and is simple and less invasive than a hyperinsulinaemic euglycemic 
clamp.  Therefore, an OGTT is more practical for the repeated measurement of MBV 
responses to insulin when evaluating the effectiveness of interventions aimed at 
improving this response in obese individuals.  
 
The primary aim of the study was to obtain an accurate estimate of baseline MBV and to 
assess the effectiveness of the CEU technique in measuring an increase in MBV in 
response to an OGTT in lean, healthy, trained individuals.  The assumed underlying 
mechanism is that the increased plasma insulin levels in response to an OGTT would 
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induce vasodilation of the terminal arterioles, subsequently increasing MBV (Barrett et 
al. 200920).  This would increase the capillary permeability surface area product and 
therefore allow for insulin stimulated glucose clearance into the muscle fibres 
(Gudbjornsdottir et al. 200316; Barrett et al. 200920).  In addition, increases in insulin 
during the OGTT may also lead to increases in MBV by inducing vasodilation and 
increasing blood flow velocity higher up the arterial tree (Barrett et al. 200920; Clark et al. 
200321).  These will be investigated by measurements of brachial artery diameter and 
flow using Doppler Ultrasound. 
 
Increases in glucose and insulin concentrations during the OGTT are expected to lead to 
rapid increases in glucose oxidation and suppression of fat oxidation (Sidossis and Wolfe 
199622; Sidossis et al. 199623), and therefore to a rapid switch between fat and 
carbohydrate (CHO) as main fuels in the transition from the early morning fasted state to 
the glucose fed state.  Such a rapid switch has been termed ‘metabolic flexibility’ 
(Storlien et al. 200424) and we hypothesise that metabolic flexibility is dependent on 
adequate increases in MBV.  Failure to increase MBV in obese subjects during meal 
ingestion (Keske et al. 200913) and during a hyperinsulinemic euglycemic clamp  (Clerk 
et al. 200611) reduced glucose uptake in skeletal muscle.  Gudbjornsdottir et al. (2005)25 
also observed a reduced increase in capillary permeability surface area product and 
reduced muscle glucose uptake in obese individuals, entirely in line with the impaired 
metabolic flexibility observed in obese individuals (Storlien et al. 200424; Corpeleijn et 
al. 200826). 
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Furthermore, the elevated insulin concentration will promote diet-induced thermogenesis 
(DIT) in healthy lean individuals measured both at whole body level (Lowell and 
Bachman 200327; de Jonge and Bray 199728; Tappy 199629) and in skeletal muscle 
(Petersen et al. 200530).  DIT has several components.  In the insulin sensitive skeletal 
muscle, the increased activation of mitochondrial oxidation, and the increase in glycogen 
and protein synthesis after meal ingestion greatly contribute to DIT (Petersen et al. 
200530; Wagenmakers 200531).  Here, we hypothesise that the increase in DIT is 
dependent on an adequate increase in MBV and that this is the mechanism behind the 
lower DIT at whole body level that has previously been observed in obese individuals (de 
Jonge and Bray 199728; Tappy 199629). As previously proposed by Wagenmakers 
(2005)31, failure of insulin to increase MBV might also explain the substantial reduction 
in the increase in muscle ATP turnover observed in the insulin resistant offspring of 
parents with type II diabetes in comparison to lean controls during a hyperinsulinemic 
euglucemic clamp (Petersen et al. 200530). 
 
In conclusion, we hypothesised that in lean trained insulin sensitive subjects the OGTT 
would induce an increase in plasma insulin, followed by an increase in MBV and blood 
flow in feeding arteries. This would be attended by a rapid transition from fat to 
carbohydrate as the primary fuel, and a substantial increase in DIT.  Originally we 
planned to make a comparison between the effect of an OGTT in the lean trained group 
and in an obese group, but as the development of the CEU method took much more time 
than expected we have not been able to investigate the other leg of the hypothesis: that in 
obese subjects the OGTT will not increase MBV and the blood flow in feeding arteries 
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and that, therefore, in the obese the transition from fat to carbohydrate as the primary fuel 
will be delayed (metabolic inflexibility; Storlien et al. 200424; Corpeleijn et al. 200826) 
and the increase in DIT will be smaller (de Jonge and Bray 199728).   
 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Subjects 
Ten lean, trained, healthy male volunteers were recruited by word of mouth in the 
University of Birmingham.  Volunteers met individually with the researcher to discuss 
the study, provide written informed consent, and complete preliminary measurements 
including a general health questionnaire, a physical activity questionnaire, measurements 
of height and weight, blood pressure, cardiac echocardiograph, and a blood sample for 
fasting glucose concentrations.  Participant characteristics are displayed in Table 6.1.  
The research was carried out in accordance with the Declaration of Helsinki (2000) of the 
World Medical Association and was approved by the Birmingham East, North and 
Solihull Research Ethics Committee.  
 
Table 6.1.  Mean participant characteristics 
Age (yrs) 28  (± 3.2) 
Height (m) 1.78  (± 0.04) 
Weight (kg) 76.2  (± 6.31) 
BMI (kg/m2) 24.1  (± 1.4) 
Fasting glucose (mmol/L) 4.65  (± 0.32) 
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Fasting insulin (μlU/ml) 7.81  (± 2.29) 
Blood pressure – systolic 122  (± 7.9) 
                          - diastolic 69 (± 5.2) 
Values are expressed as means ± standard deviations. 
 
 
6.2.2 CEU measurements 
Four vials of SonoVue microspheres (Bracco, Amsterdam, the Netherlands) were 
activated according to the company guidelines and their content was combined in a single 
20 ml syringe.  This was placed in the Vueject mixing infusion pump (Bracco, 
Amsterdam, the Netherlands) which maintained the microspheres in suspension by gentle 
rotation during the entire protocol. The participant’s arm was rested on a vacuum support 
cushion (RBF products limited, Essex, UK) which created a cast of the arm, thereby 
supporting it in a comfortable position and limiting the potential for arm movement 
during data acquisition.  A specially made ultrasound probe holder was fixed over the 
forearm flexor muscles of the participant to ensure stable positioning of the probe at a 
fixed location and angle between measurements.  The microspheres were infused at 2 
ml/min for 1 min followed by 1 ml/min to create a plateau microsphere plasma 
enrichment before data acquisition as confirmed in pilot studies (data not shown).  A 
single high energy ultrasound pulse was used to destroy the microspheres and the 
subsequent reperfusion data was recorded for 20 pulse intervals in a period of 
approximately 20 seconds.  Measurements were made with the Philips Sonos 5500 and 
the cardiac transducer (S3).  Eight such sequences were recorded per measurement time 
point and analysed via QLAB, Microsoft Excel, and SigmaPlot to generate MBV and 
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MFV data, of which the average of the 8 sequences was used to determine accurate MBV 
and MFV values for each time point.  A detailed description of the CEU protocol can be 
found in chapter 5.    
 
6.2.3 Doppler Ultrasound 
Brachial artery blood flow measurements were performed using Doppler ultrasound.  An 
ultrasound system (Philips, Sonos 5500) with a linear transducer (3-11 MHz) was used to 
acquire an image of the brachial artery in the longitudinal plane approximately 5 cm 
proximal to the antecubital fold.  Colour Doppler mode was used to identify the flow 
within the vessel and then pulse wave spectral traces were obtained in order to measure 
the velocity of the flow.  Subsequently, two-dimensional imaging of the brachial artery 
was performed.  Images were triggered to the R wave of the cardiac cycle, and the 
brachial artery diameter was measured using online video callipers.  Blood flow was 
calculated using the following equation: 
 
where Q is brachial artery blood flow, v is mean brachial artery blood flow velocity, and 
d is brachial artery diameter. 
 
6.2.4 Indirect Calorimetry 
Overnight fasted resting metabolic rate and diet induced thermogenesis were measured 
by indirect calorimetry.  This method makes indirect estimates of the heat produced by 
the combined metabolic processes going on in the human body.  Indirect calorimetry or 
respirometry measures the respiratory exchange of O2 (consumption) and CO2 
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(production).  O2-consumption can be used to calculate metabolic rate as, in the aerobic 
oxidation processes that cover the metabolic needs, the amount of heat produced is 
proportional to the quantity of oxygen consumed.  To translate the amount of oxygen 
consumed to equivalent heat production, the relative amounts of carbon and hydrogen 
oxidized must be known.  In practice this is done via simultaneous measurements of CO2-
production and the use of equations of the chemical reactions that describe the 
combustion reactions involved in the oxidation of glucose, fatty acids, and protein.   
 
The ventilated hood method is an open-circuit indirect calorimetry method.  The 
ventilated hood, constructed of transparent plastic material, covers the head and upper 
part of the participant’s body.  Air is drawn into the hood through a designated inlet by a 
pump.  The pump creates a below atmospheric pressure throughout the calorimeter and 
eliminates leakage of expired air to the atmosphere.  Expired air is continuously analyzed 
by a highly sensitive and accurate breath analysis system (Oxycon Pro, Jaeger, 
Germany).    Data is sampled every 10 sec, displayed in real time, and stored on disk for 
off-line analysis.        
 
6.2.5 Experimental Protocol  
The day before visit I.  The day before visit I participants were instructed to limit 
physical activity to light exercise of short duration.  They were asked to abstain from 
intake of alcohol and caffeine until after completion of testing the following day.  
Subjects ate their regular breakfast and lunch.  For dinner, they were provided with a 
standard evening meal (50% carbohydrate, 35% fat, half of which was saturated, and 15 
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% protein) that they were to consume at 7 pm, and a standard evening drink and snack 
that they were to consume at 10 pm (choice of glass of semi-skimmed milk or fruit juice, 
and a cereal bar, or a piece for fruit: apple or banana or orange).  After 10 pm the 
participants were instructed to drink only water and restrict physical activity to an 
absolute minimum until completion of the study the following day.   
 
Visit I.  The next morning, subjects remained fasted and drank only water.  Participants 
were requested to avoid exercise as much as possible and travel to the Wellcome Trust 
Clinical Research Facility (WT CRF) in the Queen Elizabeth Hospital by car or taxi, 
arriving at 8:30 am in the fasted state.  
 
After 15 min rest on a bed in semi-recumbent position a flexible 20-gauge Teflon catheter 
(Quickcath, Becton Dickinson, Plymouth, United Kingdom) was inserted in the 
antecubital vein of the non-dominant arm and fitted with two 3-way tap (PVB 
Medizintechnik, Kirchseean, Germany) to allow for repeated blood sampling and 
microsphere infusion.  After a further 15 min rest (at 9 am) a ventilated hood was placed 
over the participant’s head for baseline measures of energy expenditure 30 min prior to 
drink ingestion.  Energy expenditure data was acquired every 2 seconds.  Data from the 
final 10 min of this 30 min period was averaged to obtain a baseline value for energy 
expenditure and RER.  Fifteen minutes into the energy expenditure measurements, a 
Doppler ultrasound measure was taken, followed by a baseline blood sample and CEU.  
The ventilated hood was then momentarily removed as participants ingested the OGTT 
drink (75 g glucose dissolved in 300 ml water).  They were asked to consume this within 
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2 min.  Upon ingestion of the drink the ventilated hood was placed once again over the 
participant’s head and a 2 h measurement period commenced.  The hood was removed 
for a 5 min break after 1 h of measurement, to allow participants to stand up and stretch 
their legs, or go to the toilet if necessary.  Every time acquisition recommenced after a 
break from the hood, the subsequent 5 min of data were discarded to allow for the 
participant to settle again into a resting state.  The indirect calorimetry data was analysed 
in 5 min averages and the missing values (when hood was removed) were interpolated to 
obtain a complete data set of 5 min averages for the entire 2 h OGTT.  Energy 
expenditure data acquired over the first 55 min after glucose ingestion was averaged to 
create a 1st h energy expenditure value, and from 60 min to 115 min to create a 2nd h 
energy expenditure value.  Data from the last 5 min of the OGTT was averaged to create 
a 2 h energy expenditure value.  During the 2 h measurement period, Doppler ultrasound 
measurements were taken at t = 25, 55, 85, and 115 min.  Blood samples were taken at t = 
15, 30, 45, 60, 90, and 120 min, while a second CEU measurement occurred at 60 min, 
after the blood sample.  Following the final blood sample, the ventilated hood and 
intravenous catheter were removed and participants were given lunch before they went 
home.   
 
6.2.6 Blood Samples 
Recruitment visit blood samples (5 ml) were immediately analysed for fasting plasma 
glucose concentration (YSI 2300 STAT Plus Analyser, Ohio, USA).  Visit I blood 
samples (5 ml) were collected in heparin-containing tubes and centrifuged at 1000 rpm 
for 10 min at 4 °C.  Aliquots of plasma were frozen immediately in liquid nitrogen and 
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stored at -80 °C.  Plasma was analysed for glucose (Glucose HK, Horiba ABX, 
Monpellier, France) with the COBAS Mira Plus semiautomatic analyzer (ABX 
diagnostics) and insulin (EIA-2935, DRG Instruments, Marburg, Germany). 
 
6.2.7 Statistical Analysis 
The coefficient of variation (CV) for MBV was calculated by  
 
Where s is the standard deviation and is the mean.  The intra-subject CV for MBV 
was calculated by determining the CV for the 8 sequences for each of the 10 subjects and 
then averaging the CVs, while the inter-subject CV for MBV was calculated using the 
group mean and standard deviation value of the 10 subjects. 
 
Paired samples t-tests were conducted to compare baseline and 1 hour measures for 
microvascular blood volume, flow velocity and blood flow, and for brachial artery 
diameter, flow velocity, and blood flow.   Paired samples t-tests were also conducted to 
compare baseline and plateau value of carbohydrate oxidation, fat oxidation, and RER.   
 
A repeated measures ANOVA was conducted to identify significant changes in energy 
expenditure, plasma glucose and insulin concentrations over the time course of the 
OGTT.  
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To assess the magnitude of the intervention (OGTT) effect, the effect size was calculated 
using the eta squared statistic (η2) as it defines the proportion of variance associated with 
the main effect.  This was calculated by:  
 
 Where t is the t value, and df is the degrees of freedom. 
 
If significance was found the Bonferroni post hoc test was applied. 
 
All statistical tests were carried out using SPSS for windows version 16.0 software 
package (Chicago, IL, USA).  All data are reported as means ± SD and statistical 
significance was set at P < 0.05. 
 
 
6.3 RESULTS 
 
6.3.1 CEU data 
The intra-subject CV for MBV was 38.0 videointensity (VI) units ± 20.4 and 23.4 VI 
units ± 8.2 at baseline and 1 h post glucose ingestion, respectively, while the inter-subject 
CV for MBV was 45.2 and 39.1 VI units for baseline and 1 h post glucose ingestion, 
respectively.  There was a statistically significant increase in MBV from baseline to 1 
hour post OGTT ingestion (42.7 VI units ± 19.3 and 56.7 VI units ± 22.2, respectively, P 
= 0.015), and the eta squared statistic (0.50) indicated a large effect size (Figure 6.1).  
There was no statistically significant increase in MFV from baseline to 1 hour post 
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OGTT ingestion (0.22 1/sec ± 0.07 and 0.24 1/sec ± 0.06, respectively, P = 0.509; Figure 
6.2).  Microvascular blood flow (MBF) showed a statistically significant increase from 
baseline to 1 hour post OGTT ingestion (9.1 VI/sec ± 4.5 and 13.2 VI/sec ± 4.6, 
respectively, P = 0.005), and the eta squared statistic (0.61) indicated a large effect size 
(Figure 6.3).   
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Figure 6.1 Microvascular blood volume at baseline and 1 h post-glucose ingestion.  n = 10, * P = 0.015 
from baseline. 
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Figure 6.2 Microvascular flow velocity (1/sec) at baseline and 1 h post-glucose ingestion (n = 10).   
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Figure 6.3 Microvascular blood flow at baseline and 1 h post-glucose ingestion (n = 10).  * P = 0.005 from 
baseline. 
 
 
6.3.2 Brachial artery data 
Brachial artery diameter increased significantly from baseline to 1 hour post-OGTT 
ingestion (4.47 mm ± 0.40 vs 4.60 mm ± 0.30, P = 0.041).  The eta squared statistic 
(0.39) indicates a large effect size.  Brachial artery velocity and flow did not show a 
significant change from baseline to 1 hour post-OGTT ingestion.  Figure 6.4 depicts the 
brachial artery diameter, flow velocity, and blood flow data.   
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Figure 6.4 Brachial artery diameter, flow velocity, and blood flow changes from baseline to 1 h post-
glucose ingestion.  Data expressed as means ± standard error (n = 10).  * P = 0.041 from baseline. 
 
 
6.3.3 Blood data 
Plasma glucose concentrations increased significantly from baseline to peak (4.31 mM ± 
0.68 and 8.82 mM ±1.28, respectively; P = 0.001) in response to the OGTT.  Peak 
glucose concentrations were seen at 42 min ±13 post glucose ingestion.  Plasma glucose 
concentration at 2 hours post glucose ingestion was 5.34 mM ± 1.47, and was not 
significantly different from baseline (P = 0.065).  Insulin concentrations increased 
significantly from baseline to peak (7.81 μU/ml ± 2.29 and 71.1.5 μU/ml ± 20.2, 
respectively; P = 0.001) in response to the OGTT.  Peak insulin concentrations were seen 
at 47 min ± 22 post-glucose ingestion.  Plasma insulin concentration at 2 hours post 
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glucose ingestion was 20.22 μU/ml ± 9.20, and was significantly different from baseline 
(P = 0.008).  Figure 6.5 shows the plasma glucose and insulin concentration at baseline, 
peak values, and 2 hours post glucose ingestion. 
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Figure 6.5 Plasma insulin (n = 10) and glucose (n = 10) concentration at baseline, pre-glucose ingestion, 
and peak and 2 hour values post-glucose ingestion.  Values are expressed as mean ± standard error. * P < 
.01 from baseline. 
 
 
6.3.4 Energy expenditure, rate of fuel switch, and DIT 
In response to the OGTT, there was a statistically significant increase in CHO oxidation 
from baseline to plateau (81.2 mg/min ± 34.4 and 175.8 mg/min ± 23.7, respectively, P = 
0.001), and the eta squared statistic (0.97) indicated a large effect size.  A statistically 
significant decrease in fat oxidation from baseline to plateau (54.4 mg/min ± 22.9 and 
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23.5 mg/min ± 17.4, respectively, P = 0.001) was seen in response to the OGTT.  The eta 
squared statistic (0.88) indicates a large effect size.  Figure 6.6 shows the change in fat 
and CHO oxidation over time.   The respiratory exchange ratio (RER) showed a 
statistically significant increase from baseline to plateau (0.82 ± 0.06 and 0.94 ± 0.07, 
respectively, P = 0.001).  The eta squared statistic (0.93) indicates a large effect size 
(Figure 6.7).  Table 6.2 shows the CHO oxidation, fat oxidation, and RER values for 
baseline, the time at which the baseline values started to change (time of slope start), the 
rate of change (slope), the time at which a plateau is reached (time of plateau) and the 
plateau value.    
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Figure 6.6 Fatty acid and carbohydrate oxidation over 2 h OGTT (n = 10) 
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Figure 6.7 Respiratory exchange ratio over 2 h OGTT (n = 10) 
  
Table 6.2.  Kinetic analysis of time courses for CHO oxidation (n = 9), fat oxidation (n = 9), and 
respiratory exchange ratio (RER; n = 10).   
 Baseline 
 
Time of slope start 
(min) 
Slope 
 
Time of plateau 
(min) 
Plateau 
 
CHO  
 oxidation 
81.2 (± 34.4) 
mg/min 
15  (± 8.0) 4.7  (± 1.7) 
mg/min 
44  (± 11.7) 
 
175.8 *  (± 23.7) 
mg/min 
Fat  
 oxidation 
54.4  (± 22.9) 
mg/min 
21  (± 15.2) 8.8  (± 14.4) 
mg/min 
59  (± 26.2) 23.5* (± 17.4) 
mg/min 
RER 0.82  (± 0.06) 23  (± 8.19) 0.004  (± 0.0023) 59  (± 26.4) 0.94*  (± 0.07) 
Data given as mean values ± standard deviations.  * P < 0.05 from baseline. 
 
 
Energy expenditure over the 2 h OGTT is shown in Figure 6.8.  The data were divided 
into four values for analysis, namely the baseline value, followed by the average energy 
expenditure value of the first hour post-OGTT ingestion and of the average of the second 
hour post-OGTT ingestion, concluding with the 2 h energy expenditure value (Table 6.3).  
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The baseline value was obtained by averaging the last 10 min of the 30 min resting 
period, at which data was acquired every 2 sec, while the 2 h value was an average of the 
last 5 min of the 2 h measuring period post glucose ingestion.  A repeated measures 
ANOVA revealed 1st h average, 2nd h average, and 2h value to be significantly different 
from baseline (P = 0.001, P = 0.008, and P = 0.027, respectively) while not significantly 
different from each other (P = 1.000). 
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Figure 6.8 Energy expenditure over 2 h OGTT 
 
Table 6.3 Energy expenditure (kcal/min) 
Baseline 1st h average 2nd h average 2h value 
1.047  (± 0.14) 1.194*  (± 0.14) 1.183*  (± 0.14) 1.192*  (± 1.15) 
Data expressed as means ± standard deviations (n = 10).  * P < 0.05 from baseline 
 
 
6.4 DISCUSSION 
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The principal finding of the study is that MBV, measured by CEU, increased 
significantly in response to an OGTT in lean, trained, healthy individuals.  This was in 
line with our hypothesis, and to our knowledge this is the first time an increase in MBV 
has been measured in response to an OGTT. A significant increase in brachial artery 
diameter from baseline to 1 hour post-glucose ingestion was also observed again as 
hypothesised.  However, no significant change was seen in brachial artery blood flow 
velocity or blood flow.  This may be due to the OGTT not inducing a sufficient increase 
in plasma insulin to cause a measureable effect in the macrocirculation. 
 
The rapid rises in blood glucose and insulin concentration to moderate peak values 
corresponded with the hypothesis.  Peak glucose concentration occurred at 42 min ± 13 
and peak insulin concentration at 47 min ± 22.  Glucose levels subsequently began to 
decrease such that at 2 hours post glucose ingestion plasma glucose was no longer 
significantly different from baseline, while 2 hour plasma insulin had fallen but was still 
significantly elevated above baseline.   
 
The increase in plasma insulin may have induced the increase in MBV in several ways.  
Firstly, insulin has been found to stimulate NO production in terminal arterials, thereby 
inducing vasodilation and an increase in blood delivery to the capillary network (Barrett 
et al.  200920).  Secondly, insulin has also been shown to induce NO production higher up 
the arterial tree (Barrett et al. 200920) and thereby dilate the larger arteries, as seen by the 
increase in brachial artery diameter in the present study.  This would allow for an 
increase in blood delivery to the microcirculation and may therefore contribute to the 
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increase in MBV.  Thirdly, the increase in blood delivery to the skeletal muscle and its 
microcirculation due to insulin-induced NO production and subsequent vasodilation may 
increase shear stress, which in healthy arteries would induce further vasodilation (Arcaro 
et al. 199932; Pacher et al. 200733), thereby potentially contributing to the increase in 
MBV.   
 
We observed a rapid significant increase in carbohydrate oxidation and a significant 
decrease in fat oxidation, as well as a rapid significant increase in RER.  This 
corresponded with the hypothesis that lean trained individuals would have a high 
metabolic flexibility with a rapid switch from primarily fat oxidation in the fasted state to 
primarily carbohydrate oxidation after glucose ingestion (Storlien et al. 200424).  A rapid 
significant increase in energy expenditure in response to the OGTT was also observed 
and this too was in line with the hypothesis that the OGTT would increase MBV and DIT 
in parallel.  
 
In conclusion, to our knowledge this is the first study in humans in vivo to use CEU 
during an OGTT and show an increase in MBV.  This is an important observation as an 
OGTT is much simpler to conduct than a hyperinsulinaemic euglycemic clamp.  To fully 
appreciate the impact of adequate increases in MBV during the OGTT on metabolic 
flexibility (rate at which fat and carbohydrate oxidation switch after glucose ingestion) 
and on increases in DIT, future studies should investigate the effect of an OGTT in obese 
individuals. Only then we will be able to investigate the major hypothesis of this study: 
that reduced increases in MBV will reduce DIT and metabolic flexibility and will delay 
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the kinetics of the metabolic transitions that occur in the 2 h period following glucose 
ingestion.  In addition, the modifications of the CEU method that we developed in 
chapter 5 will allow measurement of changes in MBV and MBF at a high significance 
level with a high statistical power in 10 individuals.  Therefore, the modified CEU 
method should be able to evaluate the effect of exercise interventions and 
pharmacological therapies in obese and insulin resistant individuals. 
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GENERAL DISCUSSION 
 242
7.1 Overview 
 
There has been a dramatic global rise in obesity over the last thirty years (World 
Health Organisation 20061) with concomitant increases in obesity-related pathology, 
in particular type II diabetes (World Health Organisation 20062) and cardiovascular 
disease (CVD; Department of Health 20083).  The enormous cost of obesity-related 
pathology to the quality of life of individuals and to national economies warrants 
urgent action to tackle obesity and its progression into type II diabetes and CVD.  The 
loss of glycemic control is a key player in the development of obesity-related 
pathology (chapter 1).  Skeletal muscle and its microvasculature are particularly 
important in the maintenance of glucose homeostasis as skeletal muscle is the largest 
site of glucose disposal (Ferrannini et al. 19854; DeFronzo et al. 19855; Nuutila et al. 
19946) and is reliant on its microvasculature for delivery of glucose for clearance after 
meal ingestion (Orasanu and Plutzky 20097).  Obese individuals display a reduced 
capillary recruitment response to insulin (Clerk et al. 20068; de Jongh et al. 20049; 
Keske et al. 200910), as compared to their lean counterparts, which results in increased 
and prolonged glucose excursions after a meal, jeopardizing vascular health and 
glycemic control.  Obese individuals also display impaired NO-dependent 
vasodilation in response to increased flow in feeding and resistance arteries (Brook et 
al. 200111; Hamdy et al. 200312; Meyers and Gokce 200713; Arcaro et al. 199914), thus 
it is also possible that obese individuals may have a reduced microvascular perfusion 
response to exercise.  This would limit the delivery of oxygen and fuels and thus 
reduce exercise tolerance and the capacity to burn calories, as well as encourage the 
adoption of a sedentary lifestyle.  Plasma fatty acids (FA), elevated in obesity, have 
been shown to play a key role in impairing microvascular function (chapter 1), and 
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may be a target for improving the microvascular perfusion of the obese.  However, the 
extent of their contribution in impairing skeletal muscle perfusion at rest and during 
exercise is not fully understood.  Therefore, the aims of this thesis were (i) determine 
the effect of FA on muscle microvascular blood volume at rest and during exercise, 
(ii) investigate whether near-infrared spectroscopy can be used to measure skeletal 
muscle microvascular blood volume in the obese, (iii) develop the contrast enhanced 
ultrasound (CEU) method in our laboratory for measuring skeletal muscle 
microvascular blood volume and blood flow of the human forearm, and (iv) use CEU 
to measure microvascular blood volume and blood flow changes in response to an 
OGTT in lean trained individuals with the scope of using this method in the obese to 
assess the effectiveness of interventions aimed at improving microvascular perfusion 
and glycemic control. 
 
 
7.2 The effect of acute changes in FA concentrations on skeletal muscle perfusion 
in response to exercise and during the resting fasted state 
 
The prominent role of FA in inducing endothelial dysfunction and insulin resistance, 
and the impaired perfusion response to insulin in obese individuals (chapter 1), 
suggests the potential for FA to impair the skeletal muscle perfusion response to 
exercise in the obese as endothelial dysfunction impairs NO-mediated vasodilation 
and this vasodilation mechanism plays a role in exercise-induced perfusion.  In 
chapter 2 we investigated whether an acute decrease in plasma FA concentration 
would increase the MBV response to an acute exercise bout in obese individuals.  As 
endothelial dysfunction involves the loss of vasodilatory mechanisms and the 
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increased activation of pathways inducing vasoconstriction, the ability of elevated FA 
levels to impair endothelial function suggests the presence of increased 
vasoconstriction.  In chapter 3 we investigated whether an acute decrease in plasma 
FA would increase the skeletal muscle MBV of obese individuals in the resting fasted 
state.   
 
We measured microvascular blood volume as it is a major determinant of capillary 
permeability surface area product and glucose uptake (Gudbjornsdottir 200515).  Near-
infrared spectroscopy (NIRS) was used in both chapters to measure changes in total 
haemoglobin content (THC) which was considered to represent changes in blood 
volume in the measured compartment.  Niacin was used to acutely reduce plasma FA 
concentration.  Our results showed no significant differences in the exercise-induced 
increase in THC between control and low FA conditions in obese individuals 
(chapter 2).  There were also no significant differences in resting THC levels 
between control and low FA conditions (chapter 3).  We concluded that the results 
could potentially be explained by the short duration of the time window with a low 
FA concentration created by niacin. We and others (Wang et al. 200016; Carlson et al. 
196817) found plasma FA concentration reached its lowest point 1 h post niacin 
ingestion, but at 90 min FA concentrations started to increase again and baseline FA 
levels were reached approximately 2 h post niacin ingestion.  It is possible that the 
mechanisms involved in inducing endothelial dysfunction and insulin resistance 
require a longer exposure to reduced plasma FA concentrations before they are 
reversed.  For example, before alterations in gene expression lead to measurable 
changes in protein content of NADPH oxidase and NFκB, and to measurable effects 
on the balance between vasoconstriction and vasodilation (Silver et al. 200718), longer 
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periods of low FA concentration than those induced by niacin might well be required.  
Furthermore, it is possible that acute changes in plasma FA concentrations may not 
necessarily lead to acute decreases in endothelial concentrations of fatty acid 
metabolites that activate protein kinase C and increase serine phosphorylation of IRS-
1 and thus reduce NO production and vasodilation in the resting fasted state (Serne et 
al. 200619; Naruse et al. 200620).  The absence of a statistically significant difference 
between lean and obese participants in the exercise-induced THC increase did not 
confirm the hypothesis that obese individuals would have an impaired blood flow 
response to exercise (chapter 2).  This is potentially due to the inability of NIRS to 
measure haemoglobin concentration in the muscle microvasculature when a thick 
subcutaneous adipose tissue layer is present and absorbs all the NIR light (van 
Beekvelt et al. 200121).  We concluded that the large difference in resting THC 
between trained lean and obese individuals (chapter 3) was at least partially the result 
of the inability of NIRS to successfully penetrate into the skeletal muscle of the obese, 
rather than the presence of rarefaction or impaired microvascular dilation in trained 
obese individuals.  These results warranted a more detailed investigation of the effect 
of the thickness of the adipose tissue layer on the ability of NIRS to measure changes 
in THC in the skeletal muscle microvasculature. 
 
 
7.3 Evaluating the ability of NIRS to measure exercise induced increases in MBV 
in obese individuals 
 
The subcutaneous adipose tissue layer can vary greatly between individuals.  A large 
adipose tissue thickness will likely affect the THC measurements as the NIR light has 
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to travel through it before reaching the muscle (van Beekvelt et al. 200121).  
Nevertheless, it has been suggested that the measurement depth of the NIRS is equal 
to half the interoptode distance (ID; Cui et al. 199122; Homma et al. 199623), and thus 
increasing the ID would allow for photons to pass the thick adipose tissue layer and 
penetrate into skeletal muscle.  A calculation of the theoretical skeletal muscle tissue 
contribution to the returning NIRS signal would suggest an approximate 50 % muscle 
contribution for the obese participants (chapter 2 and 3).  However, the results from 
chapters 2 and 3 suggested that the large ID was not sufficient to avoid a major 
contribution of the thick subcutaneous adipose tissue layer of the obese participants to 
the NIRS absorption.  In chapter 4 we investigated the effect of subcutaneous 
adipose tissue thickness (ATT) on NIRS measurements at rest and during incremental 
exercise.  During exercise, THC in the skeletal muscle microvasculature is expected 
to increase, while haemoglobin oxygenation and especially oxygen saturation are 
expected to decrease.  The results showed a small increase in THC during exercise in 
the obese participants, as compared to lean controls. Haemoglobin oxygenation 
actually increased, while the decrease in oxygen saturation did not reach statistical 
significance (chapter 4).  The fact that we were unable to observe a substantial 
increase in THC from the skeletal muscle despite nearly half the signal theoretically 
originating from the muscle appears inconsistent with the calculations of the 
theoretical measurement depth.  This can potentially be explained by the scattering 
and absorption properties of the adipose tissue layer.  Rather than the adipose tissue 
layer simply adding to the penetration distance that the photons need to travel in order 
to reach the muscle, we concluded that adipose tissue might scatter the photons 
thereby increasing their path length within the adipose tissue and reducing their 
penetration depth (Matsushita 199824).  Therefore, although moderate ATT could be 
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overcome by increasing the ID (chapter 4), the large ATT in the obese participants 
may have caused photon scattering and increased the adipose tissue path length to 
such an extent as to significantly reduce penetration depth and skeletal muscle 
contribution to the NIRS measurement.  As a result, despite a large ID, skeletal 
muscle microvascular data could not be obtained with NIRS in obese participants.  
We concluded that in order to measure the skeletal muscle microvasculature in obese 
individuals, the contrast enhanced ultrasound (CEU) method would be required. 
 
 
7.4 Developing the CEU method to measure skeletal muscle microvascular blood 
volume in human forearm  
 
Most of the publications result from 2 laboratories using CEU to measure skeletal 
muscle microvascular blood volume in rats and humans (Rattigan et al. 200525; 
Vincent et al. 200626), and the published methodological descriptions are very 
succinct and lacking in detail.  In chapter 5 we set out to determine the optimal CEU 
procedure to measure skeletal muscle MBV of the human forearm.  The primary 
objective was to establish if the CEU technique could detect increases in skeletal 
muscle MBV in lean healthy individuals in response to an oral glucose tolerance test 
(OGTT).  The secondary objective was to compare the microvascular blood volume 
and blood flow response to an OGTT between trained lean and obese individuals, to 
establish the extent of impaired perfusion in the obese. The third objective was to 
eventually (in future studies) implement interventions aimed at improving the skeletal 
muscle perfusion in the patient groups and use CEU to measure the effect of the 
interventions.   
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 Traditionally CEU measurements have been made without arm fixation and using a 
multiple microsphere destruction protocol.  However, our endeavour to determine the 
optimal CEU protocol for measurement of MBV and MFV in the human forearm 
revealed that it is of vital importance that there is no movement of the arm or muscles 
during measurement as it will invalidate the data and the shape of the replenishment 
curve, as well as the resultant estimates of MBV and MFV.  We concluded that it is 
essential to create a stable and reproducible measurement set up.  This was achieved 
by the use of a vacuum support cushion to stabilise the arm, and fixing a specially 
made holder to the forearm into which the ultrasound probe could be inserted in a 
fixed position.  This holder also allowed removal of the probe between measurements 
while ensuring the maintenance of accurate placement and angle when the probe was 
returned.  In addition to the stable measurement set up, the use of a single microsphere 
destruction protocol, as advised by Dr. Stephen Rattigan, reduced the chances of arm 
movement during measurement as sequences only took approximately 20 sec as 
opposed to nearly 5 min with the multiple microsphere destruction protocol.  
Furthermore, the single microsphere destruction protocol also allowed repeated 
measures at baseline and during the OGTT thus improving the quality of the data.  
The analysis procedure for the CEU data has never been clearly specified in any of the 
human studies published so far and we concluded that for the most consistent and 
accurate analyses it was essential to use the full image ROI and export the data from 
QLAB to Microsoft Excel and subsequently to SigmaPlot for specific steps in the 
analysis procedure.   
 
7.5 Using CEU to measure the microvascular response to an OGTT 
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In healthy individuals, an OGTT induces an increase in plasma insulin concentration 
(Matsuda and DeFronzo 199927) which increases skeletal muscle MBV and capillary 
permeability surface area product (Gudbjornsdottir et al. 200328; Gudbjornsdottir 
200515), thereby increasing the delivery of glucose to the muscle fibre for clearance.  
In chapter 6 we investigated whether the optimised CEU protocol developed in 
chapter 5 was able to detect the increase in MBV in response to an OGTT in lean 
trained individuals.  The results showed a significant increase in MBV in response to 
the OGTT, which corresponded with the increases in glucose oxidation and energy 
expenditure in the form of diet-induced thermogenesis (DIT).  It is assumed that 
elevated circulating levels of insulin stimulate the dilation of terminal arterioles in 
vivo and thus increase skeletal muscle capillary perfusion (Clerk 20068), and this was 
supported by our increase in MBV.  In turn, increased microvascular perfusion 
increases the delivery of insulin and glucose to the muscle fibres, thereby promoting 
glucose clearance (Muniyappa et al. 200729).  Elevated insulin levels will promote 
DIT in healthy lean individuals at a whole body level (Lowell and Bachman 200330; 
de Jonge and Bray 199731; Tappy 199632) and in skeletal muscle (Petersen et al. 
200533).  DIT has several components.  In the insulin sensitive skeletal muscle, the 
increased activation of mitochondrial oxidation, and the increase in glycogen and 
protein synthesis after meal ingestion greatly contribute to DIT (Petersen et al. 200533; 
Wagenmakers 200534).  We hypothesised that the increase in DIT was dependent on 
an adequate increase in MBV.  Indeed, we saw a significant increase in energy 
expenditure in response to the OGTT.  Increased plasma insulin concentration and 
glucose uptake into the muscle fibre induces an increase in carbohydrate oxidation 
and a concomitant decrease in fat oxidation, and the rate of this switch in fuels reflects 
the metabolic flexibility of the individual (Storlien et al. 200435; Galgani et al. 
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200836).  Our data was in line with this as carbohydrate oxidation increased 
significantly while fat oxidation decreased significantly.   
 
We therefore concluded that the use of CEU with an OGTT created measureable 
increases in MBV which corresponded with changes in plasma insulin and glucose, as 
well as fat oxidation, carbohydrate oxidation, and energy expenditure responses to an 
OGTT, and that this technique was therefore suited to test the main hypothesis 
mentioned above. 
 
 
7.6 Future Research 
 
The CEU technique is emerging as an effective tool to measure MBV, MFV and MBF 
of the skeletal muscle microvasculature, as reflected by changes in MBV, in humans.  
Due to problems with setting up the method the time constraints meant we were not 
able to measure obese subjects.  Therefore future studies should use CEU to measure 
MBV in response to OGTT in obese individuals, and test the hypotheses that an 
OGTT will not induce measureable changes in MBV and that, therefore, in the obese 
the transition from fat to carbohydrate as the primary fuel will be delayed (metabolic 
inflexibility; Storlien et al. 200435; Corpeleijn et al. 200837) and the increase in DIT 
will be smaller (de Jonge and Bray 199731).  Improved glucose clearance after meal 
ingestion is of vital importance in limiting glucose excursions and the vascular 
damage hyperglycemia can induce (chapter 1).  As a larger MBV by definition leads 
to an increased capillary permeability surface area product and a faster rate of glucose 
uptake by skeletal muscle (Gudbjornsdottir et al. 200328), future studies should 
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investigate the effect of interventions aimed at improving the MBV response after 
meal ingestion so as to improve glucose disposal.   
 
To test hypothesis that increased insulin production by the pancreas would overcome 
the impairment in MBV response to meal ingestion we propose that one potential 
intervention would be the addition of amino acids to the glucose load to create a 
modified OGTT as the combined ingestion of amino acids and glucose has been 
shown to induce a greater insulin response than glucose alone (Manders et al. 200538).  
The greater insulin response may overcome the insulin resistance of the muscle fibre 
and microvasculature, thereby allowing for optimal glucose disposal.  Other 
interventions aimed at improving glycemic control involve an acute exercise bout and 
exercise training, as both are known to improve glucose tolerance (Wojtaszewski and 
Richter 200639), and their effectiveness could be assessed with the use of CEU and the 
MBV response to an OGTT pre- and post-intervention.   
 
As NIRS was found to be unable to measure the skeletal muscle microvasculature in 
the presence of a thick subcutaneous adipose tissue layer we do not have an answer to 
the important question whether limitations in skeletal muscle perfusion limit exercise 
capacity in the obese, thereby promoting the adoption of a sedentary lifestyle.  In 
future experiments, CEU should therefore be used to determine if there is a reduced 
perfusion response to exercise in obese individuals as compared to lean controls.  
Such a reduction in perfusion would limit exercise capacity and therefore could be an 
important target for interventions to help obese individuals increase their energy 
expenditure to control and reduce their excessive adiposity.  CEU could thus be used 
to assess the effectiveness of interventions at improving the perfusion response to 
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exercise so the most effective strategies can be implemented to help increase the 
exercise tolerance of the obese population.   
 
We have developed the CEU technique in such a way that it can now generate reliable 
MBV data in response to an OGTT in lean trained individuals and can likely be used 
in group comparisons and for the evaluation of interventions in the obese.  However, 
there are also alternative methods to measure endothelial function that could be 
important complimentary methods for use in future research to measure group 
differences and intervention effects.  The venous occlusion plethysmographic 
methods has been successfully used to assess the muscle microvascular exchange 
capacity, expressed as the capillary filtration coefficient (Kf), non-invasively measures 
the rate of fluid exchange from blood to muscle across the entire microvascular bed 
(Clough et al. 200940; Bates 200341; Gamble 200242).  Venous occlusion 
plethysmography is a well-validated technique which provides a measure of Kf 
through the use of small-step or cumulative increases in venous occlusion pressure 
and the subsequent changes in limb volume (Clough et al. 200940; Gamble et al. 
199343; Gamble 200242).  Furthermore, it does not affect the function of the 
vasculature being assessed (Clough et al. 200940).  Thus the use of plethysmography 
measuring Kf appears to be a favourable method to assess microvascular function 
(Anim-Nyame et al. 200344), and future studies may wish to explore the use of 
plethysmography to assess improvements in microvascular function in conjunction 
with glucose disposal in response to interventions aimed at improving glycemic 
control.  The venous occlusion plethysmography method has already been used to 
measure differences in microvascular function between trained and sedentary 
individuals, as well as the effect of training and of electrical stimulation on 
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microvascular function (Brown et al. 200145; Charles et al. 200646).  Brown et al. 
(2001)45 found that endurance trained athletes showed a greater capacity for fluid 
filtration compared to sedentary and resistance trained athletes, and that a 4-week 
electrical stimulation programme in sedentary individuals significantly increased the 
fluid filtration capacity.  Charles et al. (2006)46 found Kf nearly doubled in elderly 
individuals after 14 weeks of endurance exercise training.  Recently the 
plethysmography method also has been used to assess microvascular function after 
statin treatment (Clough et al. 200940).   
 
Statins are an important class of drugs extensively used in obesity and the metabolic 
syndrome to lower plasma lipids.  Although there are numerous drugs available for 
treating the variety of dysfunctions capable of inducing pathology in obese and 
diabetic patients, drugs may not be the solution to improving microvascular perfusion.  
An improvement in macrovascular function after 6 months of statin therapy was 
documented, however, despite reduced dislipidemia, no improvement in 
microvascular function was observed (Clough et al. 200940).  The improved lipid 
parameters and macrovascular function documented by Clough et al. (2009)40 reflect a 
reduced risk of pathology, in particular macrovascular disease (Clough et al. 200940).  
However, glycemic control is largely reliant on microvascular function, and the loss 
of glucose homeostasis is a key contributor to the pathogenesis of type II diabetes and 
its vascular complications, as well as CVD (Brownlee 200547).  Therefore, it is of vital 
importance to implement interventions at improving microvascular function and 
glycemic control even in conjunction with statin therapy.     
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Two tools are now available for the investigation of microvascular function in 
humans, namely CEU and venous occlusion plethysmography.  Future studies will 
need to investigate the microvascular function of obese individuals to define the 
suspected impairments and determine the effectiveness of interventions aimed at 
improving the microvascular response to exercise and meal ingestion so as to improve 
exercise tolerance and glycemic control and thereby halt the development of obesity-
related pathology.  
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